U.S. patent application number 13/116956 was filed with the patent office on 2011-12-22 for methods of detection of cancer using peptide profiles.
This patent application is currently assigned to Sloan-Kettering Institute for Cancer Research. Invention is credited to Paul Tempst, Josep Villanueva.
Application Number | 20110312522 13/116956 |
Document ID | / |
Family ID | 37758335 |
Filed Date | 2011-12-22 |
United States Patent
Application |
20110312522 |
Kind Code |
A1 |
Tempst; Paul ; et
al. |
December 22, 2011 |
METHODS OF DETECTION OF CANCER USING PEPTIDE PROFILES
Abstract
The disclosed methods address the identification and monitoring
of cancer in a subject using serum peptide profiles. Such profiles
allow the detection of the differential presence of certain serum
peptide markers in comparison with controls. The profiles can be
determined employing mass spectrometry.
Inventors: |
Tempst; Paul; (New York,
NY) ; Villanueva; Josep; (Barcelona, ES) |
Assignee: |
Sloan-Kettering Institute for
Cancer Research
New York
NY
|
Family ID: |
37758335 |
Appl. No.: |
13/116956 |
Filed: |
May 26, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12063968 |
Oct 20, 2008 |
7972770 |
|
|
PCT/US06/31957 |
Aug 16, 2006 |
|
|
|
13116956 |
|
|
|
|
60708676 |
Aug 16, 2005 |
|
|
|
Current U.S.
Class: |
506/9 ; 250/282;
436/501; 506/18; 506/26; 530/314; 530/324; 530/326; 530/327;
530/328; 530/329 |
Current CPC
Class: |
H01J 49/0027 20130101;
G01N 33/57484 20130101; C12Q 1/56 20130101 |
Class at
Publication: |
506/9 ; 506/18;
506/26; 436/501; 530/326; 530/327; 530/328; 530/324; 530/329;
530/314; 250/282 |
International
Class: |
C40B 30/04 20060101
C40B030/04; C40B 50/06 20060101 C40B050/06; G01N 21/64 20060101
G01N021/64; H01J 49/26 20060101 H01J049/26; C07K 7/06 20060101
C07K007/06; C07K 14/435 20060101 C07K014/435; C07K 7/18 20060101
C07K007/18; C40B 40/10 20060101 C40B040/10; C07K 7/08 20060101
C07K007/08 |
Goverment Interests
STATEMENT OF GOVERNMENTAL SUPPORT
[0003] This work was funded by NIH grant nos. 1 R21 CA1119425, 5
P30 CA08748 and 5 P50 CA 92629. The Government has certain rights
to this invention.
Claims
1. A method of identifying cancer of the prostate in a subject
comprising detecting an increase in a complement C3f peptide or a
fragment thereof, a ITIH4, clusterin, complement C4-alpha,
kininogen or factor XIII peptide fragment, or any combination
thereof in a biological sample obtained from the subject, thereby
identifying cancer of the prostate in the subject.
2. The method of claim 1, further comprising detecting a decrease
in fibrinopeptideA peptide or a fragment thereof, or a
fibrinogen-alpha peptide fragment, or any combination thereof in a
biological sample obtained from the subject.
3. A method of identifying cancer of the bladder in a subject
comprising detecting an increase in a complement C3f peptide or a
fragment thereof, a ITIH4, clusterin, complement C4-alpha,
fibrinogen-alpha, APO A-I, APO A-IV, APO E or kininogen peptide
fragment, or any combination thereof in a biological sample
obtained from the subject, thereby identifying cancer of the
bladder in the subject.
4. The method of claim 3, further comprising detecting a decrease
in a fibrinopeptideA peptide, bradykinin peptide, or a fragment
thereof, a C4-alpha, ITIH4, or fibrinogen-alpha peptide fragment,
or any combination thereof in a biological sample obtained from the
subject.
5. A method of identifying cancer of the breast in a subject
comprising detecting an increase in a fibrinopeptideA peptide,
bradykinin peptide, or a fragment thereof, a ITIH4, complement
C4-alpha, fibrinogen-alpha, APO A-IV, factorXIII or transthyretin
peptide fragment, or any combination thereof in a biological sample
obtained from the subject, thereby identifying cancer of the breast
in the subject.
6. The method of claim 5, further comprising detecting a decrease
in a fibrinopeptideA peptide, complement C3f peptide, or a fragment
thereof, or any combination thereof in a biological sample obtained
from the subject.
7. A method of identifying cancer of the prostate in a subject
comprising detecting a decrease in a fibrinopeptideA or a fragment
thereof and a fibrinogen-alpha peptide fragment and an increase in
a complement C3f peptide or a fragment thereof, a ITIH4, clusterin,
complement C4-alpha, kininogen and factor XIII peptide fragment in
a biological sample obtained from the subject, thereby identifying
cancer of the prostate in the subject.
8. A method of identifying cancer of the bladder in a subject
comprising detecting a decrease in a fibrinopeptideA peptide,
bradykinin peptide, or a fragment thereof, a C4-alpha, ITIH4, and
fibrinogen-alpha peptide fragment and an increase in a complement
C3f peptide or a fragment thereof, a ITIH4, clusterin, complement
C4-alpha, fibrinogen-alpha, APO A-I, APO A-IV, APO E and kininogen
peptide fragment in a biological sample obtained from the subject,
thereby identifying cancer of the bladder in the subject.
9. A method of identifying cancer of the breast in a subject
comprising detecting a decrease in a fibrinopeptideA peptide and
complement C3f peptide, or a fragment thereof, and an increase in a
fibrinopeptideA peptide, bradykinin peptide, or a fragment thereof,
a ITIH4, complement C4-alpha, fibrinogen-alpha, APO A-IV, factor
XIII and transthyretin peptide fragment in a biological sample
obtained from the subject, thereby identifying cancer of the breast
in the subject.
10. The method of claim 7, wherein the fibrinopeptideA peptide
fragment is selected from the group consisting of DSGEGDFLAEGGGVR
(SEQ ID NO. 1), SGEGDFLAEGGGVR (SEQ ID NO. 2), GEGDFLAEGGGVR (SEQ
ID NO. 3), EGDFLAEGGGVR (SEQ ID NO. 4), GDFLAEGGGVR (SEQ ID NO. 5),
DFLAEGGGVR (SEQ ID NO. 6) and LAEGGGVR (SEQ ID NO. 25).
11. The method of claim 8, wherein the fibrinopeptideA peptide
fragment is selected from the group consisting of DSGEGDFLAEGGGVR
(SEQ ID NO. 1), SGEGDFLAEGGGVR (SEQ ID NO. 2), GEGDFLAEGGGVR (SEQ
ID NO. 3), EGDFLAEGGGVR (SEQ ID NO. 4), GDFLAEGGGVR (SEQ ID NO. 5),
DFLAEGGGVR (SEQ ID NO. 6), FLAEGGGVR (SEQ ID NO. 24) and LAEGGGVR
(SEQ ID NO. 25).
12. The method of claim 9, wherein the fibrinopeptideA peptide
fragment that is decreased is selected from the group consisting of
SGEGDFLAEGGGVR (SEQ ID NO. 2) and GEGDFLAEGGGVR (SEQ ID NO. 3) and
the fibrinopeptideA fragment that is increased is FLAEGGGVR (SEQ ID
NO. 24).
13. The method of claim 7, wherein the complement C3f peptide
fragment is selected from the group consisting of, SSKITHRIHWESASLL
(SEQ ID NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9), KITHRIHWESASLL (SEQ
ID NO. 10), THRIHWESASLL (SEQ ID NO. 11), and IHWESASLL (SEQ ID NO.
28).
14. The method of claim 8, wherein the complement C3f peptide
fragment is selected from the group consisting of SSKITHRIHWESASLL
(SEQ ID NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9), KITHRIHWESASLL (SEQ
ID NO. 10), THRIHWESASLL (SEQ ID NO. 11), HWESASLL (SEQ ID NO. 12),
RIHWESASLL (SEQ ID NO. 27), IHWESASLL (SEQ ID NO. 28) and
SSKITHRIHWESASL (SEQ ID NO. 29).
15. The method of claim 9, wherein the complement C3f peptide
fragment is selected from the group consisting of SSKITHRIHWESASLL
(SEQ ID NO. 8), HWESASLL (SEQ ID NO. 12), and ITHRIHWESASLL (SEQ ID
NO. 26).
16. The method of claim 7, wherein the ITIH4 peptide fragment is
selected from the group consisting of PGVLSSRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO. 13), SRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 15), HAAYHPFR
(SEQ ID NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ ID NO. 35), HAAYHPF (SEQ
ID NO. 39) NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40) and
NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41).
17. The method of claim 8, wherein the ITIH4 peptide fragment that
is increased is selected from the group consisting of
PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 13), SRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO. 15), HAAYHPFR (SEQ ID NO. 34),
QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 36),
MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 37),
NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40) and
NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41), and the ITIH4 peptide
fragment that is decreased is selected from the group consisting of
GVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 14) and HAAYHPF (SEQ ID NO.
39).
18. The method of claim 9, wherein the ITIH4 peptide fragment is
selected from the group consisting of GLPGPPDVPDHAAYHPF (SEQ ID NO.
16), HAAYHPFR (SEQ ID NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ ID NO.
35), SSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 38) and
NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41).
19. The method of claim 7, wherein the clusterin peptide fragment
is HFFFPKSRIV (SEQ ID NO. 17).
20. The method of claim 8, wherein the clusterin peptide fragment
is selected from the group consisting of HFFFPKSRIV (SEQ ID NO. 17)
and HFFFPK (SEQ ID NO. 18).
21. The method of claim 8, wherein the bradykinin peptide fragment
is selected from the group consisting of RPPGFSPFR (SEQ ID NO. 19)
and RPPGFSPF (SEQ ID NO. 20).
22. The method of claim 7, wherein the complement C4-alpha peptide
fragment is GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23).
23. The method of claim 8, wherein the complement C4-alpha peptide
fragment that is increased is selected from the group consisting of
RNGFKSHALQLNNRQI (SEQ ID NO. 21), GLEEELQFSLGSKINVKVGGNS (SEQ ID
NO. 23), NGFKSHALQLNNR (SEQ ID NO. 31), and the complement C4-alpha
peptide fragment that is decreased is GLEEELQFSLGSKINV (SEQ ID NO.
33).
24. The method of claim 9, wherein the complement C4-alpha peptide
fragment is selected from the group consisting of RNGFKSHALQLNNRQI
(SEQ ID NO. 21), NGFKSHALQLNNRQI (SEQ ID NO. 22),
GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23), NGFKSHALQLNNRQ (SEQ ID NO.
30), GLEEELQFSLGSKINVKVGGNSKGTL (SEQ ID NO. 32) and
GLEEELQFSLGSKINV (SEQ ID NO. 33).
25. The method of claim 7, wherein the fibrinogen-alpha peptide
fragment is selected from the group consisting of
SSSYSKQFTSSTSYNRGDSTFESKSYKMA (SEQ ID NO. 55) and
SSSYSKQFTSSTSYNRGDSTFESKSYKM (SEQ ID NO. 56).
26. The method of claim 8, wherein the fibrinogen-alpha peptide
fragment that is increased is selected from the group consisting of
SSSYSKQFTSSTSYNRGDSTFESKSYKMA (SEQ ID NO. 55),
SSSYSKQFTSSTSYNRGDSTFESKSYKM (SEQ ID NO. 56),
SSSYSKQFTSSTSYNRGDSTFESKSY (SEQ ID NO. 57),
SSSYSKQFTSSTSYNRGDSTFESKS (SEQ ID NO. 58), and
SSYSKQFTSSTSYNRGDSTFE (SEQ ID NO. 60), and the fibrinogen-alpha
peptide fragment that is decreased is GSESGIFTNTKESSSHHPGIAEFPSRG
(SEQ ID NO. 61).
27. The method of claim 9, wherein the fibrinogen-alpha peptide
fragment is selected from the group consisting of
SSYSKQFTSSTSYNRGDSTFE (SEQ ID NO. 60) and DEAGSEADHEGTHSTKRGHAKSRPV
(SEQ ID NO. 62).
28. The method of claim 7, wherein the kininogen peptide fragment
is NLGHGHKHERDQGHGHQ (SEQ ID NO. 52).
29. The method of claim 8, wherein the kininogen peptide fragment
is selected from the group consisting of KHNLGHGHKHERDQGHGHQ (SEQ
ID NO. 51) or NLGHGHKHERDQGHGHQ (SEQ ID NO. 52).
30. The method of claim 8, wherein the APO A-I peptide fragment is
selected from the group consisting of QGLLPVLESFKVSFLSALEEYTKKLNTQ
(SEQ ID NO. 42), VSFLSALEEYTKKLNTQ (SEQ ID NO. 43) and
ATEHLSTLSEKAKPALEDL (SEQ ID NO. 44).
31. The method of claim 8, wherein the APO A-IV peptide fragment is
selected from the group consisting of GNTEGLQKSLAELGGHLDQQVEEFR
(SEQ ID NO. 46), SLAELGGHLDQQVEEFR (SEQ ID NO. 47) and
SLAELGGHLDQQVEEF (SEQ ID NO. 48).
32. The method of claim 9, wherein the APO A-IV peptide fragment is
ISASAEELRQRLAPLAEDVRGNL (SEQ ID NO. 45).
33. The method of claim 8, wherein the APO E peptide fragment is
selected from the group consisting of AATVGSLAGQPLQERAQAWGERLR (SEQ
ID NO. 49) and AATVGSLAGQPLQERAQAWGERL (SEQ ID NO. 50).
34. The method of claim 7, wherein the factor XIII peptide fragment
is AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53).
35. The method of claim 9, wherein the factor XIII peptide fragment
is AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53).
36. The method of claim 9, wherein the transthyretin peptide
fragment is ALGISPFHEHAEVVFTANDSGPR (SEQ ID NO. 54).
37. The method of claim 1, wherein the biological sample comprises
plasma or serum or a preparation thereof.
38. The method of claim 1, wherein the detecting comprises
analyzing the biological sample, or a preparation thereof using
mass spectrometry.
39. The method of claim 38, wherein the mass spectrometry is MALDI
TOF mass spectrometry.
40. The method of claim 38, wherein the mass spectrometry is
Fourier-transform ion cyclotron resonance mass spectrometry.
41. The method of claim 38, wherein the mass spectrometry is
electrospray ionization mass spectrometry.
42. The method of claim 1, wherein the detecting comprises
analyzing the biological sample or a preparation thereof on a solid
support, wherein peptides in the sample bind to the solid
support.
43. An isolated or identified peptide profile indicating cancer of
the prostate comprising an increased amount of peptides or peptide
fragments selected from the group consisting of SSKITHRIHWESASLL
(SEQ ID NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9), KITHRIHWESASLL (SEQ
ID NO. 10), THRIHWESASLL (SEQ ID NO. 11),
PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 13), SRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO. 15), HFFFPKSRIV (SEQ ID NO. 17), and
GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23), IHWESASLL (SEQ ID NO. 28),
HAAYHPFR (SEQ ID NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ ID NO. 35),
HAAYHPF (SEQ ID NO. 39) NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO.
40) NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41), NLGHGHKHERDQGHGHQ (SEQ
ID NO. 52), AVPPNNSNAAEDDLPTVELQGWPR (SEQ ID NO. 53) and
combinations thereof.
44. (canceled)
45. An isolated or identified peptide profile indicating cancer of
the bladder comprising an increased amount of peptides or peptide
fragments selected from the group consisting of SSKITHRIHWESASLL
(SEQ ID NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9), KITHRIHWESASLL (SEQ
ID NO. 10), THRIHWESASLL (SEQ ID NO. 11), HWESASLL (SEQ ID NO. 12),
PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 13), SRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO. 15), HFFFPKSRIV (SEQ ID NO. 17), HFFFPK (SEQ ID NO.
18), RNGFKSHALQLNNRQI (SEQ ID NO. 21), GLEEELQFSLGSKINVKVGGNS (SEQ
ID NO. 23), (SEQ ID NO. 27), IHWESASLL (SEQ ID NO. 28),
SSKITHRIHWESASL (SEQ ID NO. 29), NGFKSHALQLNNR (SEQ ID NO. 31),
HAAYHPFR (SEQ ID NO. 34), QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO. 36), MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 37),
NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40), NVHSAGAAGSRMNFRPGVLSS
(SEQ ID NO. 41), QGLLPVLESFKVSFLSALEEYTKKLNTQ (SEQ ID NO. 42),
VSFLSALEEYTKKLNTQ (SEQ ID NO. 43), ATEHLSTLSEKAKPALEDL (SEQ ID NO.
44), GNTEGLQKSLAELGGHLDQQVEEFR (SEQ ID NO. 46), SLAELGGHLDQQVEEFR
(SEQ ID NO. 47), SLAELGGHLDQQVEEF (SEQ ID NO. 48),
AATVGSLAGQPLQERAQAWGERLR (SEQ ID NO. 49), AATVGSLAGQPLQERAQAWGERL
(SEQ ID NO. 50), KHNLGHGHKHERDQGHGHQ (SEQ ID NO. 51),
NLGHGHKHERDQGHGHQ (SEQ ID NO. 52), GSESGIFTNTKESSSHHPGIAEFPSRG (SEQ
ID NO. 61) and combinations thereof.
46. (canceled)
47. An isolated or identified peptide profile indicating cancer of
the breast comprising an increased amount of peptides or peptide
fragments selected from the group consisting of GLPGPPDVPDHAAYHPF
(SEQ ID NO. 16), RPPGFSPFR (SEQ ID NO. 19), RPPGFSPF (SEQ ID NO.
20), RNGFKSHALQLNNRQI (SEQ ID NO. 21), NGFKSHALQLNNRQI (SEQ ID NO.
22) GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23), FLAEGGGVR (SEQ ID NO.
24), NGFKSHALQLNNRQ (SEQ ID NO. 30), GLEEELQFSLGSKINVKVGGNSKGTL
(SEQ ID NO. 32), GLEEELQFSLGSKINV (SEQ ID NO. 33), HAAYHPFR (SEQ ID
NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ ID NO. 35),
SSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 38), NVHSAGAAGSRMNFRPGVLSS (SEQ
ID NO. 41), ISASAEELRQRLAPLAEDVRGNL (SEQ ID NO. 45),
AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53), ALGISPFHEHAEVVFTANDSGPR
(SEQ ID NO. 54), SSYSKQFTSSTSYNRGDSTFE (SEQ ID NO. 60)
DEAGSEADHEGTHSTKRGHAKSRPV (SEQ ID NO. 62) and combinations
thereof.
48-50. (canceled)
51. A method of generating a peptide profile of a subject having,
or at risk of having, cancer of the prostate, comprising the steps
of: i) combining an exogenous peptide selected from the group
consisting of a complement C3f, ITIH4, clusterin, complement
C4-alpha, fibrinopeptide A kininogen, factor XIII, fibrinogenA
peptide and combinations thereof with a biological sample from the
subject; and ii) proteolytically digesting a peptide of step i),
thereby generating a peptide profile of the subject.
52-71. (canceled)
72. A kit for generating a peptide profile of a subject having, or
at risk of having, cancer of the bladder, breast, prostate or
thyroid comprising an exogenous peptide or peptide fragment
selected form the group consisting of complement C3f peptide, ITIH4
peptide, clusterin peptide, complement C4-alpha peptide,
fibrinopeptideA peptide, bradykinin peptide, APO A-I peptide,
APOA-IV peptide, APO E peptide, kininogen peptide, factor XIII
peptide, transthyretin peptide and fibrinogenA peptide and
instructions for use.
73-76. (canceled)
77. An isolated peptide fragment selected from the group consisting
of a complement C3f, ITIH4, clusterin, complement C4-alpha,
fibrinopeptideA, bradykinin, APO A-I, APOA-IV, APO E, kininogen,
factor XIII, transthyretin and fibrinogenA peptide fragment.
78. A method of identifying cancer of the thyroid in a subject
comprising detecting an increase in a complement C3f peptide or a
fragment thereof, thereby identifying cancer of the thyroid in the
subject.
79. The method of claim 78, further comprising detecting a decrease
in fibrinopeptideA peptide or a fragment thereof, or a
fibrinogen-alpha peptide fragment, or any combination thereof in a
biological sample obtained from the subject.
80. The method claim 78, wherein the step of detecting comprises an
optical detection method.
81. The method of claim 80, wherein the optical detection method
comprises a fluorescence method.
82. The method of claim 81, wherein the fluorescence method
comprises a sandwich immunoassay.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS/PATENTS & INCORPORATION
BY REFERENCE
[0001] This application is a division of U.S. patent application
Ser. No. 12/063,968, filed Oct. 20, 2008, now U.S. Pat. No.
7,972,770, which is the U.S. national phase application, pursuant
to 35 U.S.C. .sctn.371, of PCT international application Ser. No.
PCT/US2006/031957, filed Aug. 16, 2006, designating the United
States and published in English on Feb. 22, 2007, as publication WO
2007/022248 A2, which claims priority to U.S. provisional
application Ser. No. 60/708,676, filed Aug. 16, 2005. The entire
contents of the aforementioned patent applications are incorporated
herein by this reference.
[0002] Each of the applications and patents cited in this text, as
well as each document or reference cited in each of the
applications and patents (including during the prosecution of each
issued patent; "application cited documents"), and each of the PCT
and foreign applications or patents corresponding to and/or
paragraphing priority from any of these applications and patents,
and each of the documents cited or referenced in each of the
application cited documents, are hereby expressly incorporated
herein by reference. More generally, documents or references are
cited in this text, either in a Reference List before the
paragraphs, or in the text itself; and, each of these documents or
references ("herein-cited references"), as well as each document or
reference cited in each of the herein-cited references (including
any manufacturer's specifications, instructions, etc.), is hereby
expressly incorporated herein by reference.
SEQUENCE LISTING
[0004] The instant application contains a Sequence Listing which
has been submitted in ASCII format via EFS-Web and is hereby
incorporated by reference in its entirety. Said ASCII copy, created
on Aug. 19, 2011, is named 63115159.txt and is 145,202 bytes in
size.
BACKGROUND OF THE INVENTION
[0005] Serum biomarkers are used for diagnosis of disease and for
predicting and monitoring response to treatment (Sidransky, D.
2002. Nat Rev Cancer 2:210-219; Bidart, J. M., et al. 1999. Clin
Chem 45:1695-1707). Most clinically useful markers, to date, have
been plasma proteins that require individual immunoassays for
quantitation (Jortani, S. A., et al. 2004. Clin Chem 50:265-278;
Watts, N. B. 1999. Clin Chem 45:1359-1368). Human serum also
contains smaller peptides that constitute an entity known as the
serum `peptidome`. Advances in mass spectrometry (MS) now permit
the display of hundreds of small to medium sized peptides from
microliter volumes of serum (Koomen, J. M., et al., 2005. J
Proteome Res 4:972-981; Villanueva, et al., 2004. Anal Chem
76:1560-1570). Several recent reports have advocated the use of
MS-based serum peptide profiling to determine qualitative and
quantitative patterns, or `signatures`, that indicate the
presence/absence of disease such as cancer (Petricoin, E. F., et
al., 2002. Lancet 359:572-577; Adam, B. L., et al., 2002. Cancer
Res 62:3609-3614; Li, J., et al., 2002. Clin Chem 48:1296-1304;
Ebert, M. P., et al., 2004. J Proteome Res 3:1261-1266; Ornstein,
D. K., et al. 2004. J Urol 172:1302-1305; Conrads, T. P., et al.,
2004. Endocr Relat Cancer 11:163-178). To date, it has neither been
accomplished to independently reproduce entire peptidomic patterns,
nor has it been shown that the highly discriminatory peptides have
the same amino acid sequences.
[0006] TOF-MS is the most efficient mass analysis technique in
terms of detection sensitivity and readily achieves high mass
analysis at good mass accuracy (R. J. Cotter, Anal. Chem. 64 (21),
1027 (1992)). It is one of the few analysis techniques that
combines high sensitivity, selectivity and specificity with speed
of analysis. For example, TOF-MS can record a complete mass
spectrum on a microsecond timescale.
[0007] Advances in MS-based serum peptide profiling can have
important implications for cancer diagnostics.
SUMMARY OF THE INVENTION
[0008] It has now been determined that distinctive peptide patterns
that correlate with clinically relevant outcomes can be established
through mass spectrometry (MS). Methods of the present invention
employ serum peptide profiles to identify various types of
cancer.
[0009] The present invention provides peptide markers that are
differentially present in the samples of cancer subjects and in the
samples of control subjects. Measurement of these markers, alone or
in combination, in patient samples provides information correlating
with a probable diagnosis of human cancer or a negative diagnosis
(e.g., normal or disease-free). Accordingly, further disclosed are
methods and kits that employ these markers in diagnosing and
monitoring cancer.
[0010] In one aspect, the present invention provides methods of
diagnosing or monitoring cancer in a subject comprising measuring
at least one peptide marker in a sample from the subject. The
cancer can be cancer of the prostate, bladder, breast or thyroid.
Peptide markers of the invention include but are not limited to
complement C3f, ITIH4, clusterin, complement C4-alpha,
fibrinopeptideA, bradykinin, APO A-I, APOA-IV, APO E, kininogen,
factor XIII, transthyretin and fibrinogenA. Preferably, peptide
markers for ITIH4, clusterin, complement C4-alpha, APO A-I, APO
A-IV, APO E, kininogen, factor XIII, transthyretin and fibrinogenA
are present in the serum as peptide fragments.
[0011] In one embodiment, peptide marker levels are detected in a
combination of two or more of the aforementioned peptide markers.
Thus, the number of individual peptide markers measured in a sample
can range from about 2 to 10, 10 to 15, 15 to 20, 20 to 25, 25 to
30, 30 to 35, 35 to 40, 40 to 45, 45 to 50 and greater than about
50. In specific embodiments, at least about 20 of the peptide
markers are measured.
[0012] In one embodiment, the invention provides a method of
identifying cancer of the prostate in a subject comprising
detecting an increase in a complement C3f peptide or a fragment
thereof, a ITIH4, clusterin, complement C4-alpha, kininogen or
factor XIII peptide fragment, or any combination thereof in a
biological sample obtained from the subject, thereby identifying
cancer of the prostate in the subject. The method can further
comprise detecting a decrease in fibrinopeptideA peptide or a
fragment thereof, or a fibrinogen-alpha peptide fragment, or any
combination thereof in a biological sample obtained from the
subject.
[0013] In another embodiment, the invention provides a method of
identifying cancer of the bladder in a subject comprising detecting
an increase in a complement C3f peptide or a fragment thereof, a
ITIH4, clusterin, complement C4-alpha, fibrinogen-alpha, APO A-I,
APO A-IV, APO E or kininogen peptide fragment, or any combination
thereof in a biological sample obtained from the subject, thereby
identifying cancer of the bladder in the subject. The method can
further comprise detecting a decrease in a fibrinopeptideA peptide,
bradykinin peptide, or a fragment thereof, a C4-alpha, ITIH4, or
fibrinogen-alpha peptide fragment, or any combination thereof in a
biological sample obtained from the subject.
[0014] In yet another embodiment, the invention provides a method
of identifying cancer of the breast in a subject comprising
detecting an increase in a fibrinopeptideA peptide, bradykinin
peptide, or a fragment thereof, a ITIH4, complement C4-alpha,
fibrinogen-alpha, APO A-IV, factorXIII or transthyretin peptide
fragment, or any combination thereof in a biological sample
obtained from the subject, thereby identifying cancer of the breast
in the subject. The method can further comprise detecting a
decrease in a fibrinopeptideA peptide, complement C3f peptide, or a
fragment thereof, or any combination thereof in a biological sample
obtained from the subject.
[0015] In yet another embodiment, the invention provides a method
of identifying cancer of the prostate in a subject comprising
detecting a decrease in a fibrinopeptideA peptide or a fragment
thereof and a fibrinogen-alpha peptide fragment and an increase in
a complement C3f peptide or a fragment thereof, a ITIH4, clusterin,
complement C4-alpha, kininogen and factor XIII peptide fragment in
a biological sample obtained from the subject, thereby identifying
cancer of the prostate in the subject.
[0016] In yet another embodiment, the invention is provides a
method of identifying cancer of the bladder in a subject comprising
detecting a decrease in a fibrinopeptideA peptide, bradykinin
peptide, or a fragment thereof, a C4-alpha, ITIH4, and
fibrinogen-alpha peptide fragment and an increase in a complement
C3f or a fragment thereof, a ITIH4, clusterin, complement C4-alpha,
fibrinogen-alpha, APO A-I, APO A-IV, APO E and kininogen peptide
fragment in a biological sample obtained from the subject, thereby
identifying cancer of the bladder in the subject.
[0017] In yet another embodiment, the invention provides a method
of identifying cancer of the breast in a subject comprising
detecting a decrease in a fibrinopeptideA peptide and complement
C3f peptide, or a fragment thereof, and an increase in a
fibrinopeptideA peptide, bradykinin peptide, or a fragment thereof,
a ITIH4, complement C4-alpha, fibrinogen-alpha, APO A-IV,
factorXIII and transthyretin peptide fragment in a biological
sample obtained from the subject, thereby identifying cancer of the
breast in the subject.
[0018] In specific embodiments of the invention concerning cancer
of the prostate, the fibrinopeptideA peptide fragment that is
decreased includes but is not limited to DSGEGDFLAEGGGVR (SEQ ID
NO. 1), SGEGDFLAEGGGVR (SEQ ID NO. 2), GEGDFLAEGGGVR (SEQ ID NO.
3), EGDFLAEGGGVR (SEQ ID NO. 4), GDFLAEGGGVR (SEQ ID NO. 5),
DFLAEGGGVR (SEQ ID NO. 6) or LAEGGGVR (SEQ ID NO. 25).
[0019] In other specific embodiments of the invention concerning
cancer of the bladder, the fibrinopeptideA peptide fragment that is
decreased includes but is not limited to DSGEGDFLAEGGGVR (SEQ ID
NO. 1), SGEGDFLAEGGGVR (SEQ ID NO. 2), GEGDFLAEGGGVR (SEQ ID NO.
3), EGDFLAEGGGVR (SEQ ID NO. 4), GDFLAEGGGVR (SEQ ID NO. 5),
DFLAEGGGVR (SEQ ID NO. 6), FLAEGGGVR (SEQ ID NO. 24) or LAEGGGVR
(SEQ ID NO. 25).
[0020] In other specific embodiments of the invention concerning
cancer of the breast, the fibrinopeptideA peptide fragment that is
decreased includes but is not limited to SGEGDFLAEGGGVR (SEQ ID NO.
2) or GEGDFLAEGGGVR (SEQ ID NO. 3) and the fibrinopeptideA peptide
fragment that is increased is FLAEGGGVR (SEQ ID NO. 24).
[0021] In other specific embodiments of the invention concerning
cancer of the prostate, the complement C3f peptide fragment that is
increased includes but is not limited to SSKITHRIHWESASLL (SEQ ID
NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9), KITHRIHWESASLL (SEQ ID NO.
10), THRIHWESASLL (SEQ ID NO. 11) or IHWESASLL (SEQ ID NO. 28).
[0022] In other specific embodiments of the invention concerning
cancer of the bladder, the complement C3f peptide fragment that is
increased includes but is not limited to SSKITHRIHWESASLL (SEQ ID
NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9), KITHRIHWESASLL (SEQ ID NO.
10), THRIHWESASLL (SEQ ID NO. 11), HWESASLL (SEQ ID NO. 12),
RIHWESASLL (SEQ ID NO. 27), IHWESASLL (SEQ ID NO. 28) or
SSKITHRIRWESASL (SEQ ID NO. 29).
[0023] In other specific embodiments of the invention concerning
cancer of the breast, the complement C3f peptide fragment that is
decreased includes but is not limited to SSKITHRIHWESASLL (SEQ ID
NO. 8), HWESASLL (SEQ ID NO. 12) or ITHRIHWESASLL (SEQ ID NO.
26).
[0024] In other specific embodiments of the invention concerning
cancer of the prostate, ITIH4 peptide fragment that is increased
includes but is not limited to PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID
NO. 13), SRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 15), HAAYHPFR (SEQ ID
NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ ID NO. 35), HAAYHPF (SEQ ID NO.
39), NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40) or
NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41).
[0025] In other specific embodiments of the invention concerning
cancer of the bladder, the ITIH4 peptide fragment that is increased
includes but is not limited to PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID
NO. 13), SRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 15), HAAYHPFR (SEQ ID
NO. 34), QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 36),
MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 37),
NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40) or
NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41) and the ITIH4 peptide
fragment that is decreased includes but is not limited to
GVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 14) or HAAYHPF (SEQ ID NO.
39).
[0026] In other specific embodiments of the invention concerning
cancer of the breast, the ITIH4 peptide fragment that is increased
includes but is not limited to GLPGPPDVPDHAAYHPF (SEQ ID NO. 16),
HAAYHPFR (SEQ ID NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ ED NO. 35),
SSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 38) or NVHSAGAAGSRMNFRPGVLSS
(SEQ ID NO. 41).
[0027] In other specific embodiments of the invention concerning
cancer of the prostate, the clusterin peptide fragment includes but
is not limited to HFFFPKSRIV (SEQ ID NO. 17).
[0028] In other specific embodiments of the invention concerning
cancer of the bladder, the clusterin peptide fragment that is
increased includes but is not limited to HFFFPKSRIV (SEQ ID NO. 17)
or HFFFPK (SEQ ID NO. 18).
[0029] In other specific embodiments of the invention concerning
cancer of the bladder, the bradykinin peptide fragment that is
decreased includes but is not limited to RPPGFSPFR (SEQ ID NO. 19)
or RPPGFSPF (SEQ ID NO. 20).
[0030] In other specific embodiments of the invention concerning
cancer of the breast, the bradykinin peptide fragment that is
increased includes but is not limited to RPPGFSPFR (SEQ ID NO. 19)
or RPPGFSPF (SEQ ID NO. 20).
[0031] In other specific embodiments of the invention concerning
cancer of the prostate, the complement C4-alpha peptide fragment
that is increased includes but is not limited to
GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23).
[0032] In other specific embodiments of the invention concerning
cancer of the bladder, the complement C4-alpha peptide fragment
that is increased includes but is not limited to RNGFKSHALQLNNRQI
(SEQ ID NO. 21), GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23), or
NGFKSHALQLNNR (SEQ ID NO. 31) and the complement C4-alpha peptide
fragment that is decreased is GLEEELQFSLGSKINV (SEQ ID NO. 33).
[0033] In other specific embodiments of the invention concerning
cancer of the breast, the complement C4-alpha peptide fragment that
is increased includes but is not limited to RNGFKSHALQLNNRQI (SEQ
ID NO. 21), NGFKSHALQLNNRQI (SEQ ID NO. 22), GLEEELQFSLGSKINVKVGGNS
(SEQ ID NO. 23), NGFKSHALQLNNRQ (SEQ ID NO. 30),
GLEEELQFSLGSKINVKVGGNSKGTL (SEQ ID NO. 32) or GLEEELQFSLGSKINV (SEQ
ID NO. 33).
[0034] In other specific embodiments of the invention concerning
cancer of the prostate, the fibrinogen-alpha peptide fragment that
is decreased includes but is not limited to
SSSYSKQFTSSTSYNRGDSTFESKSYKMA (SEQ NO. 55) or
SSSYSKQFTSSTSYNRGDSTFESKSYKM (SEQ ID NO. 56).
[0035] In other specific embodiments of the invention concerning
cancer of the bladder, the fibrinogen-alpha peptide fragment that
is increased includes but is not limited to
SSSYSKQFTSSTSYNRGDSTFESKSYKMA (SEQ ID NO. 55),
SSSYSKQFTSSTSYNRGDSTFESKSYKM (SEQ ID NO. 56),
SSSYSKQFTSSTSYNRGDSTFESKSY (SEQ ID NO. 57),
SSSYSKQFTSSTSYNRGDSTFESKS (SEQ ID NO. 58), or SSYSKQFTSSTSYNRGDSTFE
(SEQ ID NO. 60), and the fibrinogen-alpha peptide fragment that is
decreased is GSESGIFTNTKESSSHHPGIAEFPSRG (SEQ ID NO. 61).
[0036] In other specific embodiments of the invention concerning
cancer of the breast, the fibrinogen-alpha peptide fragment that is
increased includes but is not limited to SSYSKQFTSSTSYNRGDSTFE (SEQ
ID NO. 60) or DEAGSEADHEGTHSTKRGHAKSRPV (SEQ ID NO. 62).
[0037] In other specific embodiments of the invention concerning
cancer of the prostate, the kininogen peptide fragment is
NLGHGHKHERDQGHGHQ (SEQ ID NO. 52).
[0038] In other specific embodiments of the invention concerning
cancer of the bladder, the kininogen peptide fragment that is
increased includes but is not limited to KHNLGHGHKHERDQGHGHQ (SEQ
ID NO. 51) or NLGHGHKHERDQGHGHQ (SEQ ID NO. 52).
[0039] In other specific embodiments of the invention concerning
cancer of the bladder, the APO A-I peptide fragment that is
increased includes but is not limited to
QGLLPVLESFKVSFLSALEEYTKKLNTQ (SEQ ID NO. 42), VSFLSALEEYTKKLNTQ
(SEQ ID NO. 43) or ATEHLSTLSEKAKPALEDL (SEQ ID NO. 44).
[0040] In other specific embodiments of the invention concerning
cancer of the bladder, the APO A-IV peptide fragment that is
increased includes but is not limited to GNTEGLQKSLAELGGHLDQQVEEFR
(SEQ ID NO. 46), SLAELGGHLDQQVEEFR (SEQ ID NO. 47) or
SLAELGGHLDQQVEEF (SEQ ID NO. 48).
[0041] In other specific embodiments of the invention concerning
cancer of the breast, the APO A-IV peptide fragment that is
increased is ISASAEELRQRLAPLAEDVRGNL (SEQ ID NO. 45).
[0042] In other specific embodiments of the invention concerning
cancer of the bladder, the APO E peptide fragment that is increased
includes but is not limited to AATVGSLAGQPLQERAQAWGERLR (SEQ ID NO.
49) or AATVGSLAGQPLQERAQAWGERL (SEQ ID NO. 50).
[0043] In other specific embodiments of the invention concerning
cancer of the prostate, the factor XIII peptide fragment that is
increased is AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53).
[0044] In other specific embodiments of the invention concerning
cancer of the breast, the factor XIII peptide fragment that is
increased is AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53).
[0045] In other specific embodiments of the invention concerning
cancer of the breast, the transthyretin peptide fragment that is
increased is ALGISPFHEHAEVVFTANDSGPR (SEQ ID NO. 54).
[0046] In practicing the methods of the invention, the biological
sample can comprise plasma or serum or a preparation thereof.
Detection can comprise analyzing the biological sample, or a
preparation thereof using mass spectrometry. The mass spectrometry
can be MALDI TOF, Fourier-transform ion cyclotron resonance,
electrospray ionization mass spectrometry, or combinations thereof.
In another aspect, detection can comprise analyzing the biological
sample, or a preparation thereof on a solid support, wherein
peptides in the sample bind to the solid support.
[0047] In another aspect, the invention provides peptide profiles
indicative of cancer of the prostate, bladder, and breast.
[0048] In one embodiment, the invention provides an isolated or
identified peptide profile indicating cancer of the prostate
comprising an increased amount of peptides or peptide fragments of
SSKITHRIHWESASLL (SEQ ID NO. 8), SKITHRIEIWESASLL (SEQ ID NO. 9),
KITHRIHWESASLL (SEQ ID NO. 10), THRIHWESASLL (SEQ ID NO. 11),
PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 13), SRQLGLPGPPDVPDHAAYHPF
(SEQ ID NO. 15), HFFFPKSRIV (SEQ ID NO. 17), GLEEELQFSLGSKINVKVGGNS
(SEQ ID NO. 23), IHWESASLL (SEQ ID NO. 28), HAAYHPFR (SEQ ID NO.
34), QLGLPGPPDVPDHAAYHPFR (SEQ ID NO. 35), HAAYHPF (SEQ ID NO. 39),
NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40), NVHSAGAAGSRMNFRPGVLSS
(SEQ ID NO. 41), NLGHGHKHERDQGHGHQ (SEQ ID NO. 52),
AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53), or combinations thereof.
In an additional embodiment, the isolated or identified peptide
profile indicating cancer of the prostate comprises a decreased
amount of peptides or peptide fragments of DSGEGDFLAEGGGVR (SEQ ID
NO. 1), SGEGDFLAEGGGVR (SEQ ID NO. 2), GEGDFLAEGGGVR (SEQ ID NO.
3), EGDFLAEGGGVR (SEQ ID NO. 4), GDFLAEGGGVR (SEQ ID NO. 5),
DFLAEGGGVR (SEQ ID NO. 6), LAEGGGVR (SEQ ID NO. 25),
SSSYSKQFTSSTSYNRGDSTFESKSYKMA (SEQ ID NO. 55),
SSSYSKQFTSSTSYNRGDSTFESKSYKM (SEQ ID NO. 56), or combinations
thereof.
[0049] In another embodiment, the invention provides an isolated or
identified peptide profile indicating cancer of the bladder
comprising an increased amount of peptides or peptide fragments of
SSKITHRIHWESASLL (SEQ ID NO. 8), SKITHRIHWESASLL (SEQ ID NO. 9),
KITHRIHWESASLL (SEQ ID NO. 10), THRIHWESASLL (SEQ ID NO. 11),
HWESASLL (SEQ ID NO. 12), PGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO.
13), SRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 15), HFFFPKSRIV (SEQ ID NO.
17), HFFFPK (SEQ ID NO. 18), RNGFKSHALQLNNRQI (SEQ ID NO. 21),
GLEEELQFSLGSKINVKVGGNS (SEQ ID NO. 23), (SEQ ID NO. 27), IHWESASLL
(SEQ ID NO. 28), SSKITHRIHWESASL (SEQ ID NO. 29), NGFKSHALQLNNR
(SEQ ID NO. 31), HAAYHPFR (SEQ ID NO. 34),
QAGAAGSRMNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 36),
MNFRPGVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 37),
NVHSGSTFFKYYLQGAKIPKPEASFSPR (SEQ ID NO. 40), NVHSAGAAGSRMNFRPGVLSS
(SEQ ID NO. 41), QGLLPVLESFKVSFLSALEEYTKKLNTQ (SEQ ID NO. 42),
VSFLSALEEYTKKLNTQ (SEQ ID NO. 43), ATEHLSTLSEKAKPALEDL (SEQ ID NO.
44), GNTEGLQKSLAELGGHLDQQVEEFR (SEQ ID NO. 46), SLAELGGHLDQQVEEFR
(SEQ ID NO. 47), SLAELGGHLDQQVEEF (SEQ ID NO. 48),
AATVGSLAGQPLQERAQAWGERLR (SEQ ID NO. 49), AATVGSLAGQPLQERAQAWGERL
(SEQ ID NO. 50), KHNLGHGHKHERDQGHGHQ (SEQ ID NO. 51),
NLGHGHKHERDQGHGHQ (SEQ ID NO. 52), GSESGIFTNTKESSSHHPGIAEFPSRG (SEQ
ID NO. 61), or combinations thereof. In an additional embodiment,
the isolated or identified peptide profile indicating cancer of the
bladder comprises a decreased amount of peptides or peptide
fragments of DSGEGDFLAEGGGVR (SEQ ID NO. 1), SGEGDFLAEGGGVR (SEQ ID
NO. 2), GEGDFLAEGGGVR (SEQ ID NO. 3), EGDFLAEGGGVR (SEQ ID NO. 4),
GDFLAEGGGVR (SEQ ID NO. 5), DFLAEGGGVR (SEQ ID NO. 6),
GVLSSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 14), RPPGFSPFR (SEQ ID NO.
19), RPPGFSPF (SEQ ID NO. 20), FLAEGGGVR (SEQ ID NO. 24), LAEGGGVR
(SEQ ID NO. 25), GLEEELQFSLGSKINV (SEQ ID NO. 33), HAAYHPF (SEQ ID
NO. 39), SSSYSKQFTSSTSYNRGDSTFESKSYKMA (SEQ ID NO. 55),
SSSYSKQFTSSTSYNRGDSTFESKSYKM (SEQ ID NO. 56),
SSSYSKQFTSSTSYNRGDSTFESKSY (SEQ ID NO. 57),
SSSYSKQFTSSTSYNRGDSTFESKS (SEQ ID NO. 58), SSYSKQFTSSTSYNRGDSTFE
(SEQ ID NO. 60), or combinations thereof.
[0050] In yet another embodiment, the invention provides an
isolated or identified peptide profile indicating cancer of the
breast comprising an increased amount of peptides or peptide
fragments of GLPGPPDVPDHAAYHPF (SEQ ID NO. 16), RPPGFSPFR (SEQ ID
NO. 19), RPPGFSPF (SEQ ID NO. 20), RNGFKSHALQLNNRQI (SEQ ID NO.
21), NGFKSHALQLNNRQI (SEQ ID NO. 22), GLEEELQFSLGSKINVKVGGNS (SEQ
ID NO. 23), FLAEGGGVR (SEQ ID NO. 24), NGFKSHALQLNNRQ (SEQ ID NO.
30), GLEEELQFSLGSKINVKVGGNSKGTL (SEQ ED NO. 32), GLEEELQFSLGSKINV
(SEQ ID NO. 33), HAAYHPFR (SEQ NO. 34), QLGLPGPPDVPDHAAYHPFR (SEQ
ID NO. 35), SSRQLGLPGPPDVPDHAAYHPF (SEQ ID NO. 38),
NVHSAGAAGSRMNFRPGVLSS (SEQ ID NO. 41), ISASAEELRQRLAPLAEDVRGNL (SEQ
ID NO. 45), AVPPNNSNAAEDDLPTVELQGVVPR (SEQ ID NO. 53),
ALGISPFHEHAEVVFTANDSGPR (SEQ ID NO. 54), SSYSKQFTSSTSYNRGDSTFE (SEQ
ID NO. 60), DEAGSEADHEGTHSTKRGHAKSRPV (SEQ ID NO. 62), or
combinations thereof. In an additional embodiment, the isolated or
identified peptide profile indicating cancer of the breast
comprises a decreased amount of peptides or peptide fragments of
SGEGDFLAEGGGVR (SEQ ID NO. 2), GEGDFLAEGGGVR (SEQ NO. 3),
SSKITHRIHWESASLL (SEQ ID NO. 8), HWESASLL (SEQ NO. 12),
ITHRIHWESASLL (SEQ ID NO. 26), or combinations thereof.
[0051] In one embodiment of the peptide profile of the invention,
the profile is present in an isolated biological sample. In another
embodiment, the identified profile is stored by electronic
means.
[0052] In one aspect, the invention provides a method of generating
a peptide profile of a subject having, or at risk of having, cancer
of the prostate, comprising the steps of:
[0053] i) combining an exogenous peptide including but not limited
to a complement C3f, ITIH4, clusterin, complement C4-alpha,
fibrinopeptide A, kininogen, factor XIII, and fibrinogenA peptide
or a combination thereof with a biological sample from the subject;
and
[0054] ii) proteolytically digesting a peptide of step i),
[0055] thereby generating a peptide profile of the subject.
[0056] In additional embodiments of the invention, the peptide
profile indicates that the subject has or is at risk of having
cancer of the prostate.
[0057] In one aspect, the invention provides a method of generating
a peptide profile of a subject having, or at risk of having, cancer
of the bladder, comprising the steps of:
[0058] i) combining an exogenous peptide including but not limited
to a complement C3f, ITIH4, clusterin, complement C4-alpha,
fibrinopeptide A, bradykinin, APO A-I, APO A-IV, APO E, kininogen,
and fibrinogenA peptide or a combination thereof with a biological
sample from the subject; and
[0059] ii) proteolytically digesting a peptide of step i),
thereby generating a peptide profile of the subject.
[0060] In an additional embodiment of the invention, the peptide
profile indicates that the subject has or is at risk of having
cancer of the bladder.
[0061] In one aspect, the invention provides a method of generating
a peptide profile of a subject having, or at risk of having, cancer
of the breast, comprising the steps of:
[0062] i) combining an exogenous peptide including but not limited
to a ITIH4, bradykinin, complement C4-alpha, fibrinopeptide A,
complement C3f, APO A-IV, factor XIII, transthyretin and
fibrinogenA peptide or a combination thereof with a biological
sample from the subject; and
[0063] ii) proteolytically digesting a peptide of step i),
thereby generating a peptide profile of the subject.
[0064] In an additional embodiment of the invention, the peptide
profile indicates that the subject has or is at risk of having
cancer of the breast.
[0065] In one aspect, the invention is provides a method of
generating a peptide profile of a subject having, or at risk of
having, cancer of the thyroid, comprising the steps of:
[0066] i) combining an exogenous peptide selected from the group
consisting of a fibrinopeptide A, fibrinogenA, complement C3f
peptide and combinations thereof with a biological sample from the
subject, and
[0067] ii) proteolytically digesting a peptide of step i),
thereby generating a peptide profile of the subject.
[0068] In an additional embodiment of the invention, the peptide
profile indicates that the subject has or is at risk of having
cancer of the thyroid.
[0069] In further embodiments of the invention, the exogenous
peptide is labeled with an isotope. In yet further embodiments of
the invention, the biological sample is serum or plasma. In yet
further embodiments of the invention, the exogenous peptide is a
synthetic peptide. In yet further embodiments of the invention, the
exogenous peptide is comprised of D-amino acids. In yet further
embodiments of the invention, the proteolytic digest is analyzed,
for example, using mass spectrometry.
[0070] Methods of the invention can further comprise the step of
obtaining the exogenous peptide.
[0071] In yet another aspect, the invention provides a kit for
generating a peptide profile of a subject having, or at risk of
having, cancer of the bladder, breast, prostate or thyroid
comprising an exogenous peptide or peptide fragment selected from
the group consisting of complement C3f peptide, ITIH4 peptide,
clusterin peptide, complement C4-alpha peptide, fibrinopeptideA
peptide, bradykinin peptide, APO A-I peptide, APOA-IV peptide, APO
E peptide, kininogen peptide, factor XIII peptide, transthyretin
peptide and fibrinogenA peptide and instructions for use and/or a
packaging means thereof.
BRIEF DESCRIPTION OF THE FIGURES
[0072] FIG. 1A shows the color-coding scheme followed in the
representation of data collected for the blood samples from healthy
volunteers (n=33) and from patients with advanced prostate (n=32),
bladder (n=20) and breast (n=21) cancer.
[0073] FIG. 1B shows the results of unsupervised, average-linkage
hierarchical clustering performed using standard correlation as a
distance metrics (`GeneSpring` program), between each cancer group
and the control, in binary format. The entire peak list
(651.times.106) was used. Columns represent samples; rows are
m/z-peaks (i.e., peptides). Dendrogram colors follow the
color-coding scheme of panel A. The heat map scale of normalized
intensities is from 0 (green) to 200 (red), with the midpoint at
100 (yellow).
[0074] FIG. 1C shows the results of hierarchical clustering
performed for the three cancer groups plus control (as in 1B,
above).
[0075] FIG. 1D shows the results of Principal Component Analysis
(PCA) of the three cancer groups plus controls based on the full
peak list. Color-coding is as in panel A. The first three principal
components, accounting for most of the variance in the original
data set are shown.
[0076] FIG. 2A shows pie charts depicting the peak number reduction
in three m/z ranges, which illustrates the impact of each filter on
peptides of different molecular mass.
[0077] FIG. 2B depicts the Venn-diagrams showing the number of
peptides that passed two selection steps. m/z-peaks with higher
intensities in one (or more) of the cancer groups as compared to
controls are shown in the left panel, while those with lower
intensities are shown in the right panel. The numbers shown outside
the diagrams indicate the total number of peptides of a specific
cancer group that were either up or down.
[0078] FIG. 2C shows heat maps comparing the selected features of
the three cancer groups with controls in multi-class and binary
formats. Columns represent samples (as indicated per group); rows
are peptide m/z-peaks (not in numerical order). The number of
peptides used in each binary comparison (i.e., 58, 14, and 14) is
the sum of those that were specifically higher and lower in each
cancer group; the multi-class heat map contains the total,
non-redundant number of peptides (i.e., 68). The `multi-class`,
`bladder` and `breast` heat map scales of normalized intensities
are from 0 (green) to 500 (red), with the midpoint at 250 (yellow);
those of the `prostate` heat map are, respectively, 0, 2,000 and
1,000.
[0079] FIG. 2D depicts overlays of mass spectra obtained from the
three binary comparisons (cancer vs. control). Mono-isotopic masses
are listed for each peak. Two statistically significant differences
in peptide intensities (one higher; one lower) between prostate
cancer (blue) and controls (yellow) are shown, as well as one
higher-intensity peptide for bladder cancer (green) and one for
breast cancer (red).
[0080] FIGS. 3A and 3B show MALDI-TOF mass spectral overlays of
selected peaks derived from serum peptide profiling of three groups
of cancer patients and healthy controls. Each overlay shows a
binary comparison for all spectra from either the bladder cancer
(n=20; green), or prostate cancer (n=32; blue) or breast cancer
patient group (n=21; red) versus the control group (n=33; yellow).
They are arrayed in a way that the same mass range window is shown
for each of the three binary comparisons, in which spectral
intensities were normalized and scaled to the same size, except for
`2021.05`, which is included herein as an example of the vast
majority of peptide-ions with intensities not statistically
different between any two groups. (A) Overlays of mass spectra of
selected peptides of known sequence (see FIG. 3) that showed
statistically significant differences between peak intensities in
one or more of the three binary comparisons. The mono-isotopic mass
(m/z) of the peak is shown for each peptide. (B) Overlays of mass
spectra of some as yet unidentified peptides that also showed
statistically significant differences between peak intensities in
one or more of the three binary comparisons. The bin `name` (a
number that is close to the average isotopic mass) is shown for
each peptide.
[0081] FIG. 4 shows a fragment ion spectrum for MALDI-TOF/TOF MS/MS
identification of serum peptide (SEQ ID NO: 7) 2305.20 as a
fragment of complement 4a. b''- and y''-fragment ion series are
indicated, together with the limited sequences (above arrows). Note
that y''-ions originate at the C-terminus and that the sequence
therefore reads backwards (see direction of the arrows).
[0082] FIG. 5A lists the groups ('ladders') of overlapping
sequences of the peptides identified by MALDI-TOF/TOF MS/MS. Taken
together, 61 peptide-ions on the list have clear peptide-ion marker
potential (adjusted p<0.0002; see FIG. 5B, below) for at least
one type of cancer and are color-coded in blue (prostate cancer),
green (bladder cancer) or red (breast cancer). The resulting
`barcodes` for the three cancer types consist of 26 (prostate), 50
(bladder) and 25 (breast) peptide-ions. Color-coded peptides have
either higher (no dot) or lower (black dot) differential ion
intensities in a particular cohort of cancer samples as compared to
controls. Of the 8 non-markers listed here, full-length C3f
(m/z=2021.05) and one member of the fibrinogen-alpha cluster
(m/z=2553.01) gave comparable ion signals in all patient group and
control sera (see FIG. 5B; FIG. 3, `2021`), and, therefore,
represent virtual internal standards (yellow-coded). Six peptides
(pink-coded) in the clusters were randomly observed in samples of
the cancer and control groups and have neither discriminant nor
internal control value. Note that the measured m/z values, as
listed, are mono-isotopic and, therefore, smaller than the
corresponding average isotopic values in FIG. 13a. Amino acids in
brackets were not experimentally observed but are shown to either
indicate putative full-length sequences of the founders, each
resulting from specific proteolyis of precursor proteins, and/or of
the positions of the putative `trypsin-like` cleavage sites
(Arg/Lys--Xaa). FIG. 5A discloses SEQ ID NOS 116, 1-6, 117-123, 60,
124-127, 8-10, 26, 11, 128, 27, 28, 12, 29, 76-77, 30-31, 78-81,
34-35, 82, 37, 13-14, 38, 15, 83, 16, 39, 84-88, 43, 89-91, 47-48,
92-94, 18-20 and 95-99, respectively, in order of appearance.
[0083] FIG. 5B depicts a table listing additional details of the
identified peptides as m/z values, MS-ion intensities, and
`barcodes` (blue, green or red--as described above). The actual
barcodes (blue, green or red) are composed of entries that showed
clear peptide-ion marker potential (adjusted p<0.0002) for at
least one type of cancer. Adjusted p-value is the overriding
criterion, leading to final barcodes of 26 (prostate), 50 (bladder)
and 25 (breast) peptide-ions. The second column lists median
intensities of each m/z-peak in the control samples. Peak intensity
ratios (columns 3-5) were calculated by dividing the median values
of each m/z-peak in each cancer group by the median value of the
corresponding peak in the control samples. Ratios (r) for the
peptides that are part of one or more barcodes are shaded; dark
grey when the median signal was of higher intensity in a particular
cancer (r.gtoreq.0.6), lighter grey when it was lower
(r.ltoreq.0.66). The significance levels (p values) of three
different one-way ANOVA Mann-Whitney tests (columns 6-8) and of a
multi-class Kluskal-Wallis test (column 9) are given. C3f (coded
yellow) has virtually no discriminant value.
[0084] FIG. 6 shows, in bar graph form, the median intensity for
each serum peptide in each of the three cancer groups (color-coding
as indicated) plotted as the ratio versus the median intensity of
the counterpart in the control group (r=case/control). Ratios are
plotted on a log scale ranging from 0.1 to 10. Bars pointing to the
left (r<1) or right (r>1) indicate, respectively, lower or
higher median intensities in a cancer group as in the control
group. Peptides that didn't show much difference in median ion
intensity between case and control groups map closely to or onto
the centerline (r=1). FIG. 6 discloses SEQ ID NOS 116, 1-6, 24-25,
127, 8-10, 26, 11, 27-28, 12, 21-22, 30-31, 59, 100, 33, 36-37,
13-14, 38, 15-16 and 39, respectively, in order of appearance.
[0085] FIG. 7 shows a flow chart-type diagram delineating the
approach used for development and validation of (i) the
68-peptide-ion signature and (ii) the prostate cancer barcode
consisting of 26 serum peptides with known sequence (blue-coded in
FIG. 5). Numbers that are encircled indicate total number of
selected peptides at that stage of the study.
[0086] FIG. 8A schematically depicts the independent prostate
cancer serum sample groups identified for the validation of the
established biomarkers.
[0087] FIGS. 8B and 8C show the results of Hierarchical Cluster
(HCA) and Principal Component (PCA) Analyses of all spectra from
the Prostate #1 (blue), Prostate #2 (cyan) and control groups
(yellow). Two limited sets of peptide-ions were used for the
analyses: the 68 combined peptides that had statistically
significant differences in intensity for the three binary
comparisons (FIG. 2B; FIG. 17) (left), and the 26 sequenced
peptides that constitute the prostate cancer barcode (color-coded
blue in FIG. 5) (right). The rest of the .about.650 peptide-ions
were ignored for the cluster analysis. Dendrogram colors follow the
color-coding scheme of panel A. The heat map scale of normalized
ion-intensities is from 0 (green) to 2,000 (red), with the midpoint
at 1,000 (yellow). For the PCA, the first three principal
components, accounting for most of the variance in the original
data set, are shown.
[0088] FIG. 8D shows a table listing the results of class
prediction analysis of the prostate cancer validation set (Prostate
#2) using Support Vector Machine (SVM) and either all 651
m/z-values or the 68-, 26-feature sets described above. Analyses
were done using linear kernel. The proportions of correct
predictions are listed. The binomial confidence intervals (at 95%)
were 87.1-99.9% for 40 correct predictions out of 41, and 91.4-100%
for 41/41. The training sets were either Prostate #1 versus control
(`binary`) or the 3 cancer groups (Prostate #1, bladder and breast
cancer) plus controls (`multi-class`).
[0089] FIG. 9 shows MALDI-TOF MS read-outs of fresh plasma (top
panel), indicating very low levels of small peptides, except for
bradykinin and desArg-bradykinin, of an aliquot withdrawn
immediately (i.e., after 15-20 s) after addition of synthetic C3f
(1 pmole/.mu.L plasma) (middle panel, indicating removal of the
C-terminal Arg, by a carboxypeptidase, in a matter of seconds), and
of an aliquot withdrawn after another 15 minutes at room
temperature (lower panel, indicating that C3f is then further
degraded by the activity of aminopeptidases to result in a type of
sequence ladder as endogenously present in serum).
[0090] FIG. 10 schematically depicts the activity of serum
proteases. Amino acids are color-coded to represent sequence
clusters of C3f (left) or FPA (right), which are just two examples
of all the observed clusters.
[0091] FIG. 11A graphically depicts the distribution of serum
peptides. Number of m/z-peaks are plotted as a function of m/z
range. The first bin, from m/z=0 to 700, is empty, as no data was
collected in that region. No bins are shown in the range >10
kDa.
[0092] FIG. 11B likewise graphically depicts the distribution of
serum peptides. Here, however, number of m/z-peaks are plotted as a
function of normalized intensity. No bins are shown in the region
over 1,000 arbitrary units. The highlighted area indicates the
range above the median peak-intensity threshold, used for selecting
potential biomarkers (FIG. 17).
[0093] FIG. 12 depicts a histogram that shows, starting with a
total of 651 unique m/z-peaks (blue bars) derived from three groups
of cancer patients and healthy controls, the number of peptides in
each mass range that passed two filters applied during feature
selection.
[0094] FIG. 13A shows a table listing averages plus (.+-.) standard
deviations and medians (in brackets) of the intensities of each
m/z-peak (i.e., serum peptide) within a particular data set derived
from each of the three cancer patient groups and of the healthy
controls. Intensities refer to normalized units that were
calculated for each peak by dividing its raw intensity by the total
of all of the intensities in that spectrum (TIC--Total Ion Count).
The resultant values were then multiplied by fixed scaling factor
(1.times.10.sup.7) to convert the data to a `user-friendly` scale
(i.e. most values .gtoreq.1).
[0095] FIG. 13B shows a table listing ratios calculated by dividing
the median normalized intensity of each m/z-peak in each cancer
group by the median of the same m/z-peak in the control group. To
avoid having to divide by zero, any median value of less than was
converted to 1. This was applied to all groups. Data for a second,
independent validation set of prostate cancer samples is also
listed.
[0096] FIG. 13C shows a table listing the false discovery rate
adjusted p-values calculated for each m/z-peak using the
Mann-Whitney rank sum test (for binary comparisons) or the
Kruskal-Wallis test (for multi-class comparisons). The group of 68
m/z-peaks listed were derived from the original peak list,
containing normalized ion intensities (and medians within a group,
case/control ratios and adjusted p-values) for each of the 651
m/z-peaks for each of the 106 samples, by applying p-value and
median intensity cut-off filters (p<0.00001; median intensity
.gtoreq.500 `units`). Entries which passed both filters in one or
more cancer groups are color-coded: prostate cancer (14; blue),
breast cancer (14; red) and bladder cancer (58; green).
[0097] FIG. 14 shows a table listing the total serum peptide
sequences, organized per overlapping cluster; with clusters
organized per precursor protein (NCBI ID nos. are given). Positions
in the precursor proteins are indicated. Residues between brackets
were not observed but are listed in the present table to indicate
the putative primary cleavage sites by endoproteases. Additional
information is given, as for instance the relative position of
adjacently located peptides or peptide clusters, identity of
previously known serum peptides (e.g., FPA, C3f), position of
propeptides, and location of C-termini (C-t). Key: Met.sub.ox or
M.sub.ox, oxidized methionine; Pro.sub.hydroxyl, hydroxylated
proline. FIG. 14 discloses SEQ ID NOS 25, 24, 6, 5, 4, 3, 2, 1,
116, 71, 123, 122, 121, 120, 101, 60, 102, 126, 125, 12, 28, 27,
128, 11, 26, 10, 9, 8, 127, 29, 31, 30, 77, 76, 103, 80, 79, 78,
104, 39, 16, 83, 15, 38, 14, 13, 37, 82, 35, 34, 84-85, 89, 88, 43,
87, 86, 90, 48, 105, 91, 47, 106, 107, 93, 92, 18 and 94,
respectively, in order of appearance.
[0098] FIG. 15 shows a table listing the locations of sequenced
serum peptides in the precursor proteins. NCBI ID nos. are given,
as well as the positions of known, processed serum proteins,
peptides and propeptides. The peptide sequences obtained herein are
shown in bold and are underlined. FIG. 15 discloses SEQ ID NOS
108-115, respectively, in order of appearance.
[0099] FIG. 16A shows, in table form, the data set of 651 unique
m/z-peaks derived from MALDI-TOF MS serum peptide profiling of
three groups of cancer patients and healthy controls. Presented are
the averages plus (1) standard deviations and the median values (in
brackets) of the intensities of each m/z-peak (i.e., serum peptide)
within a particular data set derived from each of the three cancer
patient groups and of the healthy controls; a second, independent
validation set of prostate cancer samples is also listed.
Intensities refer to normalized units that were calculated for each
peak by dividing its raw intensity by the total of all the
intensities in that spectrum (TIC--Total Ion Count). The resultant
values were then multiplied by fixed scaling factor
(1.times.10.sup.7) to convert the data to a `user-friendly` scale
(i.e. most values .gtoreq.1).
[0100] FIG. 16B shows, in table form, the data set of 651 unique
m/z-peaks derived from MALDI-TOF MS serum peptide profiling of
three groups of cancer patients and healthy controls.
[0101] FIG. 16C shows, in table form, the data set of 651 unique
m/z-peaks derived from MALDI-TOF MS serum peptide profiling of
three groups of cancer patients and healthy controls.
[0102] FIGS. 17A, 17B, and 17C show, in table form, the data set of
68 putative biomarker m/z-peaks, derived from MALDI-TOF MS serum
peptide profiling of three groups of cancer patients and healthy
controls. The figures contain (i) means plus (.+-.) standard
deviations, and medians (in brackets); (ii) discriminant analysis
false positive rates (p-values); and (iii) ratios of the median
intensities in a group for all 68 m/z-peaks retained after applying
p-value and median intensity cutoff filters (p<0.00001; median
intensity .gtoreq.500 units). All values were extracted from FIGS.
16A-C, above. Entries which passed both filters in one or more
cancer groups are color-coded: prostate cancer (14; blue), breast
cancer (14; red) and bladder cancer (58; green).
[0103] FIG. 18 shows SEQ ID NO:63, GENBANK Accession No. AAH00664,
C3F protein (Homo sapiens), amino acid residues 1-436.
[0104] FIG. 19 shows SEQ ID NO:64, GENBANK Accession No. Q14624,
Inter-alpha-trypsin inhibitor heavy chain H4 precursor (ITI heavy
chain H4) (Homo sapiens), amino acid residues 1 to 930, wherein
29-661="70 kDa inter-alpha-trypsin inhibitor heavy chain H4" and
689-930="35 kDa inter-alpha-trypsin inhibitor heavy chain H4."
[0105] FIG. 20 shows SEQ ID NO:65, GENBANK Accession No. AAP88927,
clusterin (complement lysis inhibitor (Homo sapiens), amino acid
residues 1 to 447.
[0106] FIG. 21 shows SEQ ID NO:66, GENBANK Accession No. AAR89159,
C4A (Homo sapiens), amino acid residues 1 to 534.
[0107] FIG. 22 shows SEQ ID NO:67, GENBANK Accession No.
NP.sub.--068657, fibrinogen, alpha chain isoform alpha
preproprotein (Homo sapiens), amino acid residues 1 to 644, wherein
20-35 product="fibrinopeptide A."
[0108] FIG. 23 shows SEQ ID NO:68, GENBANK Accession No. P01042,
kininogen precursor (Alpha-2-thiol proteinase inhibitor) (Homo
sapiens), amino acid residues 1 to 644, wherein
381-389="Bradykinin."
[0109] FIG. 24 shows SEQ ID NO:69, GENBANK Accession No.
NM.sub.--021871, Homo sapiens fibrinogen alpha chain (FGA),
transcript variant alpha, mRNA.
[0110] FIG. 25 shows SEQ ID NO:70, GENBANK Accession No.
NM.sub.--000039, Homo sapiens apolipoprotein A-I (APOA1), mRNA.
[0111] FIG. 26 shows SEQ ID NO:71, GENBANK Accession No.
NM.sub.--000482, Homo sapiens apolipoprotein A-IV (APOA4),
mRNA.
[0112] FIG. 27 shows SEQ ID NO:72, GENBANK Accession No. NM 000041,
Homo sapiens apolipoprotein E (APOE), mRNA.
[0113] FIG. 28 shows SEQ ID NO:73, GENBANK Accession No.
NM.sub.--000893, Homo sapiens kininogen (KNG1).
[0114] FIG. 29 shows SEQ ID NO:74, GENBANK Accession No.
NM.sub.--000129, Homo sapiens coagulation factor XIII, A1
polypeptide (F13A1), mRNA.
[0115] FIG. 30 shows SEQ ID NO:75, GENBANK Accession No.
NM.sub.--000371, Homo sapiens transthyretin (prealbumin,
amyloidosis type I)(TTR), mRNA.
[0116] FIG. 31 shows, in table form, 66 reference peptides. All
amino acids are D-stereo-isomers, except for the isotope-containing
(L-isomer). Isotope-labeled amino acids: L, .sup.13C(6)-Leu; F,
.sup.13C(6-ring)-Phe; V, .sup.13C(5)/.sup.15N(1)-Val. (Note:
isotope labels result in a molecular mass increase by 6 Da for each
peptide). Surrogate marker code: P, prostate cancer; B, breast
cancer; BL, bladder cancer; T, thyroid cancer; +, median ion
intensity of this particular peptide in MALDI-TOF MS is higher in
cancer samples than in controls; -, median ion intensity lower in
cancer than controls. FIG. 31 discloses SEQ ID NOS 24-25, 6, 5, 4,
3, 2, 1, 116, 61, 58, 57, 56, 55, 60, 62, 12, 28, 27, 75, 11, 26,
10, 9, 8, 129, 130, 31, 30, 22, 77, 33, 23, 32, 39, 131-132, 16,
83, 15, 38, 14, 13, 133, 35, 34, 40-41, 44, 42-43, 45, 48, 46-47,
50, 49, 18, 17, 134, 20, 19, 52, 51 and 53-54, respectively, in
order of appearance.
[0117] FIG. 32 shows the MALDI-based, relative quantitation of
serum peptides: A, normalized ion intensities as spectral overlays
and B, as a heat plot. C shows the relative quantitation of
normalized ion intensities in bar graph form. FIG. 32B discloses
SEQ ID NOS 27, 11, 10, 9, 8 and 12, respectively, in order of
appearance.
[0118] FIG. 33 shows, in table form, founder peptides. Total 15
syntheses, including 2 (#7 and 11) or more multi-samplings;
cleavages, purifications, QC and quantitation. Isotope-labeled
amino acids: L, .sup.13C(6)-Leu; F, .sup.13C(6-ring)-Phe; V,
.sup.13C(5)/.sup.15N(1)-Val; A, .sup.13C(3)/.sup.15N(1)-Ala;
resulting in molecular mass increase of 12 Da per peptide. FIG. 33
discloses SEQ ID NOS 116, 55, 135, 127, 77, 136, 137-141, 35,
142-143, 43, 47, 17, 134 and 144-145, respectively, in order of
appearance.
[0119] FIG. 34A shows median ion intensities in MALDI spectra taken
of breast cancer sera vs. control sera. FIG. 34B shows selected
views of isotopically resolved or partially resolved peptide-ion
peaks; red, breast cancer; black, controls. FIG. 34 discloses SEQ
ID NOS 127, 8-10, 26, 11, 27-28, 12 and 146-148, respectively, in
order of appearance.
[0120] FIG. 35 shows ten peptide-triplets and plots of the ratios
between exogenously derived peptides and reference peptide
calculated. Inset is a small section of the MALDI spectrum showing
the position of the monoisotopic envelopes for each of the three
iso-peptides. FIG. 34 discloses SEQ ID NOS 127, 8-10, 26, 11,
27-28, 12 and 146-148, respectively, in order of appearance.
DETAILED DESCRIPTION OF THE INVENTION
I. Definitions
[0121] Unless defined otherwise, all technical and scientific terms
used herein have the meaning commonly understood by a person
skilled in the art to which this invention belongs. As used herein,
the following terms have the meanings ascribed to them unless
specified otherwise.
[0122] A "subject" is a vertebrate, preferably a mammal, more
preferably a primate and still more preferably a human. Mammals
include, but are not limited to, primates, humans, farm animals,
sport animals, and pets.
[0123] As used herein, "serum" refers to the fluid portion of the
blood obtained after removal of the fibrin clot and blood cells,
distinguished from the plasma in circulating blood. As used herein,
"plasma" refers to the fluid, noncellular portion of the blood,
distinguished from the serum obtained after coagulation.
[0124] As used herein, "sample" or "biological sample" refers to
anything, which may contain an analyte (e.g., peptide) for which an
analyte assay is desired. The sample may be a biological sample,
such as a biological fluid or a biological tissue. Examples of
biological fluids include urine, blood, plasma, serum, saliva,
semen, stool, sputum, cerebral spinal fluid, tears, mucus, amniotic
fluid or the like. Biological tissues are aggregates of cells,
usually of a particular kind including, for example, connective,
epithelium, muscle and nerve tissues. Examples of biological
tissues also include organs, tumors, lymph nodes, arteries and
individual cell(s).
[0125] The term "isolated" refers to one or more compositions
obtained from and/or contained in a sample apart from the body.
[0126] The term "identified" as in an "identified peptide" or
"peptide profile" refers to one or more compositions or information
relating thereto (e.g., a peptide and its amino acid sequence
information) obtained under conditions of selection. Such
information may optionally be stored by electronic means.
[0127] As used herein, the terms "gene" and "recombinant gene"
refer to nucleic acid molecules comprising an open reading frame
encoding a marker protein.
[0128] "Gas phase ion spectrometer" refers to an apparatus that
detects gas phase ions. Gas phase ion spectrometers include an ion
source that supplies gas phase ions. Gas phase ion spectrometers
include, for example, mass spectrometers, ion mobility
spectrometers, and total ion current measuring devices. "Gas phase
ion spectrometry" refers to the use of a gas phase ion spectrometer
to detect gas phase ions.
[0129] "Mass spectrometer" refers to a gas phase ion spectrometer
that measures a parameter that can be translated into
mass-to-charge ratios of gas phase ions. Mass spectrometers
generally include an ion source and a mass analyzer. Examples of
mass spectrometers are time-of-flight, magnetic sector, quadrupole
filter, ion trap, ion cyclotron resonance, electrostatic sector
analyzer and hybrids of these. "Mass spectrometry" refers to the
use of a mass spectrometer to detect gas phase ions.
[0130] "Laser desorption mass spectrometer" refers to a mass
spectrometer that uses laser energy as a means to desorb,
volatilize, and ionize an analyte.
[0131] "Tandem mass spectrometer" refers to any mass spectrometer
that is capable of performing two successive stages of m/z-based
discrimination or measurement of ions, including ions in an ion
mixture. The phrase includes mass spectrometers having two mass
analyzers that are capable of performing two successive stages of
m/z-based discrimination or measurement of ions tandem-in-space.
The phrase further includes mass spectrometers having a single mass
analyzer that is capable of performing two successive stages of
m/z-based discrimination or measurement of ions tandem-in-time. The
phrase thus explicitly includes Qq-TOF mass spectrometers, ion trap
mass spectrometers, ion trap-TOF mass spectrometers, TOF-TOF mass
spectrometers, Fourier transform ion cyclotron resonance mass
spectrometers, electrostatic sector--magnetic sector mass
spectrometers, and combinations thereof.
[0132] "Mass analyzer" refers to a sub-assembly of a mass
spectrometer that comprises means for measuring a parameter that
can be translated into mass-to-charge ratios of gas phase ions. In
a time-of-flight mass spectrometer the mass analyzer comprises an
ion optic assembly, a flight tube and an ion detector.
[0133] The term "MALDI" is used herein to refer to Matrix-Assisted
Laser Desorption/Ionization, a process wherein analyte is embedded
in a solid or crystalline "matrix" of light-absorbing molecules
(e.g., nicotinic, sinapinic, or 3-hydroxypicolinic acid), then
desorbed by laser irradiation and ionized from the solid phase into
the gaseous or vapor phase, and accelerated as intact molecular
ions towards a detector. The "matrix" is typically a small organic
acid mixed in solution with the analyte in a 10,000:1 molar ratio
of matrix/analyte. The matrix solution can be adjusted to neutral
pH before use.
[0134] The term "MALDI-TOF MS" is used herein to refer to
Matrix-Assisted Laser Desorption/Ionization Time-of-Flight mass
spectrometry.
[0135] The term "MALDI ionization surface" is used herein to refer
to a surface for presentation of matrix-embedded analyte into a
mass spectrometer for MALDI. In general, the terms "probe" or
"probe element" are used interchangeably to refer to a device for
presenting analyte into a mass spectrometer for irradiation and
desorption. Metals such as gold, copper and stainless steel are
typically used to form MALDI ionization surfaces. However, other
commercially-available inert materials (e.g., glass, silica, nylon
and other synthetic polymers, agarose and other carbohydrate
polymers, and plastics) can be used where it is desired to use the
surface to actively capture an analyte or as a reaction zone for
chemical modification of the analyte.
[0136] "Solid support" refers to a solid material, which can be
derivatized with, or otherwise attached to, a capture reagent.
Exemplary solid supports include probes, microtiter plates and
chromatographic resins.
[0137] "Eluant" or "wash solution" refers to an agent, typically a
solution, which is used to affect or modify adsorption of an
analyte to an adsorbent surface and/or remove unbound materials
from the surface. The elution characteristics of an eluant can
depend on, for example, pH, ionic strength, hydrophobicity, degree
of chaotropism, detergent strength and temperature.
[0138] "Monitoring" refers to recording changes in a continuously
varying parameter (e.g. monitoring progression of a cancer).
[0139] "Biochip" refers to a solid substrate having a generally
planar surface to which an adsorbent is attached. Frequently, the
surface of the biochip comprises a plurality of addressable
locations, each of which location has the adsorbent bound there.
Biochips can be adapted to engage a probe interface, and therefore,
function as probes.
[0140] "Protein biochip" refers to a biochip adapted for the
capture of polypeptides.
[0141] The terms "polypeptide," "peptide" and "protein" are used
interchangeably herein to refer to a polymer of amino acid
residues. The terms apply to amino acid polymers in which one or
more amino acid residue is an analog or mimetic of a corresponding
naturally occurring amino acid, as well as to naturally occurring
amino acid polymers. Polypeptides can be modified, e.g., by the
addition of carbohydrate residues to form glycoproteins. The terms
"polypeptide," "peptide" and "protein" include glycoproteins, as
well as non-glycoproteins.
[0142] An "exogenous peptide" is a peptide obtained from a
biological source that is external to the subject's body or by
synthetic means.
[0143] The terms "peptide", "peptide marker", "marker" and
"biomarker" are used interchangeably in the context of the present
invention and refer to a polypeptide which is differentially
present in a sample taken from subjects having human cancer as
compared to a comparable sample taken from control subjects (e.g.,
a person with a negative diagnosis or undetectable cancer, normal
or healthy subject). The markers are identified by molecular mass
in Daltons, and include the masses centered around the identified
molecular masses for each marker.
[0144] The term "detecting" means methods which include identifying
the presence or absence of marker(s) in the sample, quantifying the
amount of marker(s) in the sample, and/or qualifying the type of
biomarker. Detecting includes identifying the presence, absence or
amount of the object to be detected (e.g. a serum peptide
marker).
[0145] "Diagnostic" means identifying the presence or nature of a
pathologic condition, i.e., cancer. While a particular diagnostic
method may not provide a definitive diagnosis of a condition, it
suffices if the method provides a positive indication that aids in
diagnosis.
[0146] As used herein, the term "sensitivity" is the percentage of
marker-detected subjects with a particular disease.
[0147] As used herein, the term "specificity" is the percentage of
subjects correctly identified as having a particular disease i.e.,
normal or healthy subjects. For example, the specificity is
calculated as the number of subjects with a particular disease as
compared to non-cancer subjects (e.g., normal healthy
subjects).
[0148] The phrase "differentially present" refers to differences in
the quantity and/or the frequency of a marker present in a sample
taken from subjects having human cancer as compared to a control
subject. For example, serum peptide markers described herein are
present at an elevated level in samples of subjects compared to
samples from control subjects. In contrast, other markers described
herein are present at a decreased level in samples of cancer
subjects compared to samples from control subjects. Furthermore, a
marker can be a polypeptide, which is detected at a higher
frequency or at a lower frequency in samples of human cancer
subjects compared to samples of control subjects. A marker can be
differentially present in terms of quantity, frequency or both. A
polypeptide is differentially present between two samples if the
amount of the polypeptide in one sample is statistically
significantly different from the amount of the polypeptide in the
other sample. Alternatively or additionally, a polypeptide is
differentially present between two sets of samples if the frequency
of detecting the polypeptide in the cancer subjects' samples is
statistically significantly higher or lower than in the control
samples.
[0149] "Optional" or "optionally" means that the subsequently
described feature or structure may or may not be present in the
analysis system or that the subsequently described event or
circumstance may or may not occur, and that the description
includes instances where said feature or structure is present and
instances where the feature or structure is absent, or instances
where the event or circumstance occurs and instances where it does
not.
[0150] The term "obtaining" as in "obtaining the exogenous peptide"
is intended to include purchasing, synthesizing or otherwise
acquiring the exogenous (or indicated substance or material).
[0151] The terms "comprises", "comprising", and the like are
intended to have the broad meaning ascribed to them in U.S. Patent
Law and can mean "includes", "including" and the like.
[0152] It is to be understood that this invention is not limited to
the particular component parts of a device described or process
steps of the methods described, as such devices and methods may
vary. It is also to be understood that the terminology used herein
is for purposes of describing particular embodiments only, and is
not intended to be limiting. As used in the specification and the
appended claims, the singular forms "a", "an", and "the" include
plural referents unless the context clearly indicates otherwise.
Thus, for example, reference to "an analyte" includes mixtures of
analytes, reference to "a MALDI ionization surface" includes two or
more such ionization surfaces, reference to "a microchannel"
includes more than one such component, and the like. Furthermore,
reference to "cancer" may signify cancer in general (i.e., cancer
of any type) or cancer of a specific type. Accordingly, the
description herein of a subject as having no detectable cancer may
signify a subject in which a specific type of cancer (for example,
bladder) is not detectable. However, such a description may not
necessarily signify that the subject has no type of cancer
whatsoever.
[0153] Other definitions appear in context throughout the
specification.
II. Methods and Peptide Profiles of the Invention
[0154] The present invention provides peptide markers generated
from comparisons of protein profiles from subjects diagnosed with
cancer and from subjects without known neoplastic diseases. In
particular, the invention provides that these markers, used
individually or in combination with other markers, provide a method
of diagnosing and monitoring cancer in a subject having cancer of
the prostate, of the bladder, or of the breast.
[0155] Markers that are differentially present in samples of cancer
subjects and control subjects find application in methods and kits
for determining cancer status. Accordingly, methods are provided
for identifying cancer of the prostate, bladder, or breast in a
subject comprising detecting a differential presence of a biomarker
in subjects with cancer of the prostate, bladder, or breast vs.
without cancer of the prostate, bladder, or breast in a biological
sample obtained from the subject. The amount of one or more
biomarkers found in a test sample compared to a control, or the
presence or absence of one or more markers in the test sample
provides useful information regarding the cancer status of the
patient.
[0156] A. Types of Samples
[0157] The markers can be measured in different types of biological
samples. The sample is preferably a biological fluid sample.
Examples of a biological fluid sample useful in this invention
include blood, blood serum, plasma, vaginal secretions, urine,
tears, saliva, urine, tissue, cells, organs, seminal fluids, bone
marrow, cerebrospinal fluid, nipple aspirate, etc. Blood serum is a
preferred sample source for embodiments of the invention.
[0158] If desired, the sample can be prepared to enhance
detectability of the markers. For example, to increase the
detectability of markers, a blood serum sample from the subject can
be preferably fractionated by, e.g., Cibacron blue agarose
chromatography and single stranded DNA affinity chromatography,
anion exchange chromatography, affinity chromatography (e.g., with
antibodies) and the like. The method of fractionation depends on
the type of detection method used. Any method that enriches for the
protein of interest can be used. Typically, preparation involves
fractionation of the sample and collection of fractions determined
to contain the biomarkers. Methods of pre-fractionation include,
for example, size exclusion chromatography, ion exchange
chromatography, heparin chromatography, affinity chromatography,
sequential extraction, gel electrophoresis and liquid
chromatography. The analytes also may be modified prior to
detection. These methods are useful to simplify the sample for
further analysis. For example, it can be useful to remove high
abundance proteins, such as albumin, from blood before
analysis.
[0159] B. Detection of Serum Peptide Markers
[0160] Serum Peptide Marker Modification
[0161] A marker can be modified before analysis to improve its
resolution or to determine its identity. For example, the markers
may be subject to proteolytic digestion before analysis. Any
protease can be used. Proteases, such as trypsin, that are likely
to cleave the markers into a discrete number of fragments are
particularly useful. The fragments that result from digestion
function as a fingerprint for the markers, thereby enabling their
detection indirectly. This is particularly useful where there are
markers with similar molecular masses that might be confused for
the marker in question. Also, proteolytic fragmentation is useful
for high molecular weight markers because smaller markers are more
easily resolved by mass spectrometry. In specific embodiments, the
proteases occur or naturally exist in the biological sample.
[0162] To improve detection resolution of the markers,
neuraminidase can, for instance, be used to remove terminal sialic
acid residues from glycoproteins to improve binding to an anionic
adsorbent (e.g., cationic exchange ProteinChip.RTM. arrays) and to
improve detection resolution. In another example, the markers can
be modified by the attachment of a tag of particular molecular
weight that specifically bind to molecular markers, further
distinguishing them. Optionally, after detecting such modified
markers, the identity of the markers can be further determined by
matching the physical and chemical characteristics of the modified
markers in a protein database (e.g., SwissProt).
[0163] It has been found that proteins frequently exist in a sample
in a plurality of different forms characterized by a detectably
different mass. These forms can result from either, or both, of
pre- and post-translational modification. Pre-translational
modified forms include allelic variants, slice variants and RNA
editing forms. Post-translationally modified forms include forms
resulting from proteolytic cleavage (e.g., fragments of a parent
protein), glycosylation, phosphorylation, lipidation, oxidation,
methylation, cystinylation, sulphonation and acetylation. Modified
forms of any marker of this invention also may be used, themselves,
as biomarkers. In certain cases the modified forms may exhibit
better discriminatory power in diagnosis than the specific forms
set forth herein.
[0164] Serum Peptide Marker Purification
[0165] For some of the method embodiments of the invention, it may
be helpful to purify the marker detected by the methods disclosed
herein prior to subsequent analysis. Nearly any means known to the
art for the purification and separation of small molecular weight
substances, e.g., anion or cation exchange chromatography, gas
chromatography, liquid chromatography or high pressure liquid
chromatography may be used. Methods of selecting suitable
separation and purification techniques and means of carrying them
out are known in the art (see, e.g., Labadarious et. al., J.
Chromatography (1984) 310:223-231, and references cited therein;
and Shahrokhin and Gehrke, J. Chromatography (1968) 36:31-41, and
Niessen J. Chromatography (1998) 794:407-435).
[0166] In another embodiment of the method of the invention,
purification of the marker comprises fractioning a sample
comprising one or more protein markers by size-exclusion
chromatography and collecting a fraction that includes the one or
more marker; and/or fractioning a sample comprising the one or more
markers by anion exchange chromatography and collecting a fraction
that includes the one or more markers. Fractionation is monitored
for purity on phase and immobilized nickel arrays. Generating data
on immobilized marker fractions on an array is accomplished by
subjecting the array to laser ionization and detecting intensity of
signal for mass/charge ratio; and transforming the data into
computer readable form. Preferably, fractions are subjected to gel
electrophoresis and correlated with data generated by mass
spectrometry. In one aspect, gel bands representative of potential
markers are excised and subjected to enzymatic treatment and are
applied to biochip arrays for peptide mapping.
[0167] Methods of Detection
[0168] Any suitable method can be used to detect one or more of the
markers described herein. Successful practice of the invention can
be achieved with one or a combination of methods that can detect
and, preferably, quantify the markers. These methods include,
without limitation, hybridization-based methods including those
employed in biochip arrays, mass spectrometry (e.g., laser
desorption/ionization mass spectrometry), fluorescence (e.g.
sandwich immunoassay), surface plasmon resonance, ellipsometry and
atomic force microscopy. Methods may further include, by one or
more of electrospray ionization mass spectrometry (ESI-MS),
ESI-MS/MS, ESI-MS/(MS).sup.n, matrix-assisted laser desorption
ionization time-of-flight mass spectrometry (MALDI-TOF-MS),
surface-enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF-MS), desorption/ionization on silicon
(DIOS), secondary ion mass spectrometry (SIMS), quadrupole
time-of-flight (Q-TOF), atmospheric pressure chemical ionization
mass spectrometry (APCI-MS), APCI-MS/MS, APCI-(MS).sup.n,
atmospheric pressure photoionization mass spectrometry (APPI-MS),
APPI-MS/MS, and APPI-(MS).sub.n, quadrupole mass spectrometry,
fourier transform mass spectrometry (FTMS), and ion trap mass
spectrometry, where n is an integer greater than zero.
[0169] Biochip-Based Methods
[0170] Detection methods may include use of a biochip array.
Biochip arrays useful in the invention include protein and nucleic
acid arrays. One or more markers are captured on the biochip array
and subjected to laser ionization to detect the molecular weight of
the markers. Analysis of the markers is, for example, by molecular
weight of the one or more markers against a threshold intensity
that is normalized against total ion current.
[0171] The biochip surfaces may, for example, be ionic, anionic,
hydrophobic; comprised of immobilized nickel or copper ions,
comprised of a mixture of positive and negative ions; and/or
comprised of one or more antibodies, single or double stranded
nucleic acids, proteins, peptides or fragments thereof; amino acid
probes, or phage display libraries. Many protein biochips are
described in the art. These include, for example, protein biochips
produced by Ciphergen Biosystems (Fremont, Calif.), Packard
BioScience Company (Meriden Conn.), Zyomyx (Hayward, Calif.) and
Phylos (Lexington, Mass.). Examples of such protein biochips are
described in the following patents or patent applications: U.S.
Pat. No. 6,225,047 (Hutchens and Yip, "Use of retentate
chromatography to generate difference maps," May 1, 2001);
International publication WO 99/51773 (Kuimelis and Wagner,
"Addressable protein arrays," Oct. 14, 1999); U.S. Pat. No.
6,329,209 (Wagner et al., "Arrays of protein-capture agents and
methods of use thereof," Dec. 11, 2001) and International
publication WO 00/56934 (Englert et al., "Continuous porous matrix
arrays," Sep. 28, 2000).
[0172] Markers may be captured with capture reagents immobilized to
a solid support, such as a biochip, a multiwell microtiter plate, a
resin, or nitrocellulose membranes that are subsequently probed for
the presence of proteins. Capture can be on a chromatographic
surface or a biospecific surface. For example, a sample containing
the markers, such as serum, may be placed on the active surface of
a biochip for a sufficient time to allow binding. Then, unbound
molecules are washed from the surface using a suitable eluant, such
as phosphate buffered saline. In general, the more stringent the
eluant, the more tightly the proteins must be bound to be retained
after the wash.
[0173] Upon capture on a biochip, analytes can be detected by a
variety of detection methods selected from, for example, a gas
phase ion spectrometry method, an optical method, an
electrochemical method, atomic force microscopy and a radio
frequency method. Gas phase ion spectrometry methods are described
herein. Of particular interest is the use of mass spectrometry, and
in particular, SELDI. Optical methods include, for example,
detection of fluorescence, luminescence, chemiluminescence,
absorbance, reflectance, transmittance, birefringence or refractive
index (e.g., surface plasmon resonance, ellipsometry, a resonant
mirror method, a grating coupler waveguide method or
interferometry). Optical methods include microscopy (both confocal
and non-confocal), imaging methods and non-imaging methods.
Immunoassays in various formats (e.g., ELISA) are popular methods
for detection of analytes captured on a solid phase.
Electrochemical methods include voltammetry and amperometry
methods. Radio frequency methods include multipolar resonance
spectroscopy.
[0174] Mass Spectrometry-Based Methods
[0175] Mass spectrometry (MS) is a well-known tool for analyzing
chemical compounds. Thus, in one embodiment, the methods of the
present invention comprise performing quantitative MS to measure
the serum peptide marker. The method may be performed in an
automated (Villanueva, et al., Nature Protocols (2006)
1(2):880-891) or semi-automated format. This can be accomplished,
for example with MS operably linked to a liquid chromatography
device (LC-MS/MS or LC-MS) or gas chromatography device (GC-MS or
GC-MS/MS). Methods for performing MS are known in the field and
have been disclosed, for example, in US Patent Application
Publication Nos: 20050023454; 20050035286; U.S. Pat. No. 5,800,979
and references disclosed therein.
[0176] The protein fragments, whether they are peptides derived
from the main chain of the protein or are residues of a side-chain,
are collected on the collection layer. They may then be analyzed by
a spectroscopic method based on matrix-assisted laser
desorption/ionization (MALDI) or electrospray ionization (ESI). The
preferred procedure is MALDI with time of flight (TOF) analysis,
known as MALDI-TOF MS. This involves forming a matrix on the
membrane, e.g. as described in the literature, with an agent which
absorbs the incident light strongly at the particular wavelength
employed. The sample is excited by UV, or IR laser light into the
vapour phase in the MALDI mass spectrometer. Ions are generated by
the vaporization and an ion plume. The ions are accelerated in an
electric field and separated according to their time of travel
along a given distance, giving a mass/charge (m/z) reading which is
very accurate and sensitive. MALDI spectrometers are commercially
available from PerSeptive Biosystems, Inc. (Frazingham, Mass., USA)
and are described in the literature, e.g. M. Kussmann and P.
Roepstorff, cited above.
[0177] Magnetic-based serum processing can be combined with
traditional MALDI-TOF. Through this approach, improved peptide
capture is achieved prior to matrix mixture and deposition of the
sample on MALDI target plates. Accordingly, methods of peptide
capture are enhanced through the use of derivatized magnetic bead
based sample processing.
[0178] MALDI-TOF MS allows scanning of the fragments of many
proteins at once. Thus, many proteins can be run simultaneously on
a polyacrylamide gel, subjected to a method of the invention to
produce an array of spots on the collecting membrane, and the array
may be analyzed. Subsequently, automated output of the results is
provided by using the ExPASy server, as at present used for
MIDI-TOF MS and to generate the data in a form suitable for
computers.
[0179] Other techniques for improving the mass accuracy and
sensitivity of the MALDI-TOF MS can be used to analyze the
fragments of protein obtained on the collection membrane. These
include the use of delayed ion extraction, energy reflectors and
ion-trap modules. In addition, post source decay and MS--MS
analysis are useful to provide further structural analysis. With
ESI, the sample is in the liquid phase and the analysis can be by
ion-trap, TOF, single quadrupole or multi-quadrupole mass
spectrometers. The use of such devices (other than a single
quadrupole) allows MS--MS or MS.sup.n analysis to be performed.
Tandem mass spectrometry allows multiple reactions to be monitored
at the same time.
[0180] Capillary infusion may be employed to introduce the marker
to a desired MS implementation, for instance, because it can
efficiently introduce small quantities of a sample into a mass
spectrometer without destroying the vacuum. Capillary columns are
routinely used to interface the ionization source of a MS with
other separation techniques including gas chromatography (GC) and
liquid chromatography (LC). GC and LC can serve to separate a
solution into its different components prior to mass analysis. Such
techniques are readily combined with MS, for instance. One
variation of the technique is that high performance liquid
chromatography (HPLC) can now be directly coupled to mass
spectrometer for integrated sample separation/and mass spectrometer
analysis.
[0181] Quadrupole mass analyzers may also be employed as needed to
practice the invention. Fourier-transform ion cyclotron resonance
(FTMS) can also be used for some invention embodiments. It offers
high resolution and the ability of tandem MS experiments. FTMS is
based on the principle of a charged particle orbiting in the
presence of a magnetic field. Coupled to ESI and MALDI, FTMS offers
high accuracy with errors as low as 0.001%.
[0182] In one embodiment, the marker qualification methods of the
invention may further comprise identifying significant peaks from
combined spectra. The methods may also further comprise searching
for outlier spectra. In another embodiment, the method of the
invention further comprises determining distant dependent K-nearest
neighbors.
[0183] In another embodiment of the method of the invention, an ion
mobility spectrometer can be used to detect and characterize serum
peptide markers. The principle of ion mobility spectrometry is
based on different mobility of ions. Specifically, ions of a sample
produced by ionization move at different rates, due to their
difference in, e.g., mass, charge, or shape, through a tube under
the influence of an electric field. The ions (typically in the form
of a current) are registered at the detector which can then be used
to identify a marker or other substances in a sample. One advantage
of ion mobility spectrometry is that it can operate at atmospheric
pressure.
[0184] For the mass values of the markers disclosed herein, the
mass accuracy of the spectral instrument is considered to be about
within +/-0.15 percent of the disclosed molecular weight value.
Additionally, to such recognized accuracy variations of the
instrument, the spectral mass determination can vary within
resolution limits of from about 400 to 1000 m/dm, where m is mass
and dm is the mass spectral peak width at 0.5 peak height. Mass
accuracy and resolution variances and thus meaning of the term
"about" with respect to the mass of each of the markers described
herein is inclusive of variants of the markers as may exist due to
sex, genotype and/or ethnicity of the subject and the particular
cancer or origin or stage thereof.
[0185] In an additional embodiment of the methods of the present
invention, multiple markers are measured. The use of multiple
markers increases the predictive value of the test and provides
greater utility in diagnosis, toxicology, patient stratification
and patient monitoring. The process called "Pattern recognition"
detects the patterns formed by multiple markers greatly improves
the sensitivity and specificity of clinical proteomics for
predictive medicine. Subtle variations in data from clinical
samples indicate that certain patterns of protein expression can
predict phenotypes such as the presence or absence of a certain
disease, a particular stage of cancer-progression, or a positive or
adverse response to drug treatments.
[0186] C. Data Analysis
[0187] Data generated by desorption and detection of markers can be
analyzed using any suitable means. In one embodiment, data is
analyzed and/or stored by electronic means, such as with the use of
a programmable digital computer. The computer program generally
contains a readable medium that stores codes. Certain code can be
devoted to memory that includes the location of each feature on a
probe, the identity of the adsorbent at that feature and the
elution conditions used to wash the adsorbent. The computer also
contains code that receives as input, data on the strength of the
signal at various molecular masses received from a particular
addressable location on the probe. This data can indicate the
number of markers detected, including the strength of the signal
generated by each marker.
[0188] Data analysis can include the steps of determining signal
strength (e.g., height of peaks) of a marker detected and removing
"outliers" (data deviating from a predetermined statistical
distribution). The observed peaks can be normalized, a process
whereby the height of each peak relative to some reference is
calculated. For example, a reference can be background noise
generated by instrument and chemicals (e.g., energy absorbing
molecule) which is set as zero in the scale. Then the signal
strength detected for each marker or other biomolecules can be
displayed in the form of relative intensities in the scale desired
(e.g., 100). Alternatively, a standard (e.g., a serum protein) may
be admitted with the sample so that a peak from the standard can be
used as a reference to calculate relative intensities of the
signals observed for each marker or other markers detected.
[0189] The computer can transform the resulting data into various
formats for displaying, such as "spectrum view or retentate map,"
"peak map," "gel view," "3-D overlays," "difference map view," and
Spotfire Scatter Plot. For each sample, markers that are detected
and the amount of markers present in the sample can be saved in a
computer readable medium. This data can then be compared to a
control (e.g., a profile or quantity of markers detected in
control, e.g., subjects in whom human cancer is undetectable).
[0190] When the sample is measured and data is generated, e.g., by
mass spectrometry, the data is then analyzed by a computer software
program. Generally, the software can comprise code that converts
signal from the mass spectrometer into computer readable form. The
software also can include code that applies an algorithm to the
analysis of the signal to determine whether the signal represents a
"peak" in the signal corresponding to a marker of this invention,
or other useful markers. The software also can include code that
executes an algorithm that compares signal from a test sample to a
typical signal characteristic of "normal" and human cancer and
determines the closeness of fit between the two signals. The
software also can include code indicating which the test sample is
closest to, thereby providing a probable diagnosis.
[0191] TOF-to-M/Z transformation involves the application of an
algorithm that transforms times-of-flight into mass-to-charge ratio
(M/Z). In this step, the signals are converted from the time domain
to the mass domain. That is, each time-of-flight is converted into
mass-to-charge ratio, or M/Z. Calibration can be done internally or
externally. In internal calibration, the sample analyzed contains
one or more analytes of known M/Z. Signal peaks at times-of-flight
representing these massed analytes are assigned the known M/Z.
Based on these assigned M/Z ratios, parameters are calculated for a
mathematical function that converts times-of-flight to M/Z. In
external calibration, a function that converts times-of-flight to
M/Z, such as one created by prior internal calibration, is applied
to a time-of-flight spectrum without the use of internal
calibrants.
[0192] Baseline subtraction improves data quantification by
eliminating artificial, reproducible instrument offsets that
perturb the spectrum. It involves calculating a spectrum baseline
using an algorithm that incorporates parameters such as peak width,
and then subtracting the baseline from the mass spectrum.
[0193] High frequency noise signals are eliminated by the
application of a smoothing function. A typical smoothing function
applies a moving average function to each time-dependent bin. In an
improved version, the moving average filter is a variable width
digital filter in which the bandwidth of the filter varies as a
function of, e.g., peak bandwidth, generally becoming broader with
increased time-of-flight. See, e.g., WO 00/70648, Nov. 23, 2000
(Gavin et al., "Variable Width Digital Filter for Time-of-flight
Mass Spectrometry").
[0194] As mentioned briefly above, analysis generally involves the
identification of peaks in the spectrum that represent signal from
an analyte. Peak data from one or more spectra can be subject to
further analysis by, for example, creating a spreadsheet in which
each row represents a particular mass spectrum, each column
represents a peak in the spectra defined by mass, and each cell
includes the intensity of the peak in that particular spectrum.
Various statistical or pattern recognition approaches can applied
to the data.
[0195] The spectra that are generated in embodiments of the
invention can be classified using a pattern recognition process
that uses a classification model. In some embodiments, data derived
from the spectra (e.g., mass spectra or time-of-flight spectra)
that are generated using samples such as "known samples" can then
be used to "train" a classification model. A "known sample" is a
sample that is pre-classified (e.g., cancer or not cancer). The
data that are derived from the spectra and are used to form the
classification model can be referred to as a "training data set".
Once trained, the classification model can recognize patterns in
data derived from spectra generated using unknown samples. The
classification model can then be used to classify the unknown
samples into classes. This can be useful, for example, in
predicting whether or not a particular biological sample is
associated with a certain biological condition (e.g., diseased vs.
non diseased).
[0196] The classification models can be formed on and used on any
suitable digital computer. The digital computer that is used may be
physically separate from the mass spectrometer that is used to
create the spectra of interest, or it may be coupled to the mass
spectrometer.
[0197] MALDI-TOF MS-Based Quantitative Profiling
[0198] Relative quantitation of serum peptides of interest can be
done by comparing the MS-ion intensities to those of added,
exogenous, isotopically labeled, reference peptides, having the
exact same sequence and otherwise same chemical properties as the
endogenous ones (i.e. distinguishable by molecular mass only). As
such, all peptide pairs will display the exact same MALD-ionization
characteristics. Comparing ion intensities will therefore provide a
means of normalizing the values for each peptide. For instance,
when the ion intensity of peptide A is two-fold higher than the
spiked reference in sample X but two-fold lower in sample Y, then
the difference would be about 4-fold between the same peptide in
the two samples. When done on a systematic, larger scale, this
approach can be referred to as relative "quantitative" profiling.
Of note, the reference peptides will be added to the raw serum
(i.e., before peptide extraction and MALDI sample prep), so that
putative losses during processing are accounted for.
[0199] 66 reference peptides (listed in FIG. 31) can be
synthesized, 44 of which have been determined to be surrogate
markers for either prostate or breast cancer, 18 additional ones
for bladder or thyroid cancer, and 4 non-marker control peptides.
These reference peptides should not degrade in serum, and are,
thus, synthesized using D-amino acids (i.e., D-stereo-isomers). One
amino acid (Leu, Val, or Phe) of each reference peptide is labeled
by incorporation of 6 (L, F) or 5 (V) .sup.13C isotopes, and one
additional .sup.15N isotope (V only). .sup.13C-labeled, FMOC-amino
acids (for solid phase-peptide synthesis) are only commercially
available in the L-form, which should not compromise stability as
peptide bonds between a D- and L-amino acids are not protease
sensitive.
[0200] MALDI-TOF MS-Based Protease Assays
[0201] A large part of the human serum `peptidome`, as detected by
MALDI-TOF MS, is generated ex vivo (i.e., after blood collection)
by protease degradation of blood proteins. Endoproteases produce
`founder peptides` which are then pared down by exoproteases into
ladder-like clusters. Panels of proteolytic activity in the blood
contribute important cancer type-specific information, and that the
resulting metabolic patterns have utility as surrogate markers for
detection and classification of cancer. Degradation occurs during
clotting. The use of exogenous synthetic peptides, identical to
previously observed founder peptides, can be used to monitor
cancer-specific proteolytic degradation in plasma or serum that
contains proteases. Conditions in terms of time, temperature and
added amounts of substrates can hereby be readily controlled.
Coupled to a MALDI-based read-out, such analyses are blood
"protease assays" to monitor the tumor-dependent activities
inferred from prior studies. Simultaneous addition of
non-degradable, exogenous reference peptides also enables relative
quantitation of all rungs in the ladders.
[0202] Exogenous peptide degradation assays can be done, for
example, in plasma, where there are no endogenous peptides that
clutter the spectra, therefore simplifying interpretation. Thus, in
addition to serving as (i) an alternative to endogenous serum
peptide profiling, and as (ii) a highly reproducible, functional
proteomics approach, the external peptide degradation assay (iii)
permit analysis of plasma by the NY consortium, which is important
as plasma is preferred by many for proteomic studies.
[0203] 15 founder peptides (listed in FIG. 33) can be synthesized,
all `double-isotopically` labeled to be 12 Da heavier in molecular
mass than their endogenous counterparts and 6 Da heavier than the
non-degradable reference peptides. Selection is based on a sequence
comparison of all previously observed peptide ladders in serum,
most of which contain some known surrogate marker peptides.
Synthesis, QC, quantitation and storage of the peptides will be
done as described previously.
[0204] The degradation conditions and times are studied and
optimized for each of the 15 synthetic founder peptides in each of
the plasmas from the different groups of cancer patients and
controls. The permissible inter-mixability of the different
founders, and, particularly, of their resulting degradation ladders
is determined in order to avoid disturbing the peak patterns (by
ion suppression effects) and to avoid overlapping isotopic
envelopes (when the peaks are too close).
[0205] As aminopeptidases come in varieties that remove one two or
three amino acids, shorter endogenous peptides may have conceivably
been derived from another precursor by leapfrogging over the
stalled position. For non-degradable "founder" peptides, limited
N-terminal ladders can be synthesized (by sequential sampling of
resin during a pilot scale synthesis of unlabeled peptides), for
instance, as shown in FIG. 33 (founder #7; five alternative `test`
founder peptides), and degradability can be tested in pooled cancer
patient plasma in a time course (15 min to 4 hours) experiment.
Similar tests are performed for founder peptides 8, 9, 10 and 12A
in FIG. 33. Each time, synthesis is carried out of the
"full-length" founder, but resin sampled at 5, 4, 3, 2 and 1 amino
acid away from the N-terminus, or as appropriate. The longest
peptide is cleaved from the resin, purified, and tested. If no
degradation in plasma is observed, the shorter versions are also
cleaved, purified and tested. An isotope-labeled version of the
peptide with the best founder properties (i.e., generating the best
ladder in plasma) is then produced.
[0206] The assay may be divided into `founder pools` if two or more
time points are too far apart or in the case of peptide
inter-mixability problems. Once the ideal conditions and founder
pools have been selected, and the resulting degradation products
are identified, a relative quantitation aspect can be added to the
blood protease assay by using the same non-degradable reference
peptides as shown in FIG. 31.
[0207] D. Diagnosis
[0208] As indicated above, the invention provides methods for
aiding a human cancer diagnosis using one or more markers, as
specified herein. These markers can be used alone, in combination
with other markers in any set, or with entirely different markers
in aiding human cancer diagnosis. The markers are differentially
present in samples of a human cancer patient and a normal subject
in whom human cancer is undetectable. For example, some of the
markers are expressed at an elevated level and/or are present at a
higher frequency in human prostate cancer subjects than in normal
subjects, while some of the markers are expressed at a decreased
level and/or are present at a lower frequency in human prostate
cancer subjects than in normal subjects. Therefore, detection of
one or more of these markers in a person would provide useful
information regarding the probability that the person may have
prostate cancer.
[0209] The detection of the peptide marker is then correlated with
a probable diagnosis of cancer. In some embodiments, the detection
of the mere presence or absence of a marker, without quantifying
the amount thereof, is useful and can be correlated with a probable
diagnosis of cancer. The measurement of markers may also involve
quantifying the markers to correlate the detection of markers with
a probable diagnosis of cancer. Thus, if the amount of the markers
detected in a subject being tested is different compared to a
control amount (i.e., higher or lower than the control, depending
on the marker), then the subject being tested has a higher
probability of having cancer.
[0210] The correlation may take into account the amount of the
marker or markers in the sample compared to a control amount of the
marker or markers (up or down regulation of the marker or markers)
(e.g., in normal subjects or in non-cancer subjects such as where
cancer is undetectable). A control can be, e.g., the average or
median amount of marker present in comparable samples of normal
subjects in normal subjects or in non-cancer subjects such as where
cancer is undetectable. The control amount is measured under the
same or substantially similar experimental conditions as in
measuring the test amount. As a result, the control can be employed
as a reference standard, where the normal (non-cancer) phenotype is
known, and each result can be compared to that standard, rather
than re-running a control.
[0211] Accordingly, a marker profile may be obtained from a subject
sample and compared to a reference marker profile obtained from a
reference population, so that it is possible to classify the
subject as belonging to or not belonging to the reference
population. The correlation may take into account the presence or
absence of the markers in a test sample and the frequency of
detection of the same markers in a control. The correlation may
take into account both of such factors to facilitate determination
of cancer status.
[0212] In certain embodiments of the methods of qualifying cancer
status, the methods further comprise managing subject treatment
based on the status. The invention also provides for such methods
where the markers (or specific combination of markers) are measured
again after subject management. In these cases, the methods are
used to monitor the status of the cancer, e.g., response to cancer
treatment, remission of the disease or progression of the
disease.
[0213] The markers of the present invention have a number of other
uses. For example, they can be used to monitor responses to certain
treatments of human cancer. In yet another example, the markers can
be used in heredity studies. For instance, certain markers may be
genetically linked. This can be determined by, e.g., analyzing
samples from a population of human cancer subjects whose families
have a history of cancer. The results can then be compared with
data obtained from, e.g., cancer subjects whose families do not
have a history of cancer. The markers that are genetically linked
may be used as a tool to determine if a subject whose family has a
history of cancer is pre-disposed to having cancer.
[0214] Any marker, individually, is useful in aiding in the
determination of cancer status. First, the selected marker is
detected in a subject sample using the methods described herein
(e.g. mass spectrometry). Then, the result is compared with a
control that distinguishes cancer status from non-cancer status. As
is well understood in the art, the techniques can be adjusted to
increase sensitivity or specificity of the diagnostic assay
depending on the preference of the diagnostician.
[0215] While individual markers are useful diagnostic markers, in
some instances, a combination of markers provides greater
predictive value than single markers alone. The detection of a
plurality of markers (or absence thereof, as the case may be) in a
sample can increase the percentage of true positive and true
negative diagnoses and decrease the percentage of false positive or
false negative diagnoses. Thus, preferred methods of the present
invention comprise the measurement of more than one marker.
[0216] E. Kits
[0217] In one aspect, the invention provides kits for monitoring
and diagnosing cancer, wherein the kits can be used to detect the
markers described herein. For example, the kits can be used to
detect any one or more of the markers potentially differentially
present in samples of cancer subjects vs. normal subjects. The kits
of the invention have many applications. For example, the kits can
be used to differentiate if a subject has cancer or has a negative
diagnosis, thus aiding a cancer diagnosis. In another embodiment,
the invention provides kits for aiding the diagnosis of cancer or
the diagnosis of a specific type of cancer such as, for example,
cancer of the prostate, of the bladder, or of the breast. The kits
can also be used to identify compounds that modulate expression of
one or more of the herein-described markers in in vitro or in vivo
animal models for cancer.
[0218] In specific embodiments, kits of the invention contain an
exogenous reference peptide, which is optionally isotopically
labeled, for use in conducting the diagnostic assays of the
invention.
[0219] The kits of the invention may include instructions for the
assay, reagents, testing equipment (test tubes, reaction vessels,
needles, syringes, etc.), standards for calibrating the assay,
and/or equipment provided or used to conduct the assay. Reagents
may include acids, bases, oxidizing agents, marker species. The
instructions provided in a kit according to the invention may be
directed to suitable operational parameters in the form of a label
or a separate insert.
[0220] The kits may also include an adsorbent, wherein the
adsorbent retains one or more markers selected from one or more of
the markers described herein, and written instructions for use of
the kit for detection of cancer. Such a kit could, for example,
comprise: (a) a substrate comprising an adsorbent thereon, wherein
the adsorbent is suitable for binding a marker, and (b)
instructions to detect the marker or markers by contacting a sample
with the adsorbent and detecting the marker or markers retained by
the adsorbent. Accordingly, the kit could comprise (a) a DNA probe
that specifically binds to a marker; and (b) a detection reagent.
Such a kit could further comprise an eluant (as an alternative or
in combination with instructions) or instructions for making an
eluant, wherein the combination of the adsorbent and the eluant
allows detection of the markers using gas phase ion
spectrometry.
[0221] Optionally, the kit may further comprise a standard or
control information so that the test sample can be compared with
the control infatuation standard to determine if the test amount of
a marker detected in a sample is a diagnostic amount consistent
with a diagnosis of cancer.
[0222] This invention is further illustrated by the following
examples, which should not be construed as limiting. A skilled
artisan should readily understand that other similar instruments
with equivalent function/specification, either commercially
available or user modified, are suitable for practicing the instant
invention. Rather, the invention should be construed to include any
and all applications provided herein and all equivalent variations
within the skill of the ordinary artisan.
EXAMPLES
Example 1
Unsupervised Hierarchical Clustering and PCA of Mass
Spectrometry-Based Serum Peptide Profiling Data
[0223] In order to determine if selected patterns of serum peptides
with known sequences can (i) separate cancer from non-cancer, (ii)
distinguish between different types of solid tumors, and (iii)
allow class prediction with an independent validation set, the
serum peptide profiles were analyzed from patients with advanced
prostate, breast, or bladder cancer, as well as control sera from
healthy volunteers, all collected using a standardized protocol
(Villanueva, J., et al., 2005. J Proteome Res: 4:1060-1072).
[0224] A. Methods
[0225] Serum Samples
[0226] Blood samples from n=33 healthy volunteers (mixed gender;
ages 23 to 49) with no known malignancies and from patients
diagnosed with advanced prostate cancer (n=32), bladder cancer
(n=20), or breast cancer (n=21) were collected following a standard
clinical protocol (Villanueva, J., et al., 2005. J Proteome Res:
4:1060-1072) and approved by the MSKCC Institutional Review and
Privacy Board. Blood samples were obtained in 8.5-mL, BD
Vacutainer, glass `red-top` tubes (Becton Dickinson # 366430,
Franklin Lakes, N.J.), allowed to clot at room temperature for 1
hour, and centrifuged at 1400-2000 RCF for 10 min, at RT.
[0227] Sera (upper phase) were transferred to four 4-mL cryovials
(Fisher # 0566966), .about.1 mL serum in each, and stored frozen at
-80.degree. C. until further use (Villanueva, J., et al. 2005. J
Proteome Res: 4:1060-1072). A similar procedure was followed for
preparation of plasma in heparin-containing `green-top` tubes (BD
#366480), except that centrifugation was done immediately after
blood collection. Upon delivery at the mass spectrometry (MS)
laboratory, the cryovials (source vials) were barcoded. One
cryovial of each sample was thawed on ice and used to generate nine
smaller aliquots (50 .mu.L each) in barcoded micro-eppendorf tubes
and stored at -80.degree. C. in barcoded freezer boxes. In the
present study, every serum sample underwent two freeze/thaw cycles,
the second thawing step occurring immediately prior to peptide
extraction and MS analysis.
[0228] All 106 serum samples were processed automatically as a
single batch with a robot liquid handler followed within one hour
by automated MALDI-TOF mass spectrometric analysis. The four
clinical groups were randomized before automated solid-phase
peptide extraction and MALDI-TOF mass spectrometry.
[0229] Automated, Solid-Phase Peptide Extraction
[0230] Serum peptide profiling was accomplished using a technology
platform developed for simultaneous measurement of large numbers of
serum polypeptides (Villanueva, J., et al. 2004. Anal Chem
76:1560-1570). It uses magnetic bead-based, solid-phase extraction
of predominantly small peptides followed by a MALDI-TOF MS
read-out. The system is intrinsically more sensitive than any
surface capture on chips, as spherical particles have larger
combined surface areas than small-diameter spots. When combined
with high-resolution MS, hundreds of peptides are detected in a
single droplet of serum.
[0231] For the present analysis, peptides were captured and
concentrated using SiMAG-C8/K superparamagnetic, silica-based
particles (micron diameter; 80% iron oxide; non-porous), bearing C8
reversed-phase (RP) ligands (Chemicell, Berlin, Germany). All
analyses were performed in a 96-well format, using the same batch
of C8 magnetic particles, in 0.2-mL polypropylene tubes
(8.times.12-tube `Temp Plate II`; USA Scientific, Ocala, Fla.).
[0232] The protocol is based on a detailed investigation of serum
handling, RP ligand and eluant selection (Villanueva, J., et al.
2004. Anal Chem 76:1560-1570), and is automated using a `Genesis
Freedom 100` (Tecan; Research Triangle Park, N.C.) liquid handling
workstation for throughput and reproducibility. The system was
programmed either directly via its standard software or, when
individual wells needed to be accessed independently, indirectly
through its work-lister capability. This system automates all of
the liquid-handling steps, including magnetic separation via a
robotic manipulating arm, mixing of eluates with MALDI matrix and
deposition onto the Bruker 384-spot MALDI target plates. A computer
randomization program was used to position case and control samples
for both solid-phase extraction and mass spectrometry.
[0233] Mass Spectrometry
[0234] Peptide profiles were analyzed with an Autoflex MALDI-TOF
mass spectrometer (Bruker; Bremen, Germany) equipped with a 337 nm
nitrogen laser, a gridless ion source, delayed-extraction (DE)
electronics, a high-resolution timed ion selector (TIS), and a 2
GHz digitizer. Separate spectra were obtained for two restricted
mass-to-charge (m/z) ranges, corresponding to polypeptides with
molecular mass of 0.7-4 kDa (".ltoreq.4 kD") and 4-15 kDa
(".gtoreq.4 kD") (assuming z=1), under specifically optimized
instrument settings. Each spectrum was the result of 400 laser
shots, per m/z segment per sample, delivered in four sets of 100
shots (at 50-Hz frequency) to each of four different locations on
the surface of the matrix spot.
[0235] The peak list (normalized intensities of 651 m/z-peaks,
i.e., peptide-ions, in all 106 samples) generated was subjected to
a Mann-Whitney U test, for each of the cancer groups individually
versus the control. In a first selection, 196 peaks with adjusted
p-values <0.00001 (arbitrarily chosen) for at least one cancer
type were retained. This number was reduced to 68 by applying an
arbitrary threshold (500 `units`) to the median intensities of each
individual peptide peak within a group. An m/z-peak was selected if
it passed the threshold in at least one of the cancer groups or the
control (FIG. 13).
[0236] A weekly performance test was carried out with commercial
human reference serum (# S-7023, lot 034K8937; Sigma, St Louis,
Mo.), and the effective laser energy delivered to the target was
adjusted when necessary. The entire irradiation program was
automated using the instrument's `AutoXecute` function. Spectra
were acquired in linear mode geometry under 20 kV (18.6 kV during
DE) of ion accelerating and -1.3 kV multiplier potentials, and with
gating of mass ions .ltoreq.400 m/z (.ltoreq.4 kD segment) or
.ltoreq.3,000 m/z (.gtoreq.4 kD segment). DE was maintained for 80
(.ltoreq.4 kD) or 50 nanoseconds (.gtoreq.4 kD) to give appropriate
time-lag focusing after each laser shot.
[0237] Peptide samples were consistently mixed with two volumes of
pre-made a-cyano-4-hydroxycinnamic acid (ACCA) matrix solution
(Agilent; Palo Alto, Calif.), deposited onto the stainless steel
target surface, in every other column of the 384-spot layout, and
allowed to dry at room temperature. Thirty fmoles (per peptide) and
500 fmoles (per protein) of commercially available calibration
standards (Bruker Daltonics # 206195 (<4 kD) and # 206355 (>4
kD)) were also mixed with ACCA matrix and separately deposited onto
the target plates, adjacent to each spotted serum sample (one
sample/one standard), in the alternating columns. All spectra were
acquired within less than 1-2 hours after completion of robotic
sample processing, as an adverse effect had previously been
observed upon increasing times between crystallization and mass
spectral acquisition.
[0238] The AutoFlex MALDI-TOF has a probe at the output of the
laser, before the attenuator. The accuracy of this monitoring
device was verified prior to the calibration of the settings of the
attenuator (displayed on the computer screen as an arbitrary scale
of 100-0%) by measuring transmitted energy at varying %. This
allowed the generation of a calibration curve to convert
before-to-after attenuation laser energy. The optimal laser setting
that had been empirically determined was then measured to yield
16-.mu.J energy per pulse, post-attenuation. Laser output energy
was measured and documented on a weekly basis, and adjustments were
made accordingly to compensate for fading laser energy over
time.
[0239] Samples from patients with different cancers and from
controls were randomly distributed during processing and
analysis.
[0240] Signal Processing
[0241] Once acquired, all data were stored with a naming convention
that allows each sample to be associated with its calibrant. The
spectra were first converted from binary format to ASCII files
containing two columns of data (x: m/z, y: intensity) by a custom
written macro in FlexAnalysis (Bruker). For the lower mass range
(700-4,000 Da), about 48,000 x,y-points were generated, while for
the upper mass range (4-15 kDa), there were about 77,000
points.
[0242] Further data processing was carried out in MATLAB with a
custom script called `Qcealign` using only the ASCII versions of
the raw spectra. `Qcealign` used the `Qpeaks` program (Spectrum
Square Associates, Ithaca, N.Y.) for smoothing, baseline
subtraction and peak labeling. The singletwidth parameter required
by `Qpeaks` was set to -400 for the lower mass range and -200 for
the upper mass range, thereby specifying the resolution,
(m/z)/.DELTA.(m/z), for processing. This peak information was used
automatically by `Qpeaks` in setting the parameters for smoothing,
baseline-subtraction, and binning. The noise statistics were
assumed `Normal`.
[0243] Following parameter selection, a setup file was created.
`Qcealign` then queries the setup file to obtain a list of all the
directories for processing. During a single processing run, all
data files in all listed directories are aligned with each other.
For each directory, singletwidth information is provided in the
setup file, along with parameters controlling calibration, peak
labeling sensitivity, alignment, etc. The files containing the
polypeptide standards are calibrated first. The centroid positions
of peaks in these calibration files are obtained from the peak
table created by `Qpeaks`, compared to the known polypeptide peak
positions, and a quadratic calibration equation for correcting the
measured masses in each calibration file is created. The
calibration equations are saved to disk for use in calibrating the
mass axes of the sample files.
[0244] `Qcealign` subsequently creates a reference file to which
all sample spectra will later be aligned. The first data file is
loaded and calibrated by applying the curve calculated from its
associated calibrant spectrum. This file's x-axis (m/z) becomes the
x-axis (and thus the calibration) used in the reference file.
`Qcealign` then loads all other sample files, calibrates them, and
adds their intensities to the reference file's intensity. After all
samples have been added, the reference spectrum becomes the average
of all the sample files. The reference is processed with `Qpeaks`
to find a baseline, which is subtracted, and is then normalized to
unit size by dividing each intensity value by the Total Ion Count
(TIC). Once normalized, a scaling factor is added by multiplying
each intensity value by a user-selected number (e.g., 10.sup.7).
This scaling factor is constant within a data set and is used to
convert the normalized spectrum to a "user friendly" scale, where
most peak heights are greater than one. Next, `Qcealign` processes
each sample file with `Qpeaks` to create a peak table, smoothed
curve and a baseline. This spectrum is then taken for
alignment.
[0245] Alignment
[0246] Processed spectra were aligned using the custom `Entropycal`
program described herein above. A custom alignment algorithm,
`Entropycal`, aligns sample data files to a reference file using a
minimum entropy algorithm by taking unsmoothed (`raw`)
baseline-corrected data. Taking raw spectra for alignment
facilitates the use of all statistical information in the data;
processed data contains less information. The alignment is
performed in two steps: `Entropycal` and binning. `Entropycal`
slides each data file by `n` data points to the right or left along
the x-axis of the reference file. At each relative position n, the
Shannon entropy of the sum of the two files is computed. The
optimal alignment occurs at the shift that produces the minimum
Shannon entropy. Second, the aligned peak lists are binned by using
the resolution of the peaks: all peaks in rows within .DELTA.(m/z)
of the strongest peak at a given value of m/z are binned together,
and a spreadsheet is created for further statistical analysis.
[0247] Three software modules, developed in MATLAB, were used for
visualization and signal processing of the spectra. (I) Signal
Processing & Preview (SPP), a graphical viewer for spectra in
ASCII format, allows to plot raw and processed spectra side-by-side
to review the outcome of signal processing. Furthermore, parameters
of `Qpeaks` (the signal processing software) can be adjusted. (II)
Mass Spectra Viewer (MSV), a visual interface for processed
spectral data, plots spectra as X-Y curves (mass vs. magnitude) for
examining the signatures of several groups of samples. MSV supports
regular browsing functions such as scroll, zoom, highlighting, etc.
(III) HeatMap (HM) displays spectra as a 2D heat map images, in
which the magnitude of the peaks are color-coded on a continuous
scale. In addition to browsing functions such as zoom and scroll,
the rank of X- and Y-position coordinates can be reorganized
without the constraints of statistical correlation that are
enforced by most HeatMap commercial software packages.
[0248] Ratios were calculated by dividing the median normalized
intensity of each m/z-peak in each cancer group by the median of
the same m/z-peak in the control group. To avoid having to divide
by zero, any median value of less than was converted to 1; this was
applied to all groups. For hierarchical clustering, the 651
m/z-values were subjected to average-linkage hierarchical
clustering analysis using the available algorithm in `GeneSpring`.
The peaks were organized by creating mock-phylogenetic trees
(dendrograms) termed `gene trees` and `experiment tree` in the
software. The trees were displayed with the samples along the
X-axis and the masses along the Y-axis. The clustering method for
both trees also measured similarity by Standard Correlation (also
known as `Pearson correlation around zero`) as the distance
matrix.
[0249] A spreadsheet (`peak list`), containing the normalized
intensities of all 651 peaks for each of the samples was taken for
unsupervised, average-linkage hierarchical clustering using
standard correlation. This resulted in a high degree of separation
between each of the cancer types and the controls in either binary
or multi-class comparisons (FIGS. 1B and 1C). Recognizing that
correlations between patient samples involving 651 features would
be difficult at different times and locations, statistical feature
selection was performed to identify the most discriminant
peaks.
[0250] The binned spreadsheet, containing data from spectra
obtained for all samples of cancer patients or healthy subjects
(106 samples total; 651 m/z values, with normalized intensities for
each sample; >70,000 data points), as well as the test set for
prostate (`Prostate #2`; 41 samples; .about.27,000 data points),
were imported into the `GeneSpring` program (Agilent; Palo Alto,
Calif.) and analyzed using various statistical algorithms, such as
one-way ANOVA, PCA, hierarchical clustering, K-NN and SVM.
[0251] Different "experiments" were created in `GeneSpring` to
represent the masses. No normalizations were applied to the
experiment, since the masses were normalized by the database that
binned them. In the parameter section of the experiments, a
parameter called `cancertype` was created to label samples as
prostate cancer, breast cancer, bladder cancer, or control. In the
Experiment's Interpretation section, the Analysis mode was set to
"Ratio (signal/control)", and all measurements were used. No
Cross-Gene Error model was used.
[0252] For ANOVA, once the experiments were created, the m/z-values
(`peaks`) were filtered by using non-parametric tests: Mann-Whitney
test (for binary comparisons) and Kluskal-Wallis test (for
multi-class comparisons) with Benjamini and Hochberg False
Discovery Rate at p<1e-5. These tests are meant to find peaks
that show statistically significant differences between the
clinical groups studied.
[0253] For class prediction, K-nearest-neighbor (K-NN) analysis and
Support Vector Machine (SVM) were carried out by using the Class
Prediction Tool in `GeneSpring`. The training groups constituted
either a binary comparison (prostate #1 and Control) or a
multi-class comparison (prostate #1, breast, bladder and control).
The test set was `prostate #2`. The Parameter to Predict was set to
Cancertype. The Gene selection was set to use different groups of
masses previously selected (e.g., 651, 68, 14, 13). In K-NN, the
number of neighbors was set to five with a p-value decision cutoff
of 1. The SVM was done with the same training sets and parameters
and set to predict the Prostate #2 test set. The kernel used was
polynomial dot product (Order 1) with a diagonal scaling of 0.
[0254] B. Results
[0255] 1. Distribution of Serum Peptides, Detected by MALDI-TOF MS,
as a Function of Mass-to-Charge (m/z) Range and Normalized
Intensity.
[0256] Peptides were extracted from 106 different serum samples (50
.mu.L), drawn from one of three groups of cancer patients or
healthy controls, analyzed by MALDI-TOF MS and the m/z-peaks were
exported from the aligned spectra, as described earlier. In FIG.
11A, a total of 651 unique m/z-peaks, i.e., peptide-ions, derived
from the combined spectra, are grouped in successive bins of 250
amu, starting at m/z=700.
[0257] In FIG. 11B, all peak intensities of all samples (i.e.,
651.times.106 peaks) are grouped in successive bins of 100
arbitrary units, starting at zero. The intensities refer to
normalized units that were calculated for each peak by dividing its
raw intensity by the total of all the intensities in that spectrum
(TIC--Total Ion Count). The resultant values were then multiplied
by fixed scaling factor (1.times.10.sup.7) to convert the data to a
`user-friendly` scale (i.e. most values .gtoreq.1) Serum peptide
profiling resulted in a total of 651 distinct mass/charge (m/z)
values resolved in the 800-15,000 Dalton range (FIG. 16A).
[0258] 2. Serum Peptides, Determined by MALDI-OF MS, Before and
after Two Successive Feature Selection Steps for Candidate
Markers.
[0259] One-way ANOVA Mann-Whitney test, for each individual cancer
versus control, selected 196 peaks (red bars, FIG. 12) with a false
positive rate of p<0.00001 (arbitrarily chosen) for at least one
cancer type. This number was further reduced to 68 (yellow bars,
FIG. 12) by applying an arbitrary threshold of 500 `units` to the
median intensities of each individual peptide peak within a group.
The threshold was set high enough to select only robust peaks in
the spectra, with intensities that would permit MALDI MS/MS-based
tandem mass spectrometric sequencing and to exclude closely
positioned neighboring peaks or `shoulders`.
[0260] An m/z-peak was selected if this criterion was met in at
least one of the cancer groups or the control (FIG. 13). When
feature selection was repeated using a multi-class Kluskal-Wallis
test (adjusted p<1e-5) and the same median intensity threshold
as above, 214 and 67 peaks were selected (data not shown). The
majority of selected peaks corresponded to peptides with molecular
mass <2,000 Da; most peptides with a mass >4,000 Da were
removed (FIG. 2A; FIG. 13). Thus, significance levels (p-values)
were calculated for each m/z-peak using the Mann-Whitney rank sum
test (for binary comparisons) or the Kruskal-Wallis test (for
multi-class comparisons) (FIG. 16B).
Example 2
Feature Selection and Comparative Analysis of Serum Peptide
Profiling Data
[0261] Feature Selection
[0262] The peak list (normalized intensities of 651 m/z-peaks in
all 106 samples), generated as described in Example 1, above, was
subjected to one-way ANOVA Mann-Whitney test for each of the three
previously identified cancer groups individually vs. the control.
For each of the three cancer groups versus the control, 196 peaks
with a p-value <1e-5 were arbitrarily selected and retained
(FIG. 12). This number was subsequently reduced to 68 by applying
an arbitrary threshold (500 `units`) to the median intensities of
each individual peptide peak within a group. The threshold was set
high enough to only select robust peaks in the spectra, with
intensities that would permit MALDI TOF/TOF-based tandem mass
spectrometric sequencing and to exclude closely positioned
neighboring peaks or `shoulders`. An m/z peak was selected if it
passed the threshold in at least one of the cancer groups or the
control.
[0263] The pie-charts depicted in FIG. 2A illustrate the effect of
using a significance level (p<0.00001) cutoff by itself, or in
combination with a cutoff for the median of normalized intensities
(.gtoreq.500) within any one group, on the m/z distribution of the
candidate biomarker peptides. After the first filter, the 196
remaining peptides were redistributed in groups of 92, 76 and 28
for the increasing mass ranges. Sixty eight peptides passed the
second filter; 39, 22 and merely 7 in the low-, medium- and
high-mass ranges, respectively (right panel, FIG. 2A).
[0264] Examples are shown in FIGS. 2D and 3. The majority of the
selected peaks corresponded to peptides with molecular mass
<2,000 Da; most peptides with a mass >4,000 Da were
eliminated (FIGS. 12 and 2A). Color-coded spectra from all samples
were subsequently overlaid to visually inspect the 68 peaks for
correct assignment, degree of separation, and overall difference
between cancer and control. Of the peptides that passed the
above-delineated two selection steps, 47 m/z peaks had higher
intensities in one or more of the cancer groups, as compared to the
controls, and 23 had lower intensities, as compared with the
control. Of those, two were higher in breast cancer but lower in
bladder cancer.
[0265] The total numbers of peptides of a specific cancer group
that were observed to be up or down (have specific biomarker
potential) were as follows: 3 peptides were up and 11 down (14
total--1 unique, 3 shared) in serum samples from prostate cancer
patients, 12 up/2 down (14 total--11 unique) in breast cancer, and
36 up/22 down (58 total--43 unique) in bladder cancer (FIG.
2B).
[0266] Comparative analysis via heat map display and mass spectral
overlay: Comparison of the selected features (Tables 17A-C) of the
three cancer groups with controls in multi-class and binary formats
was accomplished with heat maps. Heat map displays were generated
using a MATLAB custom software tool.
[0267] Three software modules, developed in MATLAB, were used for
visualization and signal processing of the spectra. (I) Signal
Processing & Preview (SPP), a graphical viewer for spectra in
ASCII format, allows the plotting of raw and processed spectra
side-by-side to review the outcome of signal processing.
Furthermore, parameters of `Qpeaks` (the signal processing
software) can be adjusted. (II) Mass Spectra Viewer (MSV), a visual
interface for processed spectral data, plots spectra as X-Y curves
(mass vs. magnitude) for examining the signatures of several groups
of samples. MSV supports regular browsing functions such as scroll,
zoom, highlighting, etc. (III) HeatMap (HM) displays spectra as 2D
heat map images, in which the magnitude of the peaks are
color-coded on a continuous scale. In addition to browsing
functions such as zoom and scroll, the rank of X- and Y-position
coordinates can be reorganized without the constraints of
statistical correlation that are enforced by most HeatMap
commercial software packages.
[0268] The results, when represented in the form of heat maps in
FIG. 2C, indicated that data reduction (by .about.90%) did not
adversely affect the separation of the clinical groups.
[0269] Subsequently, mass spectra for the three binary comparisons
(cancer vs. control) were processed as described earlier and
displayed using Mass Spectra Viewer (MSV) (FIG. 2C).
Example 3
Serum Peptide Barcodes for Advanced Prostate, Bladder, and Breast
Cancer
[0270] A. Methods
[0271] Assigning Peptide Sequences
[0272] A set of peptides previously selected on the basis of
statistical differences in intensity between cancers and control
groups was analyzed by MALDI-TOF/TOF tandem mass spectrometry,
using an UltraFlex TOF/TOF instrument (Bruker; Bremen, Germany)
operated in `LIFT` mode. The mono-isotopic masses were first
assigned by one-dimensional reflectron-TOF MS, in the presence of
three peptide calibrants (6 (moles each; calculated monoisotopic
masses of 2,108.155 Da, 1,307.762 Da and 969.575 Da in the
protonated form), as previously described (Winkler, G. S., et al;
2002, Methods 26:260-269).
[0273] Spectra were obtained by averaging multiple signals; laser
irradiance and number of acquisitions (typically 100-150) were
operator-adjusted to yield maximal peak deflections derived from
the digitizer in real time. Mono-isotopic masses were assigned for
all selected and other prominent peaks after visual inspection, and
the low- and high-end internal standards were used for
recalibration. The pass/fail criterion for recalibration is a
correct assignment of an in/z value for the `middle` calibrant with
a mass accuracy equal or better than 12 ppm.
[0274] Alternatively, a QSTAR XL Hybrid quadrupole (Q)
time-of-flight mass spectrometer (Applied Biosystems/MDS Sciex;
Concord, Canada), equipped with an o-MALDI ion source, was used for
both duplicate and additional tandem-MS analyses. By selecting
precursor ions of interest in `Q1` (operated in the mass-filter
mode), mass measurements of fragment ions could be obtained in the
TOF detector following collision-induced dissociation (CID) in
`Q2`. Typically, a mass window of 3 Da was selected in order to
transmit the entire isotopic envelope of the precursor ion species.
Collision energy was operator adjusted to yield maximum number and
intensities of the fragment ions.
[0275] Fragment ion spectra resulting from TOF/TOF analyses
(300-1,000 acquisitions averaged per spectrum) were taken to search
a "non-redundant" human database (`NCBInr`; release data: Sep. 20,
2004; 106,486 entries; National Center for Biotechnology
Information, Bethesda, Md.) using the MASCOT MS/MS ion search
program, version 2.0.04 for Windows (Matrix Science Ltd., London,
UK) with the following search parameters: mono-isotopic precursor
mass tolerance of 35 ppm, fragment mass tolerance of 0.5 Da, and
without a specified protease cleavage site.
[0276] Mascot `mowse` scores greater than 35 were considered
significant. Any identification thus obtained was verified
independently by two different people, by comparing the
computer-generated fragment ion series of the predicted peptide
with the experimental MS/MS data. Some sequence assignments had
below-threshold scores but could, nonetheless, be unequivocally
assigned, as the precursor ion mass and selected fragment ion
masses (b'' or y'') matched a particular peptide, representing a
rung in one of the serum peptide sequence ladders.
[0277] B. Results
[0278] Peptide sequence assignment: 46 of the 68 previously
selected peptides (FIGS. 2B and 17) were positively identified by
MALDI-TOF/TOF MS/MS and MALDI-Q/TOF MS/MS analysis and database
searches (FIG. 5A, additionally showing others (including
m/z=1786.86, 2021.05, 2305.20, 2627.48)). Note that the m/z values
listed in FIG. 5A are mono-isotopic and therefore smaller than the
corresponding average isotopic values listed in FIGS. 16 and 17. Of
note, all but a few of the peptide sequences clustered into the
sets of overlapping fragments, lined up within each group at either
the C- or N-terminal end, and with ladder-like truncations at the
opposite ends. Some sequence assignments had below-threshold scores
but could, nonetheless, be unequivocally assigned, as the precursor
ion mass and selected fragment ion masses (b'' or y'') matched a
particular rung in one of the ladders, taking into account whether
the limited CID patterns were in agreement with established rules
(Kapp, E. A. et al., 2003. Anal Chem 75:6251-6264) of preferential
peptide bond cleavage (e.g., Xaa-Pro or Asp/Glu-Xaa) and the
putative sequence.
[0279] Furthermore, 23 additional peptides, outside the original
group of 68, could also be matched to certain sequence clusters by
hypothesis-driven, targeted MS/MS analysis. Fifteen of those had
significant discriminant analysis adjusted p-values (<0.0002)
for at least on cancer type but typically lower ion intensities
(FIG. 5B). Two others (`2553` and `2021`; yellow-coded in FIGS. 5A
and 5B) displayed very high but similar MS ion intensities across
all cancer groups and the control, with adjusted p-values >0.04,
and can therefore be regarded as quasi-internal controls. Six more
peptides (pink-coded in FIGS. 5A and 5B) that fit into the clusters
were randomly observed in samples of the cancer and control groups
and have neither discriminant nor internal control value. It should
be noted that we used an unbiased approach to identify `marker
peptides`, in which the peptides were selected first on the basis
of discriminant analysis and then sequenced. This approach,
commonly referred to as `ion mapping`, can be taken using any type
of mass spectrometric platform (Gao, J. et al., 2003. J Proteome
Res 2:643-649; Fach, E. M. et al. 2004. Mol Cell Proteomics
3:1200-1210).
[0280] Three clusters derived from naturally occurring serum
peptides, fibrinopeptide A (FPA), complement C3f and bradykinin,
that are themselves generated from various plasma proteins through
endoproteolytic cleavage, either before (bradykinin, cleaved from
H-kininogen by a kallekrein) or during (FPA, N-terminally cleaved
from fibrinogen by thrombin to form fibrin; C3f, released by
Factors I and H after prior conversion of C3 to C3b) serum
preparation (Jandl, J. H. 1996. Blood: Textbook of hematology. New
York, N.Y.: Little, Brown and Co.; Sahu, A., and Lambris, J. D.
2001. Immunol Rev 180:35-48).
[0281] The full-length `founder` peptides end with Arg, preceded by
a hydrophobic amino acid (Val, Leu or Phe). Arg is partially
removed from C3f and bradykinin (to form desArg-bradykinin).
Similar `trypsin-like` cleavages (Arg/Lys--Xaa) underlie formation
of all other peptide clusters as well (see below). The C-terminal
basic amino acid is preceded by a hydrophobic amino acid (F, L, V,
I, W, A) in 21 and by S, Q or N in 15 out of the 39 observed
cleavage sites (FIG. 15). Arg/Lys is typically removed (fully or in
part) by a carboxypeptidase, except when preceded by Pro (3 out of
3 cases) or sometimes when preceded by Val (2 out 4). Further
exoprotease degradation then proceeds at the N-terminal or
C-terminal ends, either to completion or until it stalls; many or
all of the `intermediates` are typically represented (FIGS. 5A and
14). Of note, full-length C3f (m/z=2021.05) was found to be present
at equally high concentrations in all patient and control sera (see
B), and therefore represents a virtual internal standard.
[0282] Diagnostic MALDI-TOF spectral patterns consisting of
N-terminal FPA and C3f truncations have previously been found in
sera of myocardial infarction patients (Marshall, J. et al., 2003.
J Proteome Res 2:361-372). In contrast, nearly all of these
peptides (19 total) were detected in control sera (FIG. 3B), and
their presence was shown to be either consistently lower (all FPA
fragments in all cancers; three C3f fragments in breast cancer)
and/or higher (several Cf3 fragments in bladder and prostate
cancer; one FPA fragment in breast cancer) in patient sera (FIG.
5A). Full-length C3f was present in all samples at equally high
concentrations. Full-length FPA was virtually absent in sera from
bladder cancer patients; no fibrinopeptide B or fragments thereof
were found in any of the samples.
[0283] Decreased levels of FPA (fragments) in prostate, bladder and
breast cancer patients, as shown here, also contrast with earlier
findings indicating elevated levels of phospho-FPA in sera of
ovarian cancer patients (measured by ESI-MS (Bergen, H. R., 3rd, et
al., 2003. Dis Markers 19:239-249) and of FPA in gastrointestinal
and breast cancers (measured immunochemically (Abbasciano, V. et
al., 1987. Med Oncol Tumor Pharmacother 4:75-79; Auger, M. J. et
al., 1987. Haemostasis 17:336-339).
[0284] Bradykinin and desArg-bradykinin levels were higher in sera
of breast cancer patients and lower in bladder cancer patients. Of
note, the pro-hydroxylated forms of each peptide also followed that
trend (data not shown). The bradykinin and FPA parent proteins,
fibrinogen alpha and HMW-kininogen, each contributed one additional
sequence cluster, located in a different section of the precursor
sequence, to the cancer serum peptide barcodes (FIGS. 5A and 6;
FIGS. 14 and 15). Interestingly, the bradykinin and `other`
kininogen-derived peptides have very different marker properties.
For example, whereas bradykinin and desArg-bradykinin were
generally of lower ion intensity in bladder cancer than in control
sera, the other two peptides (`1944` and `2209`) actually showed
higher relative intensities in bladder cancer (FIGS. 5A and
16).
[0285] One of the peptides (`2724`, FIG. 5A) in a cluster of
sequences is derived from the inter-alpha-trypsin inhibitor heavy
chain H4 (ITIH4) precursor (Salier, J. P. et al., 1996. Biochem J
315 (Pt 1):1-9) and covers amino acids 662-687 (FIG. 17) and is
bracketed by two kallikrein cleavage sites (Phe-Arg--Xaa). Residues
662-688 likely represent a `propeptide` of unknown function
(Nishimura, H. et al., 1995. FEBS Lett 357:207-211). Like
bradykinin, it ends with Pro-Phe-Arg. Several longer ITIH4
precursor fragments actually span the first kallikrein cleavage
site, including `3272` at 658-687, that has been reported as a
biomarker for early stage ovarian cancer (Zhang, Z. et al., 2004.
Cancer Res 64:5882-5890). Variations in N-terminal truncation by
just a few amino acids in the ITIH4 cluster were found to produce
relatively selective `markers` for each of the three different
cancers. Median ion intensities of peptides `3971` and `3273`, for
instance, were clearly highest in bladder cancer samples, peptides
`2358` and `2184` were highest in breast cancer, and `2271` was
highest in prostate cancer. Also of note, peptide `2115` matches
the sequence of an ITIH4 splice variant (PRO1851; FIG. 15) and
appears to have strong marker capacity for each cancer type,
particularly for bladder and breast (FIG. 16).
[0286] A seventh cluster of 8 sequences, 4 on either site of a
single Ile-Arg-Xaa cleavage site, is derived from the complement
C4a precursor (Belt, K. T. et al., 1984. Cell 36:907-914) (FIGS.
5A, 14, and 15). This C4a-cluster has the highest incidence of ion
markers for breast cancer; more than any in other cluster and also
more than C4a-derived bladder cancer markers (FIG. 16). Only a
single ion (`1763`) of this cluster is an ion marker for prostate
cancer, and is shared in that capacity with the other two cancer
types. On the other hand, all but one ion marker derived from
apolipoproteins (APO) A-I, A-IV and E are bladder cancer specific,
all with appreciably higher ion intensities; the exception (APO
A-IV, peptide `1971`) is actually highly selective and
statistically the most significant (p=5.5e-13) ion marker for
breast cancer (FIGS. 5A and 16).
[0287] Up-regulation of clusterin, i.e., `APO J`, has been
correlated, by immuno-histochemistry, with progression of both
prostate and bladder cancer (Jul., L. V. et al., 2002. Prostate
50:179-188; Scaltriti, M. et al., 2004. Int J Cancer 108:23-30;
Miyake, H. et al., 2002. Urology 59:150-154). The 10-amino acid
clusterin fragment detected at elevated concentrations in sera of
bladder and prostate cancer patients is located at the C-terminus
of the beta-chain. A single cut is, therefore, sufficient to
release this peptide, following separation of the clusterin beta
(N-t) and alpha (C-t) chains by cleavage of a Val-Arg--Xaa bond. A
6-amino acid sub-fragment has statistically relevant marker
potential for bladder cancer (FIGS. 5A and 16), which is in keeping
with the trend for most other peptides from APO A-I, A-IV, and E.
Two ions (`2602`; `2451`), each with significantly higher median
intensities in breast cancer samples than in controls, corresponded
to peptides derived from, respectively, Factor XIIIa and
transthyretin (FIGS. 5A and 5B). In contrast to the aforementioned
clusters, each peptide was the only fragment from the respective
precursors that we observed. Peptide `2602` actually represents the
C-terminal 25 amino acids of the Factor XIIIa propeptide
(37-residues long) (FIGS. 14 and 15). Interestingly, Factor XIII
itself has been found significantly down-regulated in breast tumors
compared to normal mammary tissues (Jiang, W. G. et al., 2003.
Oncol Rep 10:2039-2044).
Example 4
MALDI-TOF Mass Spectral Overlays of Selected Peaks Derived from
Serum Peptide Profiling of Three Groups of Cancer Patients and
Healthy Controls
[0288] All spectra were obtained and aligned as described above,
and subsequently displayed using the Mass Spectra Viewer (MSV)
(FIGS. 3A and 3B). Overlays of mass spectra of selected peptides of
known sequence (FIG. 5) that showed statistically significant
differences between peak intensities in one or more of the three
binary comparisons are shown in FIG. 3A. Peptide `2021.05` (i.e.,
C3f) is shown as an example of a peptide that is present in about
equal concentrations in all serum samples analyzed in this study.
Overlays of mass spectra of some as yet unidentified peptides that
also showed statistically significant differences between peak
intensities in one or more of the three binary comparisons are
shown in FIG. 3B.
[0289] Peptides from a serum sample obtained from a breast cancer
patient were extracted and analyzed by MS, and the ion of choice
selected for MS/MS analysis. The fragment ion spectrum shown herein
was taken for a MASCOT MS/MS on Search of the human segment of NR
database, and retrieved a peptide sequence, GLEEELQFSLGSKINVKVGGNS
(SEQ ID NO:23) ([MH].sup.+=2305.19; .DELTA.=4 ppm) with a Mascot
score of 38.
[0290] Taken together, a total of 69 serum peptides are listed in
FIG. 5A (with matching information provided in FIG. 5B; all 79
sequenced peptides listed in FIG. 14). Of those, 61 have clear
MALDI-TOF MS-ion marker potential (adjusted p<0.0002; and, in
most cases, much lower) for at least one type of cancer and are
color-coded in blue (prostate cancer), green (bladder cancer) or
red (breast cancer). The resulting `barcodes` for the three cancer
types consist of 26 (prostate), 50 (bladder) and 25 (breast)
`bars`, i.e., peptides, several in common between any two or all
three. Compared to healthy control samples, median intensities of
ion markers could be up or down (represented by black dots in the
colored barcodes in FIG. 5A) in any particular cancer group; 16
higher and 10 lower (16+/10-) in prostate cancer, 31+/-19 in
bladder cancer, and 19+/6- in breast cancer. Only three peptides in
each of the up- or down-categories were shared by all cancer
groups.
[0291] One peptide from the C4a- and two from the ITIH4-cluster had
consistently higher ion intensities in all cancers than in healthy
controls; three FPA fragments were lower in all cancers. The rest
of the ion markers were either in common between 2 groups or, more
often, unique to a single patient cohort (FIG. 5A). Twenty six
(17+/9-) of those were unique for bladder cancer and 16 (13+/3-)
for breast cancer. To be noted are the nine APO[A-I, A-IV, E,
J]-peptides and three C3f-peptides exclusively of higher ion
intensities in bladder cancer, and the four C4a- two bradykinin-
and one transthyretin-peptides in breast cancer. All three serum
peptide ions that were uniquely of lower intensity in the breast
cancer cohort each derived from C3f. Interestingly, a number of
`shared` marker ions had, in fact, higher median intensities than
the controls in one type cancer and lower in another (FIGS. 5A and
5B). For instance, one ITIH4-peptide (`842`) and one C3f-peptide
(`1865`) had higher median ion intensities in sera from prostate
cancer patients than in, respectively, bladder and breast cancer.
Five peptide ions (including those corresponding to bradykinin and
desArg-bradykinin) that had higher median intensities in breast
cancer samples were lower in bladder cancer and had no appreciable
marker value for prostate cancer.
[0292] In an attempt to find trends in what clusters might have ion
marker value for a type of cancer, or to at least better visualize
any global differences that might exist, we plotted the ratios of
the median ion intensities were plotted, for each of the peptides
in the four major clusters, between each cancer group and the
healthy controls (i.e., r=case/control). The center line in the
panels of FIG. 6 represents no difference (r=1); bars pointing to
the left (r<1) or right (r>1) indicate, respectively, lower
or higher median. Even in case of the FPA ladder where nearly all
peptides in cancer sera produced ion signals of lower intensities
than in controls, the actual ratios vary for each `rung` and for
each cancer type. Of particular note is the seemingly total absence
(r=0) of full-length FPA in sera of bladder cancer patients. The
three other clusters exhibit an even more pronounced `internal`
variability, with median intensity ratios that were mostly over,
but also equal to or under 1.
[0293] Visual inspection of the 4 color-coded graphs (33.times.3
total data points) in FIG. 6 readily distinguishes the three cancer
types. There is a trend for peptides in bladder cancer sera to
exhibit relatively high ion intensities in the C3f cluster and
rather variable intensities in the C4a and ITIH4 clusters, and for
some peptides in the C3f-cluster to be of lower intensity and
others in the C4a-cluster to be of higher intensity in breast
cancer sera. Ion intensities of peptides in prostate cancer sera
don't seem to follow those trends, but are selectively more
pronounced in some of the smaller peptides of the ITIH4-cluster.
Interestingly, there is one rung in each of the C3f-, C4a- and
ITIH4-ladders (respectively the 6.sup.th, 5.sup.th and 5.sup.th
rung in the corresponding panels in FIG. 6) for which median ion
intensities in the control samples were virtually zero, yet much
higher in all three cancer types, resulting in very high ratios for
each.
[0294] Taken together, the data in FIG. 6, based in parts on
statistical analysis (FIG. 5B), visual inspection of spectra
overlays (FIG. 3), peptide sequencing (FIGS. 4 and 5A) and relative
ion intensity analysis, now strongly indicate that the human serum
peptidome holds information, in the form of barcodes consisting of
a few dozen peptides each, that can distinguish three different
cancers from controls as well as from each other.
Example 5
Independent Set of Prostate Cancer Serum Samples for Validation of
Established `Peptide-Signature` Biomarkers
[0295] It was next tested whether the identified markers would
correctly predict the class of an external validation set.
[0296] Sample Groups
[0297] An initial set of 32 serum samples from patients with
advanced prostate cancer (Prostate #1) were analyzed together with
33 samples from healthy controls and two additional groups of
cancer patient samples (FIG. 1A). One month later, an entirely
different group of 41 advanced prostate cancer patients (Prostate
#2), none previously studied, was analyzed using identical
methodology (FIG. 8A), and a new spreadsheet with all data from the
original 106 subjects and the new validation set, was generated.
The assignment of the prostate cancer samples into the training set
(Prostate 1--`PR1`) or the test set (Prostate 2--`PR2`) was random,
but preserving the same demographic/pathological parameters (e.g.,
age, PSA levels, Gleason score, survival time).
[0298] Peptide ions from `feature list #2` (68 peptides; see FIGS.
2A and 7) and from the `prostate cancer barcode` (26 sequenced
peptides; blue `barcode` in FIGS. 5A and 5B) were then selectively
used for comparison of the control, PR1 and PR2 groups by
hierarchical clustering and principal component analysis. While not
a perfect fit, samples from prostate cancer sets #1 and #2 were
mixed to some extent but for the most part separated from the
controls. Individual comparisons of each of these 26 peptide ions
between the three sample groups indicated that the intensities of
26 out of 26 were statistically different (adjusted p<0.0002;
i.e. the p-value to create the barcode--FIG. 5B) between PR1 and
control, 23 out of 26 between PR2 and control, and only 1 out of 26
between PR1 and PR2.
[0299] Class Prediction Analysis of the Prostate Cancer
Validation
[0300] Support vector machine (SVM)-based class predictions, in
either binary or multi-class formats, were carried out using all
651, or the 68 or 14 previously selected peptides. Analyses were
carried out using linear kernel (as described earlier). Similar
sensitivities were obtained in all three instances, namely 100%
(41/41) and 97.5% (40/41) accuracy for, respectively, binary and
multi-group class predictions.
Example 6
Aminoprotease Activities in Plasma
[0301] The serum peptidome is likely largely the product of
resident substrates, more specifically their proteolytic breakdown
products (Koomen, J. M. et al., 2005. J Proteome Res 4:972-981);
findings herein), and, therefore, represents a read-out of the
repertoire of proteases that exist in plasma and/or become
activated during clotting. With the exception of bradykinin, much
higher peptide concentrations were consistently observed in serum
than in plasma (FIG. 9; and data not shown). The data presented
herein indicate that cancer cells contribute unique proteases,
perhaps exoproteases, which result in subtle but signature
alterations of the complex equation of hundreds of peptides that
can be resolved from human serum.
[0302] In an effort to begin to understand the presence and roles
of exoproteases, synthetic C3f was added to fresh plasma at a
concentration close to that observed in serum. As shown in FIG. 9,
degradation is very fast. C-terminal Arg was removed within
seconds, and the N-terminal truncations occurred in 10-15 min. The
resulting pattern was similar to the endogenous one observed in
serum and also illustrated the disparate ion intensities for
different rungs in the ladder. However, most of the C3f ladder,
except its smallest rung, disappeared upon prolonged incubation
(data not shown). Exoproteolytic degradation of synthetic FPA in
plasma followed a similar time course, but FPB was completely
degraded in just a few minutes (data not shown. The results suggest
that the operative exoprotease concentrations and activities are
roughly equivalent in plasma and serum, and therefore not the
consequence of coagulation.
[0303] As per Example 6, above, it is indicated that a sizable part
of the human serum `peptidome`, as detected by MALDI-TOF MS, is
generated by degradation of endogenous substrates by endogenous
proteases. Peptide profiling is, therefore, a form of
activity-based proteomics, by using a `metabolomic` read-out that
is subject to variations in enzyme panels, cofactors and
inhibitors. Here, proteolytic activities of the ex-vivo coagulation
and complement-degradation pathways, in combination with
exoproteases, have been shown to contribute to generation of not
only cancer-specific, but also `cancer type`-specific serum
peptides. The specificity derives largely from aminopeptidase
panels in serum, which is consistent with previous observations
(van Hensbergen, Y., et al., 2002, Clin Cancer Res 8:3747-3754;
Matrisian, L. M., et al., 2003, Cancer Res 63:6105-6109; Moffatt,
S., et al., 2005, Hum Gene Ther 16:57-67; Kehlen, A., et al., 2003,
Cancer Res 63:8500-8506; Rocken, C., et al., 2004, Int J Oncol
24:487-495; Carl-McGrath, S, et al., 2004, Int J Oncol
25:1223-1232; Kojima, K., et al., 1987, Biochem Med Metab Biol
37:35-41; Essler, M., et al., 2002, Proc Natl Acad Sci USA
99:2252-2257; Carrera, M. P., et al., 2005, Anticancer Res
25:193-196; Pulido-Cejudo, G., et al., 2004, Biotechnol Lett
26:1335-1339; Suganuma, T., et al., 2004, Lab Invest 84:639-648;
Selvakumar, P., et al., 2004, Clin Cancer Res 10:2771-2775; Ni, R.
Z., et al., 2003, World J Gastroenterol 9:710-713; Sheppard, G. S.,
et al., 2004, Bioorg Med Chem Lett 14:865-868; Griffith, E. C., et
al., 1998, Proc Natl Acad Sci USA 95:15183-15188; Pasqualini, R.,
et al., 2000, Cancer Res 60:722-727; Petrovic, N., et al., 2003, J
Biol Chem 278:49358-49368; O'Malley, P. G., et al., 2005, Biochem
J; Fair, W. R., et al., 1997, Prostate 32:140-148).
[0304] In the discovery phase of the present studies, hundreds of
features were sorted through to identify several that are most
predictive of outcome. Reduction in the number of key peptides to
only a few that are easily recognized between samples has been
shown not to adversely affect class predictions. Focused mass
spectrometric quantitation of key peptides should facilitate
introduction of this technology into general clinical practice.
Example 7
MALDI-TOF MS-Based Quantitative Profiling
[0305] Relative quantitation of the rungs of a C3f ladder in a pool
of 50 serum samples from thyroid carcinoma patients and a pool of
50 healthy controls was carried out. Ten reference peptides (FIG.
31) were added to the raw sera (2 picomoles/50 .mu.L), peptides
extracted on magnetic beads, MALDI spectra taken and ion intensity
ratios calculated for each pair, for each pool. The relative ion
intensities (ratio: endogenous/REF) were consistently higher for
the peptides in the `cancer sera` compared to the controls
(.about.20% to 100% higher) (FIG. 32, panel C). These results are
in agreement with the normalized ion intensity comparisons of 40
individual cancer and 40 individual control samples; presented as
spectral overlays and a heat plot in FIG. 32, panels A and B.
Example 8
MALDI-TOF MS-Based Protease Assays
[0306] The degradation conditions and times were studied for C3f
and FPA in serum and plasma as described above. Synthetic C3f and
FPA readily degraded in control serum and plasma; C3f rapidly
(within 15-30 min), FPA rather slowly (up to 4 hours). 2 picomoles
[.sup.13C-Leu]-labeled C3f was incubated for 30 min at RT with 50-4
aliquots of serum from 20 different breast cancer patients and 20
control samples. Four rungs (m/z=942, 1212, 1563, 1865) of the
endogenous C3f degradation ladder were previously found to have a
lower median ion intensity in MALDI spectra taken of breast cancer
sera than control sera (FIG. 34, top panel). Upon overlay of the 40
color-coded spectra (FIG. 34, bottom panel), the equivalent four
rungs in the ladder resulting from degradation of exogenous
[.sup.13C-Leu]C3f had also generally lower ion intensities in the
spectra of cancer patient sera compared to the controls, thus
closely matching the endogenous patterns.
[0307] A synthetic version of the longest ITIH4-derived founder
peptide (FIG. 33; #7, with N-t Pro) did not degrade in serum or
plasma (data not shown), indicating that it probably is not a
founder but rather a stalled degradation product of a bigger
peptide.
[0308] Labeled C3f was added to two pools of serum, one from 50
samples obtained from thyroid carcinoma patients, and one from age-
and gender-matched healthy controls. Aliquots were retrieved at
various time points, ranging from 5 min to 5 hours, and analyzed by
magnetic bead processing and a MALDI read-out; in triplicate. The
10 peptide-triplets (one for each rung in the C3f ladder) were then
selected for each time point and each of the triplicates, the
ratios between exogenously derived peptide and reference peptide
calculated and plotted (FIG. 35).
[0309] The exogenous peptide was singly labeled (.sup.13C-Leu), and
the reference peptide doubly labeled with .sup.13C/.sup.15N-Leu,
hence the 14 Da mass difference from the endogenous peptide. The
time course results indicate that during the first 5 or so minutes,
peptide degradation (removal of the C-t Arg) kinetics are faster in
the cancer sera than in the controls. Furthermore, after 1-2 hours
of incubation, clear differences in relative ion intensity were
observed for the two smallest peptides in the ladder between the
two samples; both higher in the cancer sample, indicating that the
founder peptide was either more rapidly degraded in the cancer
serum or that, alternatively, it was completely degraded to single
amino acids in the control serum.
Sequence CWU 1
1
148115PRTHomo sapiens 1Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly
Gly Gly Val Arg1 5 10 15214PRTHomo sapiens 2Ser Gly Glu Gly Asp Phe
Leu Ala Glu Gly Gly Gly Val Arg1 5 10313PRTHomo sapiens 3Gly Glu
Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg1 5 10412PRTHomo sapiens
4Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg1 5 10511PRTHomo
sapiens 5Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg1 5
10610PRTHomo sapiens 6Asp Phe Leu Ala Glu Gly Gly Gly Val Arg1 5
10716PRTHomo sapiens 7Glu Glu Glu Leu Gln Phe Ser Gly Leu Ser Phe
Asn Val Lys Val Ser1 5 10 15816PRTHomo sapiens 8Ser Ser Lys Ile Thr
His Arg Ile His Trp Glu Ser Ala Ser Leu Leu1 5 10 15915PRTHomo
sapiens 9Ser Lys Ile Thr His Arg Ile His Trp Glu Ser Ala Ser Leu
Leu1 5 10 151014PRTHomo sapiens 10Lys Ile Thr His Arg Ile His Trp
Glu Ser Ala Ser Leu Leu1 5 101112PRTHomo sapiens 11Thr His Arg Ile
His Trp Glu Ser Ala Ser Leu Leu1 5 10128PRTHomo sapiens 12His Trp
Glu Ser Ala Ser Leu Leu1 51326PRTHomo sapiens 13Pro Gly Val Leu Ser
Ser Arg Gln Leu Gly Leu Pro Gly Pro Pro Asp1 5 10 15Val Pro Asp His
Ala Ala Tyr His Pro Phe 20 251425PRTHomo sapiens 14Gly Val Leu Ser
Ser Arg Gln Leu Gly Leu Pro Gly Pro Pro Asp Val1 5 10 15Pro Asp His
Ala Ala Tyr His Pro Phe 20 251521PRTHomo sapiens 15Ser Arg Gln Leu
Gly Leu Pro Gly Pro Pro Asp Val Pro Asp His Ala1 5 10 15Ala Tyr His
Pro Phe 201617PRTHomo sapiens 16Gly Leu Pro Gly Pro Pro Asp Val Pro
Asp His Ala Ala Tyr His Pro1 5 10 15Phe1710PRTHomo sapiens 17His
Phe Phe Phe Pro Lys Ser Arg Ile Val1 5 10186PRTHomo sapiens 18His
Phe Phe Phe Pro Lys1 5199PRTHomo sapiens 19Arg Pro Pro Gly Phe Ser
Pro Phe Arg1 5208PRTHomo sapiens 20Arg Pro Pro Gly Phe Ser Pro Phe1
52116PRTHomo sapiens 21Arg Asn Gly Phe Lys Ser His Ala Leu Gln Leu
Asn Asn Arg Gln Ile1 5 10 152215PRTHomo sapiens 22Asn Gly Phe Lys
Ser His Ala Leu Gln Leu Asn Asn Arg Gln Ile1 5 10 152322PRTHomo
sapiens 23Gly Leu Glu Glu Glu Leu Gln Phe Ser Leu Gly Ser Lys Ile
Asn Val1 5 10 15Lys Val Gly Gly Asn Ser 20249PRTHomo sapiens 24Phe
Leu Ala Glu Gly Gly Gly Val Arg1 5258PRTHomo sapiens 25Leu Ala Glu
Gly Gly Gly Val Arg1 52613PRTHomo sapiens 26Ile Thr His Arg Ile His
Trp Glu Ser Ala Ser Leu Leu1 5 102710PRTHomo sapiens 27Arg Ile His
Trp Glu Ser Ala Ser Leu Leu1 5 10289PRTHomo sapiens 28Ile His Trp
Glu Ser Ala Ser Leu Leu1 52915PRTHomo sapiens 29Ser Ser Lys Ile Thr
His Arg Ile His Trp Glu Ser Ala Ser Leu1 5 10 153014PRTHomo sapiens
30Asn Gly Phe Lys Ser His Ala Leu Gln Leu Asn Asn Arg Gln1 5
103113PRTHomo sapiens 31Asn Gly Phe Lys Ser His Ala Leu Gln Leu Asn
Asn Arg1 5 103226PRTHomo sapiens 32Gly Leu Glu Glu Glu Leu Gln Phe
Ser Leu Gly Ser Lys Ile Asn Val1 5 10 15Lys Val Gly Gly Asn Ser Lys
Gly Thr Leu 20 253316PRTHomo sapiens 33Gly Leu Glu Glu Glu Leu Gln
Phe Ser Leu Gly Ser Lys Ile Asn Val1 5 10 15348PRTHomo sapiens
34His Ala Ala Tyr His Pro Phe Arg1 53520PRTHomo sapiens 35Gln Leu
Gly Leu Pro Gly Pro Pro Asp Val Pro Asp His Ala Ala Tyr1 5 10 15His
Pro Phe Arg 203638PRTHomo sapiens 36Gln Ala Gly Ala Ala Gly Ser Arg
Met Asn Phe Arg Pro Gly Val Leu1 5 10 15Ser Ser Arg Gln Leu Gly Leu
Pro Gly Pro Pro Asp Val Pro Asp His 20 25 30Ala Ala Tyr His Pro Phe
353730PRTHomo sapiens 37Met Asn Phe Arg Pro Gly Val Leu Ser Ser Arg
Gln Leu Gly Leu Pro1 5 10 15Gly Pro Pro Asp Val Pro Asp His Ala Ala
Tyr His Pro Phe 20 25 303822PRTHomo sapiens 38Ser Ser Arg Gln Leu
Gly Leu Pro Gly Pro Pro Asp Val Pro Asp His1 5 10 15Ala Ala Tyr His
Pro Phe 20397PRTHomo sapiens 39His Ala Ala Tyr His Pro Phe1
54028PRTHomo sapiens 40Asn Val His Ser Gly Ser Thr Phe Phe Lys Tyr
Tyr Leu Gln Gly Ala1 5 10 15Lys Ile Pro Lys Pro Glu Ala Ser Phe Ser
Pro Arg 20 254121PRTHomo sapiens 41Asn Val His Ser Ala Gly Ala Ala
Gly Ser Arg Met Asn Phe Arg Pro1 5 10 15Gly Val Leu Ser Ser
204228PRTHomo sapiens 42Gln Gly Leu Leu Pro Val Leu Glu Ser Phe Lys
Val Ser Phe Leu Ser1 5 10 15Ala Leu Glu Glu Tyr Thr Lys Lys Leu Asn
Thr Gln 20 254317PRTHomo sapiens 43Val Ser Phe Leu Ser Ala Leu Glu
Glu Tyr Thr Lys Lys Leu Asn Thr1 5 10 15Gln4419PRTHomo sapiens
44Ala Thr Glu His Leu Ser Thr Leu Ser Glu Lys Ala Lys Pro Ala Leu1
5 10 15Glu Asp Leu4523PRTHomo sapiens 45Ile Ser Ala Ser Ala Glu Glu
Leu Arg Gln Arg Leu Ala Pro Leu Ala1 5 10 15Glu Asp Val Arg Gly Asn
Leu 204625PRTHomo sapiens 46Gly Asn Thr Glu Gly Leu Gln Lys Ser Leu
Ala Glu Leu Gly Gly His1 5 10 15Leu Asp Gln Gln Val Glu Glu Phe Arg
20 254717PRTHomo sapiens 47Ser Leu Ala Glu Leu Gly Gly His Leu Asp
Gln Gln Val Glu Glu Phe1 5 10 15Arg4816PRTHomo sapiens 48Ser Leu
Ala Glu Leu Gly Gly His Leu Asp Gln Gln Val Glu Glu Phe1 5 10
154924PRTHomo sapiens 49Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro
Leu Gln Glu Arg Ala1 5 10 15Gln Ala Trp Gly Glu Arg Leu Arg
205023PRTHomo sapiens 50Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro
Leu Gln Glu Arg Ala1 5 10 15Gln Ala Trp Gly Glu Arg Leu
205119PRTHomo sapiens 51Lys His Asn Leu Gly His Gly His Lys His Glu
Arg Asp Gln Gly His1 5 10 15Gly His Gln5217PRTHomo sapiens 52Asn
Leu Gly His Gly His Lys His Glu Arg Asp Gln Gly His Gly His1 5 10
15Gln5325PRTHomo sapiens 53Ala Val Pro Pro Asn Asn Ser Asn Ala Ala
Glu Asp Asp Leu Pro Thr1 5 10 15Val Glu Leu Gln Gly Val Val Pro Arg
20 255423PRTHomo sapiens 54Ala Leu Gly Ile Ser Pro Phe His Glu His
Ala Glu Val Val Phe Thr1 5 10 15Ala Asn Asp Ser Gly Pro Arg
205529PRTHomo sapiens 55Ser Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser
Thr Ser Tyr Asn Arg1 5 10 15Gly Asp Ser Thr Phe Glu Ser Lys Ser Tyr
Lys Met Ala 20 255628PRTHomo sapiens 56Ser Ser Ser Tyr Ser Lys Gln
Phe Thr Ser Ser Thr Ser Tyr Asn Arg1 5 10 15Gly Asp Ser Thr Phe Glu
Ser Lys Ser Tyr Lys Met 20 255726PRTHomo sapiens 57Ser Ser Ser Tyr
Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg1 5 10 15Gly Asp Ser
Thr Phe Glu Ser Lys Ser Tyr 20 255825PRTHomo sapiens 58Ser Ser Ser
Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg1 5 10 15Gly Asp
Ser Thr Phe Glu Ser Lys Ser 20 255925PRTHomo sapiens 59Gly Leu Glu
Glu Glu Leu Gln Phe Ser Leu Gly Ser Lys Ile Asn Val1 5 10 15Lys Gly
Gly Asn Ser Lys Gly Thr Ile 20 256021PRTHomo sapiens 60Ser Ser Tyr
Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly1 5 10 15Asp Ser
Thr Phe Glu 206127PRTHomo sapiens 61Gly Ser Glu Ser Gly Ile Phe Thr
Asn Thr Lys Glu Ser Ser Ser His1 5 10 15His Pro Gly Ile Ala Glu Phe
Pro Ser Arg Gly 20 256225PRTHomo sapiens 62Asp Glu Ala Gly Ser Glu
Ala Asp His Glu Gly Thr His Ser Thr Lys1 5 10 15Arg Gly His Ala Lys
Ser Arg Pro Val 20 2563436PRTHomo sapiens 63Tyr Pro Phe Ala Leu Phe
Tyr Arg His Tyr Leu Phe Tyr Lys Glu Thr1 5 10 15Tyr Leu Ile His Leu
Phe His Thr Phe Thr Gly Leu Ser Ile Ala Tyr 20 25 30Phe Asn Phe Gly
Asn Gln Leu Tyr His Ser Leu Leu Cys Ile Val Leu 35 40 45Gln Phe Leu
Ile Leu Arg Leu Met Gly Arg Thr Ile Thr Ala Val Leu 50 55 60Thr Thr
Phe Cys Phe Gln Met Ala Tyr Leu Leu Ala Gly Tyr Tyr Tyr65 70 75
80Thr Ala Thr Gly Asn Tyr Asp Ile Lys Trp Thr Met Pro His Cys Val
85 90 95Leu Thr Leu Lys Leu Ile Gly Leu Ala Val Asp Tyr Phe Asp Gly
Gly 100 105 110Lys Asp Gln Asn Ser Leu Ser Ser Glu Gln Gln Lys Tyr
Ala Ile Arg 115 120 125Gly Val Pro Ser Leu Leu Glu Val Ala Gly Phe
Ser Tyr Phe Tyr Gly 130 135 140Ala Phe Leu Val Gly Pro Gln Phe Ser
Met Asn His Tyr Met Lys Leu145 150 155 160Val Gln Gly Glu Leu Ile
Asp Ile Pro Gly Lys Ile Pro Asn Ser Ile 165 170 175Ile Pro Ala Leu
Lys Arg Leu Ser Leu Gly Leu Phe Tyr Leu Val Gly 180 185 190Tyr Thr
Leu Leu Ser Pro His Ile Thr Glu Asp Tyr Leu Leu Thr Glu 195 200
205Asp Tyr Asp Asn His Pro Phe Trp Phe Arg Cys Met Tyr Met Leu Ile
210 215 220Trp Gly Lys Phe Val Leu Tyr Lys Tyr Val Thr Cys Trp Leu
Val Thr225 230 235 240Glu Gly Val Cys Ile Leu Thr Gly Leu Gly Phe
Asn Gly Phe Glu Glu 245 250 255Lys Gly Lys Ala Lys Trp Asp Ala Cys
Ala Asn Met Lys Val Trp Leu 260 265 270Phe Glu Thr Asn Pro Arg Phe
Thr Gly Thr Ile Ala Ser Phe Asn Ile 275 280 285Asn Thr Asn Ala Trp
Val Ala Arg Tyr Ile Phe Lys Arg Leu Lys Phe 290 295 300Leu Gly Asn
Lys Glu Leu Ser Gln Gly Leu Ser Leu Leu Phe Leu Ala305 310 315
320Leu Trp His Gly Leu His Ser Gly Tyr Leu Val Cys Phe Gln Met Lys
325 330 335Phe Leu Ile Val Ile Val Glu Arg Gln Ala Ala Arg Leu Ile
Gln Glu 340 345 350Ser Pro Thr Leu Ser Lys Leu Ala Ala Ile Thr Val
Leu Gln Pro Phe 355 360 365Tyr Tyr Leu Val Gln Gln Thr Ile His Trp
Leu Phe Met Gly Tyr Ser 370 375 380Met Thr Ala Phe Cys Leu Phe Thr
Trp Asp Lys Trp Leu Lys Val Tyr385 390 395 400Lys Ser Ile Tyr Phe
Leu Gly His Ile Phe Phe Leu Ser Leu Leu Phe 405 410 415Ile Leu Pro
Tyr Ile His Lys Ala Met Val Pro Arg Lys Glu Lys Leu 420 425 430Lys
Lys Met Glu 43564930PRTHomo sapiens 64Met Lys Pro Pro Arg Pro Val
Arg Thr Cys Ser Lys Val Leu Val Leu1 5 10 15Leu Ser Leu Leu Ala Ile
His Gln Thr Thr Thr Ala Glu Lys Asn Gly 20 25 30Ile Asp Ile Tyr Ser
Leu Thr Val Asp Ser Arg Val Ser Ser Arg Phe 35 40 45Ala His Thr Val
Val Thr Ser Arg Val Val Asn Arg Ala Asn Thr Val 50 55 60Gln Glu Ala
Thr Phe Gln Met Glu Leu Pro Lys Lys Ala Phe Ile Thr65 70 75 80Asn
Phe Ser Met Asn Ile Asp Gly Met Thr Tyr Pro Gly Ile Ile Lys 85 90
95Glu Lys Ala Glu Ala Gln Ala Gln Tyr Ser Ala Ala Val Ala Lys Gly
100 105 110Lys Ser Ala Gly Leu Val Lys Ala Thr Gly Arg Asn Met Glu
Gln Phe 115 120 125Gln Val Ser Val Ser Val Ala Pro Asn Ala Lys Ile
Thr Phe Glu Leu 130 135 140Val Tyr Glu Glu Leu Leu Lys Arg Arg Leu
Gly Val Tyr Glu Leu Leu145 150 155 160Leu Lys Val Arg Pro Gln Gln
Leu Val Lys His Leu Gln Met Asp Ile 165 170 175His Ile Phe Glu Pro
Gln Gly Ile Ser Phe Leu Glu Thr Glu Ser Thr 180 185 190Phe Met Thr
Asn Gln Leu Val Asp Ala Leu Thr Thr Trp Gln Asn Lys 195 200 205Thr
Lys Ala His Ile Arg Phe Lys Pro Thr Leu Ser Gln Gln Gln Lys 210 215
220Ser Pro Glu Gln Gln Glu Thr Val Leu Asp Gly Asn Leu Ile Ile
Arg225 230 235 240Tyr Asp Val Asp Arg Ala Ile Ser Gly Gly Ser Ile
Gln Ile Glu Asn 245 250 255Gly Tyr Phe Val His Tyr Phe Ala Pro Glu
Gly Leu Thr Thr Met Pro 260 265 270Lys Asn Val Val Phe Val Ile Asp
Lys Ser Gly Ser Met Ser Gly Arg 275 280 285Lys Ile Gln Gln Thr Arg
Glu Ala Leu Ile Lys Ile Leu Asp Asp Leu 290 295 300Ser Pro Arg Asp
Gln Phe Asn Leu Ile Val Phe Ser Thr Glu Ala Thr305 310 315 320Gln
Trp Arg Pro Ser Leu Val Pro Ala Ser Ala Glu Asn Val Asn Lys 325 330
335Ala Arg Ser Phe Ala Ala Gly Ile Gln Ala Leu Gly Gly Thr Asn Ile
340 345 350Asn Asp Ala Met Leu Met Ala Val Gln Leu Leu Asp Ser Ser
Asn Gln 355 360 365Glu Glu Arg Leu Pro Glu Gly Ser Val Ser Leu Ile
Ile Leu Leu Thr 370 375 380Asp Gly Asp Pro Thr Val Gly Glu Thr Asn
Pro Arg Ser Ile Gln Asn385 390 395 400Asn Val Arg Glu Ala Val Ser
Gly Arg Tyr Ser Leu Phe Cys Leu Gly 405 410 415Phe Gly Phe Asp Val
Ser Tyr Ala Phe Leu Glu Lys Leu Ala Leu Asp 420 425 430Asn Gly Gly
Leu Ala Arg Arg Ile His Glu Asp Ser Asp Ser Ala Leu 435 440 445Gln
Leu Gln Asp Phe Tyr Gln Glu Val Ala Asn Pro Leu Leu Thr Ala 450 455
460Val Thr Phe Glu Tyr Pro Ser Asn Ala Val Glu Glu Val Thr Gln
Asn465 470 475 480Asn Phe Arg Leu Leu Phe Lys Gly Ser Glu Met Val
Val Ala Gly Lys 485 490 495Leu Gln Asp Arg Gly Pro Asp Val Leu Thr
Ala Thr Val Ser Gly Lys 500 505 510Leu Pro Thr Gln Asn Ile Thr Phe
Gln Thr Glu Ser Ser Val Ala Glu 515 520 525Gln Glu Ala Glu Phe Gln
Ser Pro Lys Tyr Ile Phe His Asn Phe Met 530 535 540Glu Arg Leu Trp
Ala Tyr Leu Thr Ile Gln Gln Leu Leu Glu Gln Thr545 550 555 560Val
Ser Ala Ser Asp Ala Asp Gln Gln Ala Leu Arg Asn Gln Ala Leu 565 570
575Asn Leu Ser Leu Ala Tyr Ser Phe Val Thr Pro Leu Thr Ser Met Val
580 585 590Val Thr Lys Pro Asp Asp Gln Glu Gln Ser Gln Val Ala Glu
Lys Pro 595 600 605Met Glu Gly Glu Ser Arg Asn Arg Asn Val His Ser
Gly Ser Thr Phe 610 615 620Phe Lys Tyr Tyr Leu Gln Gly Ala Lys Ile
Pro Lys Pro Glu Ala Ser625 630 635 640Phe Ser Pro Arg Arg Gly Trp
Asn Arg Gln Ala Gly Ala Ala Gly Ser 645 650 655Arg Met Asn Phe Arg
Pro Gly Val Leu Ser Ser Arg Gln Leu Gly Leu 660 665 670Pro Gly Pro
Pro Asp Val Pro Asp His Ala Ala Tyr His Pro Phe Arg 675 680 685Arg
Leu Ala Ile Leu Pro Ala Ser Ala Pro Pro Ala Thr Ser Asn Pro 690 695
700Asp Pro Ala Val Ser Arg Val Met Asn Met Lys Ile Glu Glu Thr
Thr705 710 715 720Met Thr Thr Gln Thr Pro Ala Pro Ile Gln Ala Pro
Ser Ala Ile Leu 725 730 735Pro Leu Pro
Gly Gln Ser Val Glu Arg Leu Cys Val Asp Pro Arg His 740 745 750Arg
Gln Gly Pro Val Asn Leu Leu Ser Asp Pro Glu Gln Gly Val Glu 755 760
765Val Thr Gly Gln Tyr Glu Arg Glu Lys Ala Gly Phe Ser Trp Ile Glu
770 775 780Val Thr Phe Lys Asn Pro Leu Val Trp Val His Ala Ser Pro
Glu His785 790 795 800Val Val Val Thr Arg Asn Arg Arg Ser Ser Ala
Tyr Lys Trp Lys Glu 805 810 815Thr Leu Phe Ser Val Met Pro Gly Leu
Lys Met Thr Met Asp Lys Thr 820 825 830Gly Leu Leu Leu Leu Ser Asp
Pro Asp Lys Val Thr Ile Gly Leu Leu 835 840 845Phe Trp Asp Gly Arg
Gly Glu Gly Leu Arg Leu Leu Leu Arg Asp Thr 850 855 860Asp Arg Phe
Ser Ser His Val Gly Gly Thr Leu Gly Gln Phe Tyr Gln865 870 875
880Glu Val Leu Trp Gly Ser Pro Ala Ala Ser Asp Asp Gly Arg Arg Thr
885 890 895Leu Arg Val Gln Gly Asn Asp His Ser Ala Thr Arg Glu Arg
Arg Leu 900 905 910Asp Tyr Gln Glu Gly Pro Pro Gly Val Glu Ile Ser
Cys Trp Ser Val 915 920 925Glu Leu 93065447PRTHomo sapiens 65Met
Met Lys Thr Leu Leu Leu Phe Val Gly Leu Leu Leu Thr Trp Glu1 5 10
15Ser Gly Gln Val Leu Gly Asp Gln Thr Val Ser Asp Asn Glu Leu Gln
20 25 30Glu Met Ser Asn Gln Gly Ser Lys Tyr Val Asn Lys Glu Ile Gln
Asn 35 40 45Ala Val Asn Gly Val Lys Gln Ile Lys Thr Leu Ile Glu Lys
Thr Asn 50 55 60Glu Glu Arg Lys Thr Leu Leu Ser Asn Leu Glu Glu Ala
Lys Lys Lys65 70 75 80Lys Glu Asp Ala Leu Asn Glu Thr Arg Glu Ser
Glu Thr Lys Leu Lys 85 90 95Glu Leu Pro Gly Val Cys Asn Glu Thr Met
Met Ala Leu Trp Glu Glu 100 105 110Cys Lys Pro Cys Leu Lys Gln Thr
Cys Met Lys Phe Tyr Ala Arg Val 115 120 125Cys Arg Ser Gly Ser Gly
Leu Val Gly Arg Gln Leu Glu Glu Phe Leu 130 135 140Asn Gln Ser Ser
Pro Phe Tyr Phe Trp Met Asn Gly Asp Arg Ile Asp145 150 155 160Ser
Leu Leu Glu Asn Asp Arg Gln Gln Thr His Met Leu Asp Val Met 165 170
175Gln Asp His Phe Ser Arg Ala Ser Ser Ile Ile Asp Glu Leu Phe Gln
180 185 190Asp Arg Phe Phe Thr Arg Glu Pro Gln Asp Thr Tyr His Tyr
Leu Pro 195 200 205Phe Ser Leu Pro His Arg Arg Pro His Phe Phe Phe
Pro Lys Ser Arg 210 215 220Ile Val Arg Ser Leu Met Pro Phe Ser Pro
Tyr Glu Pro Leu Asn Phe225 230 235 240His Ala Met Phe Gln Pro Phe
Leu Glu Met Ile His Glu Ala Gln Gln 245 250 255Ala Met Asp Ile His
Phe His Ser Pro Ala Phe Gln His Pro Pro Thr 260 265 270Glu Phe Ile
Arg Glu Gly Asp Asp Asp Arg Thr Val Cys Arg Glu Ile 275 280 285Arg
His Asn Ser Thr Gly Cys Leu Arg Met Lys Asp Gln Cys Asp Lys 290 295
300Cys Arg Glu Ile Leu Ser Val Asp Cys Ser Thr Asn Asn Pro Ser
Gln305 310 315 320Ala Lys Leu Arg Arg Glu Leu Asp Glu Ser Leu Gln
Val Ala Glu Arg 325 330 335Leu Thr Arg Lys Tyr Asn Glu Leu Leu Lys
Ser Tyr Gln Trp Lys Met 340 345 350Leu Asn Thr Ser Ser Leu Leu Glu
Gln Leu Asn Glu Gln Phe Asn Trp 355 360 365Val Ser Arg Leu Ala Asn
Leu Thr Gln Gly Glu Asp Gln Tyr Tyr Leu 370 375 380Arg Val Thr Thr
Val Ala Ser His Thr Ser Asp Ser Asp Val Pro Ser385 390 395 400Gly
Val Thr Glu Val Val Val Lys Leu Phe Asp Ser Asp Pro Ile Thr 405 410
415Val Thr Val Pro Val Glu Val Ser Arg Lys Asn Pro Lys Phe Met Glu
420 425 430Thr Val Ala Glu Lys Ala Leu Gln Glu Tyr Arg Lys Lys His
Arg 435 440 44566534PRTHomo sapiensMOD_RES(485)..(485)Any amino
acid 66Gly Gln Tyr Ala Ser Pro Thr Ala Lys Arg Cys Cys Gln Asp Gly
Val1 5 10 15Thr Arg Leu Pro Met Met Arg Ser Cys Glu Gln Arg Ala Ala
Arg Val 20 25 30Gln Gln Pro Asp Cys Arg Glu Pro Phe Leu Ser Cys Cys
Gln Phe Ala 35 40 45Glu Ser Leu Arg Lys Lys Ser Arg Asp Lys Gly Gln
Ala Gly Leu Gln 50 55 60Arg Ala Leu Glu Ile Leu Gln Glu Glu Asp Leu
Ile Asp Glu Asp Asp65 70 75 80Ile Pro Val Arg Ser Phe Phe Pro Glu
Asn Trp Leu Trp Arg Val Glu 85 90 95Thr Val Asp Arg Phe Gln Ile Leu
Thr Leu Trp Leu Pro Asp Ser Leu 100 105 110Thr Thr Trp Glu Ile His
Gly Leu Ser Leu Ser Lys Thr Lys Gly Leu 115 120 125Cys Val Ala Thr
Pro Val Gln Leu Arg Val Phe Arg Glu Phe His Leu 130 135 140His Leu
Arg Leu Pro Met Ser Val Arg Arg Phe Glu Gln Leu Glu Leu145 150 155
160Arg Pro Val Leu Tyr Asn Tyr Leu Asp Lys Asn Leu Thr Val Ser Val
165 170 175His Val Ser Pro Val Glu Gly Leu Cys Leu Ala Gly Gly Gly
Gly Leu 180 185 190Ala Gln Gln Val Leu Val Pro Ala Gly Ser Ala Arg
Pro Val Ala Phe 195 200 205Ser Val Val Pro Thr Ala Ala Thr Ala Val
Ser Leu Lys Val Val Ala 210 215 220Arg Gly Ser Phe Glu Phe Pro Val
Gly Asp Ala Val Ser Lys Val Leu225 230 235 240Gln Ile Glu Lys Glu
Gly Ala Ile His Arg Glu Glu Leu Val Tyr Glu 245 250 255Leu Asn Pro
Leu Asp His Arg Gly Arg Thr Leu Glu Ile Pro Gly Asn 260 265 270Ser
Asp Pro Asn Met Ile Pro Asp Gly Asp Phe Asn Ser Tyr Val Arg 275 280
285Val Thr Ala Ser Asp Pro Leu Asp Thr Leu Gly Ser Glu Gly Ala Leu
290 295 300Ser Pro Gly Gly Val Ala Ser Leu Leu Arg Leu Pro Arg Gly
Cys Gly305 310 315 320Glu Gln Thr Met Ile Tyr Leu Ala Pro Thr Leu
Ala Ala Ser Arg Tyr 325 330 335Leu Asp Lys Thr Glu Gln Trp Ser Thr
Leu Pro Pro Glu Thr Lys Asp 340 345 350His Ala Val Asp Leu Ile Gln
Lys Gly Tyr Met Arg Ile Gln Gln Phe 355 360 365Arg Lys Ala Asp Gly
Ser Tyr Ala Ala Trp Leu Ser Arg Gly Ser Ser 370 375 380Thr Trp Leu
Thr Ala Phe Val Leu Lys Val Leu Ser Leu Ala Gln Glu385 390 395
400Gln Val Gly Gly Ser Pro Glu Lys Leu Gln Glu Thr Ser Asn Trp Leu
405 410 415Leu Ser Gln Gln Gln Ala Asp Gly Ser Phe Gln Asp Pro Cys
Pro Val 420 425 430Leu Asp Arg Ser Met Gln Gly Gly Leu Val Gly Asn
Asp Glu Thr Val 435 440 445Ala Leu Thr Ala Phe Val Thr Ile Ala Leu
His His Gly Leu Ala Val 450 455 460Phe Gln Asp Glu Gly Ala Glu Pro
Leu Lys Gln Arg Val Glu Ala Ser465 470 475 480Ile Ser Lys Ala Xaa
Ser Phe Leu Gly Glu Lys Ala Ser Ala Gly Leu 485 490 495Leu Gly Ala
His Ala Ala Ala Ile Thr Ala Tyr Ala Leu Thr Leu Thr 500 505 510Lys
Ala Pro Val Asp Leu Leu Gly Val Ala His Asn Asn Leu Met Ala 515 520
525Met Ala Gln Glu Thr Gly 53067644PRTHomo sapiens 67Met Phe Ser
Met Arg Ile Val Cys Leu Val Leu Ser Val Val Gly Thr1 5 10 15Ala Trp
Thr Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly 20 25 30Gly
Val Arg Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys 35 40
45Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys Cys
50 55 60Pro Ser Gly Cys Arg Met Lys Gly Leu Ile Asp Glu Val Asn Gln
Asp65 70 75 80Phe Thr Asn Arg Ile Asn Lys Leu Lys Asn Ser Leu Phe
Glu Tyr Gln 85 90 95Lys Asn Asn Lys Asp Ser His Ser Leu Thr Thr Asn
Ile Met Glu Ile 100 105 110Leu Arg Gly Asp Phe Ser Ser Ala Asn Asn
Arg Asp Asn Thr Tyr Asn 115 120 125Arg Val Ser Glu Asp Leu Arg Ser
Arg Ile Glu Val Leu Lys Arg Lys 130 135 140Val Ile Glu Lys Val Gln
His Ile Gln Leu Leu Gln Lys Asn Val Arg145 150 155 160Ala Gln Leu
Val Asp Met Lys Arg Leu Glu Val Asp Ile Asp Ile Lys 165 170 175Ile
Arg Ser Cys Arg Gly Ser Cys Ser Arg Ala Leu Ala Arg Glu Val 180 185
190Asp Leu Lys Asp Tyr Glu Asp Gln Gln Lys Gln Leu Glu Gln Val Ile
195 200 205Ala Lys Asp Leu Leu Pro Ser Arg Asp Arg Gln His Leu Pro
Leu Ile 210 215 220Lys Met Lys Pro Val Pro Asp Leu Val Pro Gly Asn
Phe Lys Ser Gln225 230 235 240Leu Gln Lys Val Pro Pro Glu Trp Lys
Ala Leu Thr Asp Met Pro Gln 245 250 255Met Arg Met Glu Leu Glu Arg
Pro Gly Gly Asn Glu Ile Thr Arg Gly 260 265 270Gly Ser Thr Ser Tyr
Gly Thr Gly Ser Glu Thr Glu Ser Pro Arg Asn 275 280 285Pro Ser Ser
Ala Gly Ser Trp Asn Ser Gly Ser Ser Gly Pro Gly Ser 290 295 300Thr
Gly Asn Arg Asn Pro Gly Ser Ser Gly Thr Gly Gly Thr Ala Thr305 310
315 320Trp Lys Pro Gly Ser Ser Gly Pro Gly Ser Thr Gly Ser Trp Asn
Ser 325 330 335Gly Ser Ser Gly Thr Gly Ser Thr Gly Asn Gln Asn Pro
Gly Ser Pro 340 345 350Arg Pro Gly Ser Thr Gly Thr Trp Asn Pro Gly
Ser Ser Glu Arg Gly 355 360 365Ser Ala Gly His Trp Thr Ser Glu Ser
Ser Val Ser Gly Ser Thr Gly 370 375 380Gln Trp His Ser Glu Ser Gly
Ser Phe Arg Pro Asp Ser Pro Gly Ser385 390 395 400Gly Asn Ala Arg
Pro Asn Asn Pro Asp Trp Gly Thr Phe Glu Glu Val 405 410 415Ser Gly
Asn Val Ser Pro Gly Thr Arg Arg Glu Tyr His Thr Glu Lys 420 425
430Leu Val Thr Ser Lys Gly Asp Lys Glu Leu Arg Thr Gly Lys Glu Lys
435 440 445Val Thr Ser Gly Ser Thr Thr Thr Thr Arg Arg Ser Cys Ser
Lys Thr 450 455 460Val Thr Lys Thr Val Ile Gly Pro Asp Gly His Lys
Glu Val Thr Lys465 470 475 480Glu Val Val Thr Ser Glu Asp Gly Ser
Asp Cys Pro Glu Ala Met Asp 485 490 495Leu Gly Thr Leu Ser Gly Ile
Gly Thr Leu Asp Gly Phe Arg His Arg 500 505 510His Pro Asp Glu Ala
Ala Phe Phe Asp Thr Ala Ser Thr Gly Lys Thr 515 520 525Phe Pro Gly
Phe Phe Ser Pro Met Leu Gly Glu Phe Val Ser Glu Thr 530 535 540Glu
Ser Arg Gly Ser Glu Ser Gly Ile Phe Thr Asn Thr Lys Glu Ser545 550
555 560Ser Ser His His Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys
Ser 565 570 575Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr
Asn Arg Gly 580 585 590Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met
Ala Asp Glu Ala Gly 595 600 605Ser Glu Ala Asp His Glu Gly Thr His
Ser Thr Lys Arg Gly His Ala 610 615 620Lys Ser Arg Pro Val Arg Gly
Ile His Thr Ser Pro Leu Gly Lys Pro625 630 635 640Ser Leu Ser
Pro68644PRTHomo sapiens 68Met Lys Leu Ile Thr Ile Leu Phe Leu Cys
Ser Arg Leu Leu Leu Ser1 5 10 15Leu Thr Gln Glu Ser Gln Ser Glu Glu
Ile Asp Cys Asn Asp Lys Asp 20 25 30Leu Phe Lys Ala Val Asp Ala Ala
Leu Lys Lys Tyr Asn Ser Gln Asn 35 40 45Gln Ser Asn Asn Gln Phe Val
Leu Tyr Arg Ile Thr Glu Ala Thr Lys 50 55 60Thr Val Gly Ser Asp Thr
Phe Tyr Ser Phe Lys Tyr Glu Ile Lys Glu65 70 75 80Gly Asp Cys Pro
Val Gln Ser Gly Lys Thr Trp Gln Asp Cys Glu Tyr 85 90 95Lys Asp Ala
Ala Lys Ala Ala Thr Gly Glu Cys Thr Ala Thr Val Gly 100 105 110Lys
Arg Ser Ser Thr Lys Phe Ser Val Ala Thr Gln Thr Cys Gln Ile 115 120
125Thr Pro Ala Glu Gly Pro Val Val Thr Ala Gln Tyr Asp Cys Leu Gly
130 135 140Cys Val His Pro Ile Ser Thr Gln Ser Pro Asp Leu Glu Pro
Ile Leu145 150 155 160Arg His Gly Ile Gln Tyr Phe Asn Asn Asn Thr
Gln His Ser Ser Leu 165 170 175Phe Met Leu Asn Glu Val Lys Arg Ala
Gln Arg Gln Val Val Ala Gly 180 185 190Leu Asn Phe Arg Ile Thr Tyr
Ser Ile Val Gln Thr Asn Cys Ser Lys 195 200 205Glu Asn Phe Leu Phe
Leu Thr Pro Asp Cys Lys Ser Leu Trp Asn Gly 210 215 220Asp Thr Gly
Glu Cys Thr Asp Asn Ala Tyr Ile Asp Ile Gln Leu Arg225 230 235
240Ile Ala Ser Phe Ser Gln Asn Cys Asp Ile Tyr Pro Gly Lys Asp Phe
245 250 255Val Gln Pro Pro Thr Lys Ile Cys Val Gly Cys Pro Arg Asp
Ile Pro 260 265 270Thr Asn Ser Pro Glu Leu Glu Glu Thr Leu Thr His
Thr Ile Thr Lys 275 280 285Leu Asn Ala Glu Asn Asn Ala Thr Phe Tyr
Phe Lys Ile Asp Asn Val 290 295 300Lys Lys Ala Arg Val Gln Val Val
Ala Gly Lys Lys Tyr Phe Ile Asp305 310 315 320Phe Val Ala Arg Glu
Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu Leu 325 330 335Thr Glu Ser
Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu Asp Cys Asn 340 345 350Ala
Glu Val Tyr Val Val Pro Trp Glu Lys Lys Ile Tyr Pro Thr Val 355 360
365Asn Cys Gln Pro Leu Gly Met Ile Ser Leu Met Lys Arg Pro Pro Gly
370 375 380Phe Ser Pro Phe Arg Ser Ser Arg Ile Gly Glu Ile Lys Glu
Glu Thr385 390 395 400Thr Val Ser Pro Pro His Thr Ser Met Ala Pro
Ala Gln Asp Glu Glu 405 410 415Arg Asp Ser Gly Lys Glu Gln Gly His
Thr Arg Arg His Asp Trp Gly 420 425 430His Glu Lys Gln Arg Lys His
Asn Leu Gly His Gly His Lys His Glu 435 440 445Arg Asp Gln Gly His
Gly His Gln Arg Gly His Gly Leu Gly His Gly 450 455 460His Glu Gln
Gln His Gly Leu Gly His Gly His Lys Phe Lys Leu Asp465 470 475
480Asp Asp Leu Glu His Gln Gly Gly His Val Leu Asp His Gly His Lys
485 490 495His Lys His Gly His Gly His Gly Lys His Lys Asn Lys Gly
Lys Lys 500 505 510Asn Gly Lys His Asn Gly Trp Lys Thr Glu His Leu
Ala Ser Ser Ser 515 520 525Glu Asp Ser Thr Thr Pro Ser Ala Gln Thr
Gln Glu Lys Thr Glu Gly 530 535 540Pro Thr Pro Ile Pro Ser Leu Ala
Lys Pro Gly Val Thr Val Thr Phe545 550 555 560Ser Asp Phe Gln Asp
Ser Asp Leu Ile Ala Thr Met Met Pro Pro Ile 565 570 575Ser Pro Ala
Pro Ile Gln Ser Asp Asp Asp Trp Ile Pro Asp Ile Gln 580 585 590Thr
Asp Pro Asn Gly Leu Ser Phe Asn Pro Ile Ser Asp Phe Pro Asp 595 600
605Thr Thr Ser Pro Lys Cys Pro Gly Arg Pro Trp Lys Ser Val Ser Glu
610 615 620Ile Asn Pro Thr Thr Gln Met Lys Glu Ser Tyr Tyr Phe Asp
Leu Thr625 630 635 640Asp Gly Leu Ser69644PRTHomo sapiens 69Met Phe
Ser Met Arg Ile
Val Cys Leu Val Leu Ser Val Val Gly Thr1 5 10 15Ala Trp Thr Ala Asp
Ser Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly 20 25 30Gly Val Arg Gly
Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys 35 40 45Asp Ser Asp
Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys Cys 50 55 60Pro Ser
Gly Cys Arg Met Lys Gly Leu Ile Asp Glu Val Asn Gln Asp65 70 75
80Phe Thr Asn Arg Ile Asn Lys Leu Lys Asn Ser Leu Phe Glu Tyr Gln
85 90 95Lys Asn Asn Lys Asp Ser His Ser Leu Thr Thr Asn Ile Met Glu
Ile 100 105 110Leu Arg Gly Asp Phe Ser Ser Ala Asn Asn Arg Asp Asn
Thr Tyr Asn 115 120 125Arg Val Ser Glu Asp Leu Arg Ser Arg Ile Glu
Val Leu Lys Arg Lys 130 135 140Val Ile Glu Lys Val Gln His Ile Gln
Leu Leu Gln Lys Asn Val Arg145 150 155 160Ala Gln Leu Val Asp Met
Lys Arg Leu Glu Val Asp Ile Asp Ile Lys 165 170 175Ile Arg Ser Cys
Arg Gly Ser Cys Ser Arg Ala Leu Ala Arg Glu Val 180 185 190Asp Leu
Lys Asp Tyr Glu Asp Gln Gln Lys Gln Leu Glu Gln Val Ile 195 200
205Ala Lys Asp Leu Leu Pro Ser Arg Asp Arg Gln His Leu Pro Leu Ile
210 215 220Lys Met Lys Pro Val Pro Asp Leu Val Pro Gly Asn Phe Lys
Ser Gln225 230 235 240Leu Gln Lys Val Pro Pro Glu Trp Lys Ala Leu
Thr Asp Met Pro Gln 245 250 255Met Arg Met Glu Leu Glu Arg Pro Gly
Gly Asn Glu Ile Thr Arg Gly 260 265 270Gly Ser Thr Ser Tyr Gly Thr
Gly Ser Glu Thr Glu Ser Pro Arg Asn 275 280 285Pro Ser Ser Ala Gly
Ser Trp Asn Ser Gly Ser Ser Gly Pro Gly Ser 290 295 300Thr Gly Asn
Arg Asn Pro Gly Ser Ser Gly Thr Gly Gly Thr Ala Thr305 310 315
320Trp Lys Pro Gly Ser Ser Gly Pro Gly Ser Thr Gly Ser Trp Asn Ser
325 330 335Gly Ser Ser Gly Thr Gly Ser Thr Gly Asn Gln Asn Pro Gly
Ser Pro 340 345 350Arg Pro Gly Ser Thr Gly Thr Trp Asn Pro Gly Ser
Ser Glu Arg Gly 355 360 365Ser Ala Gly His Trp Thr Ser Glu Ser Ser
Val Ser Gly Ser Thr Gly 370 375 380Gln Trp His Ser Glu Ser Gly Ser
Phe Arg Pro Asp Ser Pro Gly Ser385 390 395 400Gly Asn Ala Arg Pro
Asn Asn Pro Asp Trp Gly Thr Phe Glu Glu Val 405 410 415Ser Gly Asn
Val Ser Pro Gly Thr Arg Arg Glu Tyr His Thr Glu Lys 420 425 430Leu
Val Thr Ser Lys Gly Asp Lys Glu Leu Arg Thr Gly Lys Glu Lys 435 440
445Val Thr Ser Gly Ser Thr Thr Thr Thr Arg Arg Ser Cys Ser Lys Thr
450 455 460Val Thr Lys Thr Val Ile Gly Pro Asp Gly His Lys Glu Val
Thr Lys465 470 475 480Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys
Pro Glu Ala Met Asp 485 490 495Leu Gly Thr Leu Ser Gly Ile Gly Thr
Leu Asp Gly Phe Arg His Arg 500 505 510His Pro Asp Glu Ala Ala Phe
Phe Asp Thr Ala Ser Thr Gly Lys Thr 515 520 525Phe Pro Gly Phe Phe
Ser Pro Met Leu Gly Glu Phe Val Ser Glu Thr 530 535 540Glu Ser Arg
Gly Ser Glu Ser Gly Ile Phe Thr Asn Thr Lys Glu Ser545 550 555
560Ser Ser His His Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser
565 570 575Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn
Arg Gly 580 585 590Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met Ala
Asp Glu Ala Gly 595 600 605Ser Glu Ala Asp His Glu Gly Thr His Ser
Thr Lys Arg Gly His Ala 610 615 620Lys Ser Arg Pro Val Arg Gly Ile
His Thr Ser Pro Leu Gly Lys Pro625 630 635 640Ser Leu Ser
Pro70267PRTHomo sapiens 70Met Lys Ala Ala Val Leu Thr Leu Ala Val
Leu Phe Leu Thr Gly Ser1 5 10 15Gln Ala Arg His Phe Trp Gln Gln Asp
Glu Pro Pro Gln Ser Pro Trp 20 25 30Asp Arg Val Lys Asp Leu Ala Thr
Val Tyr Val Asp Val Leu Lys Asp 35 40 45Ser Gly Arg Asp Tyr Val Ser
Gln Phe Glu Gly Ser Ala Leu Gly Lys 50 55 60Gln Leu Asn Leu Lys Leu
Leu Asp Asn Trp Asp Ser Val Thr Ser Thr65 70 75 80Phe Ser Lys Leu
Arg Glu Gln Leu Gly Pro Val Thr Gln Glu Phe Trp 85 90 95Asp Asn Leu
Glu Lys Glu Thr Glu Gly Leu Arg Gln Glu Met Ser Lys 100 105 110Asp
Leu Glu Glu Val Lys Ala Lys Val Gln Pro Tyr Leu Asp Asp Phe 115 120
125Gln Lys Lys Trp Gln Glu Glu Met Glu Leu Tyr Arg Gln Lys Val Glu
130 135 140Pro Leu Arg Ala Glu Leu Gln Glu Gly Ala Arg Gln Lys Leu
His Glu145 150 155 160Leu Gln Glu Lys Leu Ser Pro Leu Gly Glu Glu
Met Arg Asp Arg Ala 165 170 175Arg Ala His Val Asp Ala Leu Arg Thr
His Leu Ala Pro Tyr Ser Asp 180 185 190Glu Leu Arg Gln Arg Leu Ala
Ala Arg Leu Glu Ala Leu Lys Glu Asn 195 200 205Gly Gly Ala Arg Leu
Ala Glu Tyr His Ala Lys Ala Thr Glu His Leu 210 215 220Ser Thr Leu
Ser Glu Lys Ala Lys Pro Ala Leu Glu Asp Leu Arg Gln225 230 235
240Gly Leu Leu Pro Val Leu Glu Ser Phe Lys Val Ser Phe Leu Ser Ala
245 250 255Leu Glu Glu Tyr Thr Lys Lys Leu Asn Thr Gln 260
26571396PRTHomo sapiens 71Met Phe Leu Lys Ala Val Val Leu Thr Leu
Ala Leu Val Ala Val Ala1 5 10 15Gly Ala Arg Ala Glu Val Ser Ala Asp
Gln Val Ala Thr Val Met Trp 20 25 30Asp Tyr Phe Ser Gln Leu Ser Asn
Asn Ala Lys Glu Ala Val Glu His 35 40 45Leu Gln Lys Ser Glu Leu Thr
Gln Gln Leu Asn Ala Leu Phe Gln Asp 50 55 60Lys Leu Gly Glu Val Asn
Thr Tyr Ala Gly Asp Leu Gln Lys Lys Leu65 70 75 80Val Pro Phe Ala
Thr Glu Leu His Glu Arg Leu Ala Lys Asp Ser Glu 85 90 95Lys Leu Lys
Glu Glu Ile Gly Lys Glu Leu Glu Glu Leu Arg Ala Arg 100 105 110Leu
Leu Pro His Ala Asn Glu Val Ser Gln Lys Ile Gly Asp Asn Leu 115 120
125Arg Glu Leu Gln Gln Arg Leu Glu Pro Tyr Ala Asp Gln Leu Arg Thr
130 135 140Gln Val Asn Thr Gln Ala Glu Gln Leu Arg Arg Gln Leu Thr
Pro Tyr145 150 155 160Ala Gln Arg Met Glu Arg Val Leu Arg Glu Asn
Ala Asp Ser Leu Gln 165 170 175Ala Ser Leu Arg Pro His Ala Asp Glu
Leu Lys Ala Lys Ile Asp Gln 180 185 190Asn Val Glu Glu Leu Lys Gly
Arg Leu Thr Pro Tyr Ala Asp Glu Phe 195 200 205Lys Val Lys Ile Asp
Gln Thr Val Glu Glu Leu Arg Arg Ser Leu Ala 210 215 220Pro Tyr Ala
Gln Asp Thr Gln Glu Lys Leu Asn His Gln Leu Glu Gly225 230 235
240Leu Thr Phe Gln Met Lys Lys Asn Ala Glu Glu Leu Lys Ala Arg Ile
245 250 255Ser Ala Ser Ala Glu Glu Leu Arg Gln Arg Leu Ala Pro Leu
Ala Glu 260 265 270Asp Val Arg Gly Asn Leu Arg Gly Asn Thr Glu Gly
Leu Gln Lys Ser 275 280 285Leu Ala Glu Leu Gly Gly His Leu Asp Gln
Gln Val Glu Glu Phe Arg 290 295 300Arg Arg Val Glu Pro Tyr Gly Glu
Asn Phe Asn Lys Ala Leu Val Gln305 310 315 320Gln Met Glu Gln Leu
Arg Thr Lys Leu Gly Pro His Ala Gly Asp Val 325 330 335Glu Gly His
Leu Ser Phe Leu Glu Lys Asp Leu Arg Asp Lys Val Asn 340 345 350Ser
Phe Phe Ser Thr Phe Lys Glu Lys Glu Ser Gln Asp Lys Thr Leu 355 360
365Ser Leu Pro Glu Leu Glu Gln Gln Gln Glu Gln His Gln Glu Gln Gln
370 375 380Gln Glu Gln Val Gln Met Leu Ala Pro Leu Glu Ser385 390
39572317PRTHomo sapiens 72Met Lys Val Leu Trp Ala Ala Leu Leu Val
Thr Phe Leu Ala Gly Cys1 5 10 15Gln Ala Lys Val Glu Gln Ala Val Glu
Thr Glu Pro Glu Pro Glu Leu 20 25 30Arg Gln Gln Thr Glu Trp Gln Ser
Gly Gln Arg Trp Glu Leu Ala Leu 35 40 45Gly Arg Phe Trp Asp Tyr Leu
Arg Trp Val Gln Thr Leu Ser Glu Gln 50 55 60Val Gln Glu Glu Leu Leu
Ser Ser Gln Val Thr Gln Glu Leu Arg Ala65 70 75 80Leu Met Asp Glu
Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu 85 90 95Glu Glu Gln
Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser 100 105 110Lys
Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp 115 120
125Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
130 135 140Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His
Leu Arg145 150 155 160Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp
Asp Leu Gln Lys Arg 165 170 175Leu Ala Val Tyr Gln Ala Gly Ala Arg
Glu Gly Ala Glu Arg Gly Leu 180 185 190Ser Ala Ile Arg Glu Arg Leu
Gly Pro Leu Val Glu Gln Gly Arg Val 195 200 205Arg Ala Ala Thr Val
Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg 210 215 220Ala Gln Ala
Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly225 230 235
240Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
245 250 255Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu
Gln Ala 260 265 270Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu
Pro Leu Val Glu 275 280 285Asp Met Gln Arg Gln Trp Ala Gly Leu Val
Glu Lys Val Gln Ala Ala 290 295 300Val Gly Thr Ser Ala Ala Pro Val
Pro Ser Asp Asn His305 310 31573427PRTHomo sapiens 73Met Lys Leu
Ile Thr Ile Leu Phe Leu Cys Ser Arg Leu Leu Leu Ser1 5 10 15Leu Thr
Gln Glu Ser Gln Ser Glu Glu Ile Asp Cys Asn Asp Lys Asp 20 25 30Leu
Phe Lys Ala Val Asp Ala Ala Leu Lys Lys Tyr Asn Ser Gln Asn 35 40
45Gln Ser Asn Asn Gln Phe Val Leu Tyr Arg Ile Thr Glu Ala Thr Lys
50 55 60Thr Val Gly Ser Asp Thr Phe Tyr Ser Phe Lys Tyr Glu Ile Lys
Glu65 70 75 80Gly Asp Cys Pro Val Gln Ser Gly Lys Thr Trp Gln Asp
Cys Glu Tyr 85 90 95Lys Asp Ala Ala Lys Ala Ala Thr Gly Glu Cys Thr
Ala Thr Val Gly 100 105 110Lys Arg Ser Ser Thr Lys Phe Ser Val Ala
Thr Gln Thr Cys Gln Ile 115 120 125Thr Pro Ala Glu Gly Pro Val Val
Thr Ala Gln Tyr Asp Cys Leu Gly 130 135 140Cys Val His Pro Ile Ser
Thr Gln Ser Pro Asp Leu Glu Pro Ile Leu145 150 155 160Arg His Gly
Ile Gln Tyr Phe Asn Asn Asn Thr Gln His Ser Ser Leu 165 170 175Phe
Met Leu Asn Glu Val Lys Arg Ala Gln Arg Gln Val Val Ala Gly 180 185
190Leu Asn Phe Arg Ile Thr Tyr Ser Ile Val Gln Thr Asn Cys Ser Lys
195 200 205Glu Asn Phe Leu Phe Leu Thr Pro Asp Cys Lys Ser Leu Trp
Asn Gly 210 215 220Asp Thr Gly Glu Cys Thr Asp Asn Ala Tyr Ile Asp
Ile Gln Leu Arg225 230 235 240Ile Ala Ser Phe Ser Gln Asn Cys Asp
Ile Tyr Pro Gly Lys Asp Phe 245 250 255Val Gln Pro Pro Thr Lys Ile
Cys Val Gly Cys Pro Arg Asp Ile Pro 260 265 270Thr Asn Ser Pro Glu
Leu Glu Glu Thr Leu Thr His Thr Ile Thr Lys 275 280 285Leu Asn Ala
Glu Asn Asn Ala Thr Phe Tyr Phe Lys Ile Asp Asn Val 290 295 300Lys
Lys Ala Arg Val Gln Val Val Ala Gly Lys Lys Tyr Phe Ile Asp305 310
315 320Phe Val Ala Arg Glu Thr Thr Cys Ser Lys Glu Ser Asn Glu Glu
Leu 325 330 335Thr Glu Ser Cys Glu Thr Lys Lys Leu Gly Gln Ser Leu
Asp Cys Asn 340 345 350Ala Glu Val Tyr Val Val Pro Trp Glu Lys Lys
Ile Tyr Pro Thr Val 355 360 365Asn Cys Gln Pro Leu Gly Met Ile Ser
Leu Met Lys Arg Pro Pro Gly 370 375 380Phe Ser Pro Phe Arg Ser Ser
Arg Ile Gly Glu Ile Lys Glu Glu Thr385 390 395 400Thr Ser His Leu
Arg Ser Cys Glu Tyr Lys Gly Arg Pro Pro Lys Ala 405 410 415Gly Ala
Glu Pro Ala Ser Glu Arg Glu Val Ser 420 42574732PRTHomo sapiens
74Met Ser Glu Thr Ser Arg Thr Ala Phe Gly Gly Arg Arg Ala Val Pro1
5 10 15Pro Asn Asn Ser Asn Ala Ala Glu Asp Asp Leu Pro Thr Val Glu
Leu 20 25 30Gln Gly Val Val Pro Arg Gly Val Asn Leu Gln Glu Phe Leu
Asn Val 35 40 45Thr Ser Val His Leu Phe Lys Glu Arg Trp Asp Thr Asn
Lys Val Asp 50 55 60His His Thr Asp Lys Tyr Glu Asn Asn Lys Leu Ile
Val Arg Arg Gly65 70 75 80Gln Ser Phe Tyr Val Gln Ile Asp Leu Ser
Arg Pro Tyr Asp Pro Arg 85 90 95Arg Asp Leu Phe Arg Val Glu Tyr Val
Ile Gly Arg Tyr Pro Gln Glu 100 105 110Asn Lys Gly Thr Tyr Ile Pro
Val Pro Ile Val Ser Glu Leu Gln Ser 115 120 125Gly Lys Trp Gly Ala
Lys Ile Val Met Arg Glu Asp Arg Ser Val Arg 130 135 140Leu Ser Ile
Gln Ser Ser Pro Lys Cys Ile Val Gly Lys Phe Arg Met145 150 155
160Tyr Val Ala Val Trp Thr Pro Tyr Gly Val Leu Arg Thr Ser Arg Asn
165 170 175Pro Glu Thr Asp Thr Tyr Ile Leu Phe Asn Pro Trp Cys Glu
Asp Asp 180 185 190Ala Val Tyr Leu Asp Asn Glu Lys Glu Arg Glu Glu
Tyr Val Leu Asn 195 200 205Asp Ile Gly Val Ile Phe Tyr Gly Glu Val
Asn Asp Ile Lys Thr Arg 210 215 220Ser Trp Ser Tyr Gly Gln Phe Glu
Asp Gly Ile Leu Asp Thr Cys Leu225 230 235 240Tyr Val Met Asp Arg
Ala Gln Met Asp Leu Ser Gly Arg Gly Asn Pro 245 250 255Ile Lys Val
Ser Arg Val Gly Ser Ala Met Val Asn Ala Lys Asp Asp 260 265 270Glu
Gly Val Leu Val Gly Ser Trp Asp Asn Ile Tyr Ala Tyr Gly Val 275 280
285Pro Pro Ser Ala Trp Thr Gly Ser Val Asp Ile Leu Leu Glu Tyr Arg
290 295 300Ser Ser Glu Asn Pro Val Arg Tyr Gly Gln Cys Trp Val Phe
Ala Gly305 310 315 320Val Phe Asn Thr Phe Leu Arg Cys Leu Gly Ile
Pro Ala Arg Ile Val 325 330 335Thr Asn Tyr Phe Ser Ala His Asp Asn
Asp Ala Asn Leu Gln Met Asp 340 345 350Ile Phe Leu Glu Glu Asp Gly
Asn Val Asn Ser Lys Leu Thr Lys Asp 355 360 365Ser Val Trp Asn Tyr
His Cys Trp Asn Glu Ala Trp Met Thr Arg Pro 370 375 380Asp Leu Pro
Val Gly Phe Gly Gly Trp Gln Ala Val Asp Ser Thr Pro385 390 395
400Gln Glu Asn Ser Asp Gly Met Tyr Arg Cys Gly Pro Ala Ser Val Gln
405 410 415Ala Ile Lys His Gly
His Val Cys Phe Gln Phe Asp Ala Pro Phe Val 420 425 430Phe Ala Glu
Val Asn Ser Asp Leu Ile Tyr Ile Thr Ala Lys Lys Asp 435 440 445Gly
Thr His Val Val Glu Asn Val Asp Ala Thr His Ile Gly Lys Leu 450 455
460Ile Val Thr Lys Gln Ile Gly Gly Asp Gly Met Met Asp Ile Thr
Asp465 470 475 480Thr Tyr Lys Phe Gln Glu Gly Gln Glu Glu Glu Arg
Leu Ala Leu Glu 485 490 495Thr Ala Leu Met Tyr Gly Ala Lys Lys Pro
Leu Asn Thr Glu Gly Val 500 505 510Met Lys Ser Arg Ser Asn Val Asp
Met Asp Phe Glu Val Glu Asn Ala 515 520 525Val Leu Gly Lys Asp Phe
Lys Leu Ser Ile Thr Phe Arg Asn Asn Ser 530 535 540His Asn Arg Tyr
Thr Ile Thr Ala Tyr Leu Ser Ala Asn Ile Thr Phe545 550 555 560Tyr
Thr Gly Val Pro Lys Ala Glu Phe Lys Lys Glu Thr Phe Asp Val 565 570
575Thr Leu Glu Pro Leu Ser Phe Lys Lys Glu Ala Val Leu Ile Gln Ala
580 585 590Gly Glu Tyr Met Gly Gln Leu Leu Glu Gln Ala Ser Leu His
Phe Phe 595 600 605Val Thr Ala Arg Ile Asn Glu Thr Arg Asp Val Leu
Ala Lys Gln Lys 610 615 620Ser Thr Val Leu Thr Ile Pro Glu Ile Ile
Ile Lys Val Arg Gly Thr625 630 635 640Gln Val Val Gly Ser Asp Met
Thr Val Thr Val Gln Phe Thr Asn Pro 645 650 655Leu Lys Glu Thr Leu
Arg Asn Val Trp Val His Leu Asp Gly Pro Gly 660 665 670Val Thr Arg
Pro Met Lys Lys Met Phe Arg Glu Ile Arg Pro Asn Ser 675 680 685Thr
Val Gln Trp Glu Glu Val Cys Arg Pro Trp Val Ser Gly His Arg 690 695
700Lys Leu Ile Ala Ser Met Ser Ser Asp Ser Leu Arg His Val Tyr
Gly705 710 715 720Glu Leu Asp Val Gln Ile Gln Arg Arg Pro Ser Met
725 73075147PRTHomo sapiens 75Met Ala Ser His Arg Leu Leu Leu Leu
Cys Leu Ala Gly Leu Val Phe1 5 10 15Val Ser Glu Ala Gly Pro Thr Gly
Thr Gly Glu Ser Lys Cys Pro Leu 20 25 30Met Val Lys Val Leu Asp Ala
Val Arg Gly Ser Pro Ala Ile Asn Val 35 40 45Ala Val His Val Phe Arg
Lys Ala Ala Asp Asp Thr Trp Glu Pro Phe 50 55 60Ala Ser Gly Lys Thr
Ser Glu Ser Gly Glu Leu His Gly Leu Thr Thr65 70 75 80Glu Glu Glu
Phe Val Glu Gly Ile Tyr Lys Val Glu Ile Asp Thr Lys 85 90 95Ser Tyr
Trp Lys Ala Leu Gly Ile Ser Pro Phe His Glu His Ala Glu 100 105
110Val Val Phe Thr Ala Asn Asp Ser Gly Pro Arg Arg Tyr Thr Ile Ala
115 120 125Ala Leu Leu Ser Pro Tyr Ser Tyr Ser Thr Thr Ala Val Val
Thr Asn 130 135 140Pro Lys Glu1457617PRTHomo sapiens 76Arg Asn Gly
Phe Lys Ser His Ala Leu Gln Leu Asn Asn Arg Gln Ile1 5 10
15Arg7716PRTHomo sapiens 77Asn Gly Phe Lys Ser His Ala Leu Gln Leu
Asn Asn Arg Gln Ile Arg1 5 10 157831PRTHomo sapiens 78Arg Gly Leu
Glu Glu Glu Leu Gln Phe Ser Leu Gly Ser Lys Ile Asn1 5 10 15Val Lys
Val Gly Gly Asn Ser Lys Gly Thr Leu Lys Val Leu Arg 20 25
307927PRTHomo sapiens 79Arg Gly Leu Glu Glu Glu Leu Gln Phe Ser Leu
Gly Ser Lys Ile Asn1 5 10 15Val Lys Val Gly Gly Asn Ser Lys Gly Thr
Leu 20 258023PRTHomo sapiens 80Arg Gly Leu Glu Glu Glu Leu Gln Phe
Ser Leu Gly Ser Lys Ile Asn1 5 10 15Val Lys Val Gly Gly Asn Ser
208117PRTHomo sapiens 81Arg Gly Leu Glu Glu Glu Leu Gln Phe Ser Leu
Gly Ser Lys Ile Asn1 5 10 15Val8239PRTHomo sapiens 82Arg Gln Ala
Gly Ala Ala Gly Ser Arg Met Asn Phe Arg Pro Gly Val1 5 10 15Leu Ser
Ser Arg Gln Leu Gly Leu Pro Gly Pro Pro Asp Val Pro Asp 20 25 30His
Ala Ala Tyr His Pro Phe 358319PRTHomo sapiens 83Gln Leu Gly Leu Pro
Gly Pro Pro Asp Val Pro Asp His Ala Ala Tyr1 5 10 15His Pro
Phe8429PRTHomo sapiens 84Arg Asn Val His Ser Gly Ser Thr Phe Phe
Lys Tyr Tyr Leu Gln Gly1 5 10 15Ala Lys Ile Pro Lys Pro Glu Ala Ser
Phe Ser Pro Arg 20 258523PRTHomo sapiens 85Arg Asn Val His Ser Ala
Gly Ala Ala Gly Ser Arg Met Asn Phe Arg1 5 10 15Pro Gly Val Leu Ser
Ser Arg 208631PRTHomo sapiensMOD_RES(26)..(26)Oxidated Met 86Arg
Ala Glu Leu Gln Glu Gly Ala Arg Gln Lys Leu His Glu Leu Gln1 5 10
15Glu Lys Leu Ser Pro Leu Gly Glu Glu Met Arg Asp Arg Ala Arg 20 25
308715PRTHomo sapiens 87Glu Leu Gln Glu Gly Ala Arg Gln Lys Leu His
Glu Leu Gln Glu1 5 10 158829PRTHomo sapiens 88Arg Gln Gly Leu Leu
Pro Val Leu Glu Ser Phe Lys Val Ser Phe Leu1 5 10 15Ser Ala Leu Glu
Glu Tyr Thr Lys Lys Leu Asn Thr Gln 20 258921PRTHomo sapiens 89Lys
Ala Thr Glu His Leu Ser Thr Leu Ser Glu Lys Ala Lys Pro Ala1 5 10
15Leu Glu Asp Leu Arg 209024PRTHomo sapiens 90Ile Ser Ala Ser Ala
Glu Glu Leu Arg Gln Arg Leu Ala Pro Leu Ala1 5 10 15Glu Asp Val Arg
Gly Asn Leu Lys 209126PRTHomo sapiens 91Lys Gly Asn Thr Glu Gly Leu
Gln Lys Ser Leu Ala Glu Leu Gly Gly1 5 10 15His Leu Asp Gln Gln Val
Glu Glu Phe Arg 20 259225PRTHomo sapiens 92Arg Ala Ala Thr Val Gly
Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg1 5 10 15Ala Gln Ala Trp Gly
Glu Arg Leu Arg 20 259324PRTHomo sapiens 93Arg Ala Ala Thr Val Gly
Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg1 5 10 15Ala Gln Ala Trp Gly
Glu Arg Leu 209411PRTHomo sapiens 94His Phe Phe Phe Pro Lys Ser Arg
Ile Val Arg1 5 109521PRTHomo sapiens 95Arg Lys His Asn Leu Gly His
Gly His Lys His Glu Arg Asp Gln Gly1 5 10 15His Gly His Gln Arg
209618PRTHomo sapiens 96Asn Leu Gly His Gly His Lys His Glu Arg Asp
Gln Gly His Gly His1 5 10 15Gln Arg9722PRTHomo sapiens 97Arg Gly
His Gly Leu Gly His Gly His Glu Gln Gln His Gly Leu Gly1 5 10 15His
Gly His Lys Phe Lys 209826PRTHomo sapiens 98Arg Ala Val Pro Pro Asn
Asn Ser Asn Ala Ala Glu Asp Asp Leu Pro1 5 10 15Thr Val Glu Leu Gln
Gly Val Val Pro Arg 20 259924PRTHomo sapiens 99Lys Ala Leu Gly Ile
Ser Pro Phe His Glu His Ala Glu Val Val Phe1 5 10 15Thr Ala Asn Asp
Ser Gly Pro Arg 2010021PRTHomo sapiens 100Gly Leu Glu Glu Glu Leu
Gln Phe Ser Leu Gly Ser Lys Ile Asn Val1 5 10 15Lys Gly Gly Asn Ser
2010130PRTHomo sapiens 101Lys Ser Ser Ser Tyr Ser Lys Gln Phe Thr
Ser Ser Thr Ser Tyr Asn1 5 10 15Arg Gly Asp Ser Thr Phe Glu Ser Lys
Ser Tyr Lys Met Ala 20 25 3010257PRTHomo sapiens 102Gly Ser Glu Ser
Gly Ile Phe Thr Asn Thr Lys Glu Ser Ser Ser His1 5 10 15His Pro Gly
Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser Ser Ser Tyr 20 25 30Ser Lys
Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly Asp Ser Thr 35 40 45Phe
Glu Ser Lys Ser Tyr Lys Met Ala 50 5510319PRTHomo sapiens 103Arg
Gly Leu Glu Glu Glu Leu Gln Phe Ser Leu Gly Ser Lys Ile Asn1 5 10
15Val Lys Val10424PRTHomo sapiens 104Arg Thr Leu Glu Ile Pro Gly
Asn Ser Asp Pro Asn Met Ile Pro Asp1 5 10 15Gly Asp Phe Asn Ser Tyr
Val Arg 2010525PRTHomo sapiens 105Lys Gly Asn Thr Glu Gly Leu Gln
Lys Ser Leu Ala Glu Leu Gly Gly1 5 10 15His Leu Asp Gln Gln Val Glu
Glu Phe 20 2510626PRTHomo sapiens 106Asp Val Ser Ser Ala Leu Asp
Lys Leu Lys Glu Phe Gly Asn Thr Leu1 5 10 15Glu Asp Lys Ala Arg Glu
Leu Ile Ser Arg 20 2510721PRTHomo sapiens 107Thr Val Gly Ser Leu
Ala Gly Gln Pro Leu Gln Glu Arg Ala Gln Ala1 5 10 15Trp Gly Glu Arg
Leu 20108644PRTHomo sapiens 108Met Phe Ser Met Arg Ile Val Cys Leu
Val Leu Ser Val Val Gly Thr1 5 10 15Ala Trp Thr Ala Asp Ser Gly Glu
Gly Asp Phe Leu Ala Glu Gly Gly 20 25 30Gly Val Arg Gly Pro Arg Val
Val Glu Arg His Gln Ser Ala Cys Lys 35 40 45Asp Ser Asp Trp Pro Phe
Cys Ser Asp Glu Asp Trp Asn Tyr Lys Cys 50 55 60Pro Ser Gly Cys Arg
Met Lys Gly Leu Ile Asp Glu Val Asn Gln Asp65 70 75 80Phe Thr Asn
Arg Ile Asn Lys Leu Lys Asn Ser Leu Phe Glu Tyr Gln 85 90 95Lys Asn
Asn Lys Asp Ser His Ser Leu Thr Thr Asn Ile Met Glu Ile 100 105
110Leu Arg Gly Asp Phe Ser Ser Ala Asn Asn Arg Asp Asn Thr Tyr Asn
115 120 125Arg Val Ser Glu Asp Leu Arg Ser Arg Ile Glu Val Leu Lys
Arg Lys 130 135 140Val Ile Glu Lys Val Gln His Ile Gln Leu Leu Gln
Lys Asn Val Arg145 150 155 160Ala Gln Leu Val Asp Met Lys Arg Leu
Glu Val Asp Ile Asp Ile Lys 165 170 175Ile Arg Ser Cys Arg Gly Ser
Cys Ser Arg Ala Leu Ala Arg Glu Val 180 185 190Asp Leu Lys Asp Tyr
Glu Asp Gln Gln Lys Gln Leu Glu Gln Val Ile 195 200 205Ala Lys Asp
Leu Leu Pro Ser Arg Asp Arg Gln His Leu Pro Leu Ile 210 215 220Lys
Met Lys Pro Val Pro Asp Leu Val Pro Gly Asn Phe Lys Ser Gln225 230
235 240Leu Gln Lys Val Pro Pro Glu Trp Lys Ala Leu Thr Asp Met Pro
Gln 245 250 255Met Arg Met Glu Leu Glu Arg Pro Gly Gly Asn Glu Ile
Thr Arg Gly 260 265 270Gly Ser Thr Ser Tyr Gly Thr Gly Ser Glu Thr
Glu Ser Pro Arg Asn 275 280 285Pro Ser Ser Ala Gly Ser Trp Asn Ser
Gly Ser Ser Gly Pro Gly Ser 290 295 300Thr Gly Asn Arg Asn Pro Gly
Ser Ser Gly Thr Gly Gly Thr Ala Thr305 310 315 320Trp Lys Pro Gly
Ser Ser Gly Pro Gly Ser Thr Gly Ser Trp Asn Ser 325 330 335Gly Ser
Ser Gly Thr Gly Ser Thr Gly Asn Gln Asn Pro Gly Ser Pro 340 345
350Arg Pro Gly Ser Thr Gly Thr Trp Asn Pro Gly Ser Ser Glu Arg Gly
355 360 365Ser Ala Gly His Trp Thr Ser Glu Ser Ser Val Ser Gly Ser
Thr Gly 370 375 380Gln Trp His Ser Glu Ser Gly Ser Phe Arg Pro Asp
Ser Pro Gly Ser385 390 395 400Gly Asn Ala Arg Pro Asn Asn Pro Asp
Trp Gly Thr Phe Glu Glu Val 405 410 415Ser Gly Asn Val Ser Pro Gly
Thr Arg Arg Glu Tyr His Thr Glu Lys 420 425 430Leu Val Thr Ser Lys
Gly Asp Lys Glu Leu Arg Thr Gly Lys Glu Lys 435 440 445Val Thr Ser
Gly Ser Thr Thr Thr Thr Arg Arg Ser Cys Ser Lys Thr 450 455 460Val
Thr Lys Thr Val Ile Gly Pro Asp Gly His Lys Glu Val Thr Lys465 470
475 480Glu Val Val Thr Ser Glu Asp Gly Ser Asp Cys Pro Glu Ala Met
Asp 485 490 495Leu Gly Thr Leu Ser Gly Ile Gly Thr Leu Asp Gly Phe
Arg His Arg 500 505 510His Pro Asp Glu Ala Ala Phe Phe Asp Thr Ala
Ser Thr Gly Lys Thr 515 520 525Phe Pro Gly Phe Phe Ser Pro Met Leu
Gly Glu Phe Val Ser Glu Thr 530 535 540Glu Ser Arg Gly Ser Glu Ser
Gly Ile Phe Thr Asn Thr Lys Glu Ser545 550 555 560Ser Ser His His
Pro Gly Ile Ala Glu Phe Pro Ser Arg Gly Lys Ser 565 570 575Ser Ser
Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn Arg Gly 580 585
590Asp Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met Ala Asp Glu Ala Gly
595 600 605Ser Glu Ala Asp His Glu Gly Thr His Ser Thr Lys Arg Gly
His Ala 610 615 620Lys Ser Arg Pro Val Arg Gly Ile His Thr Ser Pro
Leu Gly Lys Pro625 630 635 640Ser Leu Ser Pro1091663PRTHomo sapiens
109Met Gly Pro Thr Ser Gly Pro Ser Leu Leu Leu Leu Leu Leu Thr His1
5 10 15Leu Pro Leu Ala Leu Gly Ser Pro Met Tyr Ser Ile Ile Thr Pro
Asn 20 25 30Ile Leu Arg Leu Glu Ser Glu Glu Thr Met Val Leu Glu Ala
His Asp 35 40 45Ala Gln Gly Asp Val Pro Val Thr Val Thr Val His Asp
Phe Pro Gly 50 55 60Lys Lys Leu Val Leu Ser Ser Glu Lys Thr Val Leu
Thr Pro Ala Thr65 70 75 80Asn His Met Gly Asn Val Thr Phe Thr Ile
Pro Ala Asn Arg Glu Phe 85 90 95Lys Ser Glu Lys Gly Arg Asn Lys Phe
Val Thr Val Gln Ala Thr Phe 100 105 110Gly Thr Gln Val Val Glu Lys
Val Val Leu Val Ser Leu Gln Ser Gly 115 120 125Tyr Leu Phe Ile Gln
Thr Asp Lys Thr Ile Tyr Thr Pro Gly Ser Thr 130 135 140Val Leu Tyr
Arg Ile Phe Thr Val Asn His Lys Leu Leu Pro Val Gly145 150 155
160Arg Thr Val Met Val Asn Ile Glu Asn Pro Glu Gly Ile Pro Val Lys
165 170 175Gln Asp Ser Leu Ser Ser Gln Asn Gln Leu Gly Val Leu Pro
Leu Ser 180 185 190Trp Asp Ile Pro Glu Leu Val Asn Met Gly Gln Trp
Lys Ile Arg Ala 195 200 205Tyr Tyr Glu Asn Ser Pro Gln Gln Val Phe
Ser Thr Glu Phe Glu Val 210 215 220Lys Glu Tyr Val Leu Pro Ser Phe
Glu Val Ile Val Glu Pro Thr Glu225 230 235 240Lys Phe Tyr Tyr Ile
Tyr Asn Glu Lys Gly Leu Glu Val Thr Ile Thr 245 250 255Ala Arg Phe
Leu Tyr Gly Lys Lys Val Glu Gly Thr Ala Phe Val Ile 260 265 270Phe
Gly Ile Gln Asp Gly Glu Gln Arg Ile Ser Leu Pro Glu Ser Leu 275 280
285Lys Arg Ile Pro Ile Glu Asp Gly Ser Gly Glu Val Val Leu Ser Arg
290 295 300Lys Val Leu Leu Asp Gly Val Gln Asn Leu Arg Ala Glu Asp
Leu Val305 310 315 320Gly Lys Ser Leu Tyr Val Ser Ala Thr Val Ile
Leu His Ser Gly Ser 325 330 335Asp Met Val Gln Ala Glu Arg Ser Gly
Ile Pro Ile Val Thr Ser Pro 340 345 350Tyr Gln Ile His Phe Thr Lys
Thr Pro Lys Tyr Phe Lys Pro Gly Met 355 360 365Pro Phe Asp Leu Met
Val Phe Val Thr Asn Pro Asp Gly Ser Pro Ala 370 375 380Tyr Arg Val
Pro Val Ala Val Gln Gly Glu Asp Thr Val Gln Ser Leu385 390 395
400Thr Gln Gly Asp Gly Val Ala Lys Leu Ser Ile Asn Thr His Pro Ser
405 410 415Gln Lys Pro Leu Ser Ile Thr Val Arg Thr Lys Lys Gln Glu
Leu Ser 420 425 430Glu Ala Glu Gln Ala Thr Arg Thr Met Gln Ala Leu
Pro Tyr Ser Thr 435 440 445Val Gly Asn Ser Asn Asn Tyr Leu His Leu
Ser Val Leu Arg Thr Glu 450 455 460Leu Arg Pro Gly Glu Thr Leu Asn
Val Asn Phe Leu Leu Arg Met Asp465 470 475 480Arg Ala His Glu Ala
Lys Ile Arg Tyr Tyr Thr Tyr Leu Ile Met Asn 485 490 495Lys Gly Arg
Leu Leu
Lys Ala Gly Arg Gln Val Arg Glu Pro Gly Gln 500 505 510Asp Leu Val
Val Leu Pro Leu Ser Ile Thr Thr Asp Phe Ile Pro Ser 515 520 525Phe
Arg Leu Val Ala Tyr Tyr Thr Leu Ile Gly Ala Ser Gly Gln Arg 530 535
540Glu Val Val Ala Asp Ser Val Trp Val Asp Val Lys Asp Ser Cys
Val545 550 555 560Gly Ser Leu Val Val Lys Ser Gly Gln Ser Glu Asp
Arg Gln Pro Val 565 570 575Pro Gly Gln Gln Met Thr Leu Lys Ile Glu
Gly Asp His Gly Ala Arg 580 585 590Val Val Leu Val Ala Val Asp Lys
Gly Val Phe Val Leu Asn Lys Lys 595 600 605Asn Lys Leu Thr Gln Ser
Lys Ile Trp Asp Val Val Glu Lys Ala Asp 610 615 620Ile Gly Cys Thr
Pro Gly Ser Gly Lys Asp Tyr Ala Gly Val Phe Ser625 630 635 640Asp
Ala Gly Leu Thr Phe Thr Ser Ser Ser Gly Gln Gln Thr Ala Gln 645 650
655Arg Ala Glu Leu Gln Cys Pro Gln Pro Ala Ala Arg Arg Arg Arg Ser
660 665 670Val Gln Leu Thr Glu Lys Arg Met Asp Lys Val Gly Lys Tyr
Pro Lys 675 680 685Glu Leu Arg Lys Cys Cys Glu Asp Gly Met Arg Glu
Asn Pro Met Arg 690 695 700Phe Ser Cys Gln Arg Arg Thr Arg Phe Ile
Ser Leu Gly Glu Ala Cys705 710 715 720Lys Lys Val Phe Leu Asp Cys
Cys Asn Tyr Ile Thr Glu Leu Arg Arg 725 730 735Gln His Ala Arg Ala
Ser His Leu Gly Leu Ala Arg Ser Asn Leu Asp 740 745 750Glu Asp Ile
Ile Ala Glu Glu Asn Ile Val Ser Arg Ser Glu Phe Pro 755 760 765Glu
Ser Trp Leu Trp Asn Val Glu Asp Leu Lys Glu Pro Pro Lys Asn 770 775
780Gly Ile Ser Thr Lys Leu Met Asn Ile Phe Leu Lys Asp Ser Ile
Thr785 790 795 800Thr Trp Glu Ile Leu Ala Val Ser Met Ser Asp Lys
Lys Gly Ile Cys 805 810 815Val Ala Asp Pro Phe Glu Val Thr Val Met
Gln Asp Phe Phe Ile Asp 820 825 830Leu Arg Leu Pro Tyr Ser Val Val
Arg Asn Glu Gln Val Glu Ile Arg 835 840 845Ala Val Leu Tyr Asn Tyr
Arg Gln Asn Gln Glu Leu Lys Val Arg Val 850 855 860Glu Leu Leu His
Asn Pro Ala Phe Cys Ser Leu Ala Thr Thr Lys Arg865 870 875 880Arg
His Gln Gln Thr Val Thr Ile Pro Pro Lys Ser Ser Leu Ser Val 885 890
895Pro Tyr Val Ile Val Pro Leu Lys Thr Gly Leu Gln Glu Val Glu Val
900 905 910Lys Ala Ala Val Tyr His His Phe Ile Ser Asp Gly Val Arg
Lys Ser 915 920 925Leu Lys Val Val Pro Glu Gly Ile Arg Met Asn Lys
Thr Val Ala Val 930 935 940Arg Thr Leu Asp Pro Glu Arg Leu Gly Arg
Glu Gly Val Gln Lys Glu945 950 955 960Asp Ile Pro Pro Ala Asp Leu
Ser Asp Gln Val Pro Asp Thr Glu Ser 965 970 975Glu Thr Arg Ile Leu
Leu Gln Gly Thr Pro Val Ala Gln Met Thr Glu 980 985 990Asp Ala Val
Asp Ala Glu Arg Leu Lys His Leu Ile Val Thr Pro Ser 995 1000
1005Gly Cys Gly Glu Gln Asn Met Ile Gly Met Thr Pro Thr Val Ile
1010 1015 1020Ala Val His Tyr Leu Asp Glu Thr Glu Gln Trp Glu Lys
Phe Gly 1025 1030 1035Leu Glu Lys Arg Gln Gly Ala Leu Glu Leu Ile
Lys Lys Gly Tyr 1040 1045 1050Thr Gln Gln Leu Ala Phe Arg Gln Pro
Ser Ser Ala Phe Ala Ala 1055 1060 1065Phe Val Lys Arg Ala Pro Ser
Thr Trp Leu Thr Ala Tyr Val Val 1070 1075 1080Lys Val Phe Ser Leu
Ala Val Asn Leu Ile Ala Ile Asp Ser Gln 1085 1090 1095Val Leu Cys
Gly Ala Val Lys Trp Leu Ile Leu Glu Lys Gln Lys 1100 1105 1110Pro
Asp Gly Val Phe Gln Glu Asp Ala Pro Val Ile His Gln Glu 1115 1120
1125Met Ile Gly Gly Leu Arg Asn Asn Asn Glu Lys Asp Met Ala Leu
1130 1135 1140Thr Ala Phe Val Leu Ile Ser Leu Gln Glu Ala Lys Asp
Ile Cys 1145 1150 1155Glu Glu Gln Val Asn Ser Leu Pro Gly Ser Ile
Thr Lys Ala Gly 1160 1165 1170Asp Phe Leu Glu Ala Asn Tyr Met Asn
Leu Gln Arg Ser Tyr Thr 1175 1180 1185Val Ala Ile Ala Gly Tyr Ala
Leu Ala Gln Met Gly Arg Leu Lys 1190 1195 1200Gly Pro Leu Leu Asn
Lys Phe Leu Thr Thr Ala Lys Asp Lys Asn 1205 1210 1215Arg Trp Glu
Asp Pro Gly Lys Gln Leu Tyr Asn Val Glu Ala Thr 1220 1225 1230Ser
Tyr Ala Leu Leu Ala Leu Leu Gln Leu Lys Asp Phe Asp Phe 1235 1240
1245Val Pro Pro Val Val Arg Trp Leu Asn Glu Gln Arg Tyr Tyr Gly
1250 1255 1260Gly Gly Tyr Gly Ser Thr Gln Ala Thr Phe Met Val Phe
Gln Ala 1265 1270 1275Leu Ala Gln Tyr Gln Lys Asp Ala Pro Asp His
Gln Glu Leu Asn 1280 1285 1290Leu Asp Val Ser Leu Gln Leu Pro Ser
Arg Ser Ser Lys Ile Thr 1295 1300 1305His Arg Ile His Trp Glu Ser
Ala Ser Leu Leu Arg Ser Glu Glu 1310 1315 1320Thr Lys Glu Asn Glu
Gly Phe Thr Val Thr Ala Glu Gly Lys Gly 1325 1330 1335Gln Gly Thr
Leu Ser Val Val Thr Met Tyr His Ala Lys Ala Lys 1340 1345 1350Asp
Gln Leu Thr Cys Asn Lys Phe Asp Leu Lys Val Thr Ile Lys 1355 1360
1365Pro Ala Pro Glu Thr Glu Lys Arg Pro Gln Asp Ala Lys Asn Thr
1370 1375 1380Met Ile Leu Glu Ile Cys Thr Arg Tyr Arg Gly Asp Gln
Asp Ala 1385 1390 1395Thr Met Ser Ile Leu Asp Ile Ser Met Met Thr
Gly Phe Ala Pro 1400 1405 1410Asp Thr Asp Asp Leu Lys Gln Leu Ala
Asn Gly Val Asp Arg Tyr 1415 1420 1425Ile Ser Lys Tyr Glu Leu Asp
Lys Ala Phe Ser Asp Arg Asn Thr 1430 1435 1440Leu Ile Ile Tyr Leu
Asp Lys Val Ser His Ser Glu Asp Asp Cys 1445 1450 1455Leu Ala Phe
Lys Val His Gln Tyr Phe Asn Val Glu Leu Ile Gln 1460 1465 1470Pro
Gly Ala Val Lys Val Tyr Ala Tyr Tyr Asn Leu Glu Glu Ser 1475 1480
1485Cys Thr Arg Phe Tyr His Pro Glu Lys Glu Asp Gly Lys Leu Asn
1490 1495 1500Lys Leu Cys Arg Asp Glu Leu Cys Arg Cys Ala Glu Glu
Asn Cys 1505 1510 1515Phe Ile Gln Lys Ser Asp Asp Lys Val Thr Leu
Glu Glu Arg Leu 1520 1525 1530Asp Lys Ala Cys Glu Pro Gly Val Asp
Tyr Val Tyr Lys Thr Arg 1535 1540 1545Leu Val Lys Val Gln Leu Ser
Asn Asp Phe Asp Glu Tyr Ile Met 1550 1555 1560Ala Ile Glu Gln Thr
Ile Lys Ser Gly Ser Asp Glu Val Gln Val 1565 1570 1575Gly Gln Gln
Arg Thr Phe Ile Ser Pro Ile Lys Cys Arg Glu Ala 1580 1585 1590Leu
Lys Leu Glu Glu Lys Lys His Tyr Leu Met Trp Gly Leu Ser 1595 1600
1605Ser Asp Phe Trp Gly Glu Lys Pro Asn Leu Ser Tyr Ile Ile Gly
1610 1615 1620Lys Asp Thr Trp Val Glu His Trp Pro Glu Glu Asp Glu
Cys Gln 1625 1630 1635Asp Glu Glu Asn Gln Lys Gln Cys Gln Asp Leu
Gly Ala Phe Thr 1640 1645 1650Glu Ser Met Val Val Phe Gly Cys Pro
Asn 1655 16601101744PRTHomo sapiens 110Met Arg Leu Leu Trp Gly Leu
Ile Trp Ala Ser Ser Phe Phe Thr Leu1 5 10 15Ser Leu Gln Lys Pro Arg
Leu Leu Leu Phe Ser Pro Ser Val Val His 20 25 30Leu Gly Val Pro Leu
Ser Val Gly Val Gln Leu Gln Asp Val Pro Arg 35 40 45Gly Gln Val Val
Lys Gly Ser Val Phe Leu Arg Asn Pro Ser Arg Asn 50 55 60Asn Val Pro
Cys Ser Pro Lys Val Asp Phe Thr Leu Ser Ser Glu Arg65 70 75 80Asp
Phe Ala Leu Leu Ser Leu Gln Val Pro Leu Lys Asp Ala Lys Ser 85 90
95Cys Gly Leu His Gln Leu Leu Arg Gly Pro Glu Val Gln Leu Val Ala
100 105 110His Ser Pro Trp Leu Lys Asp Ser Leu Ser Arg Thr Thr Asn
Ile Gln 115 120 125Gly Ile Asn Leu Leu Phe Ser Ser Arg Arg Gly His
Leu Phe Leu Gln 130 135 140Thr Asp Gln Pro Ile Tyr Asn Pro Gly Gln
Arg Val Arg Tyr Arg Val145 150 155 160Phe Ala Leu Asp Gln Lys Met
Arg Pro Ser Thr Asp Thr Ile Thr Val 165 170 175Met Val Glu Asn Ser
His Gly Leu Arg Val Arg Lys Lys Glu Val Tyr 180 185 190Met Pro Ser
Ser Ile Phe Gln Asp Asp Phe Val Ile Pro Asp Ile Ser 195 200 205Glu
Pro Gly Thr Trp Lys Ile Ser Ala Arg Phe Ser Asp Gly Leu Glu 210 215
220Ser Asn Ser Ser Thr Gln Phe Glu Val Lys Lys Tyr Val Leu Pro
Asn225 230 235 240Phe Glu Val Lys Ile Thr Pro Gly Lys Pro Tyr Ile
Leu Thr Val Pro 245 250 255Gly His Leu Asp Glu Met Gln Leu Asp Ile
Gln Ala Arg Tyr Ile Tyr 260 265 270Gly Lys Pro Val Gln Gly Val Ala
Tyr Val Arg Phe Gly Leu Leu Asp 275 280 285Glu Asp Gly Lys Lys Thr
Phe Phe Arg Gly Leu Glu Ser Gln Thr Lys 290 295 300Leu Val Asn Gly
Gln Ser His Ile Ser Leu Ser Lys Ala Glu Phe Gln305 310 315 320Asp
Ala Leu Glu Lys Leu Asn Met Gly Ile Thr Asp Leu Gln Gly Leu 325 330
335Arg Leu Tyr Val Ala Ala Ala Ile Ile Glu Ser Pro Gly Gly Glu Met
340 345 350Glu Glu Ala Glu Leu Thr Ser Trp Tyr Phe Val Ser Ser Pro
Phe Ser 355 360 365Leu Asp Leu Ser Lys Thr Lys Arg His Leu Val Pro
Gly Ala Pro Phe 370 375 380Leu Leu Gln Ala Leu Val Arg Glu Met Ser
Gly Ser Pro Ala Ser Gly385 390 395 400Ile Pro Val Lys Val Ser Ala
Thr Val Ser Ser Pro Gly Ser Val Pro 405 410 415Glu Val Gln Asp Ile
Gln Gln Asn Thr Asp Gly Ser Gly Gln Val Ser 420 425 430Ile Pro Ile
Ile Ile Pro Gln Thr Ile Ser Glu Leu Gln Leu Ser Val 435 440 445Ser
Ala Gly Ser Pro His Pro Ala Ile Ala Arg Leu Thr Val Ala Ala 450 455
460Pro Pro Ser Gly Gly Pro Gly Phe Leu Ser Ile Glu Arg Pro Asp
Ser465 470 475 480Arg Pro Pro Arg Val Gly Asp Thr Leu Asn Leu Asn
Leu Arg Ala Val 485 490 495Gly Ser Gly Ala Thr Phe Ser His Tyr Tyr
Tyr Met Ile Leu Ser Arg 500 505 510Gly Gln Ile Val Phe Met Asn Arg
Glu Pro Lys Arg Thr Leu Thr Ser 515 520 525Val Ser Val Phe Val Asp
His His Leu Ala Pro Ser Phe Tyr Phe Val 530 535 540Ala Phe Tyr Tyr
His Gly Asp His Pro Val Ala Asn Ser Leu Arg Val545 550 555 560Asp
Val Gln Ala Gly Ala Cys Glu Gly Lys Leu Glu Leu Ser Val Asp 565 570
575Gly Ala Lys Gln Tyr Arg Asn Gly Glu Ser Val Lys Leu His Leu Glu
580 585 590Thr Asp Ser Leu Ala Leu Val Ala Leu Gly Ala Leu Asp Thr
Ala Leu 595 600 605Tyr Ala Ala Gly Ser Lys Ser His Lys Pro Leu Asn
Met Gly Lys Val 610 615 620Phe Glu Ala Met Asn Ser Tyr Asp Leu Gly
Cys Gly Pro Gly Gly Gly625 630 635 640Asp Ser Ala Leu Gln Val Phe
Gln Ala Ala Gly Leu Ala Phe Ser Asp 645 650 655Gly Asp Gln Trp Thr
Leu Ser Arg Lys Arg Leu Ser Cys Pro Lys Glu 660 665 670Lys Thr Thr
Arg Lys Lys Arg Asn Val Asn Phe Gln Lys Ala Ile Asn 675 680 685Glu
Lys Leu Gly Gln Tyr Ala Ser Pro Thr Ala Lys Arg Cys Cys Gln 690 695
700Asp Gly Val Thr Arg Leu Pro Met Met Arg Ser Cys Glu Gln Arg
Ala705 710 715 720Ala Arg Val Gln Gln Pro Asp Cys Arg Glu Pro Phe
Leu Ser Cys Cys 725 730 735Gln Phe Ala Glu Ser Leu Arg Lys Lys Ser
Arg Asp Lys Gly Gln Ala 740 745 750Gly Leu Gln Arg Ala Leu Glu Ile
Leu Gln Glu Glu Asp Leu Ile Asp 755 760 765Glu Asp Asp Ile Pro Val
Arg Ser Phe Phe Pro Glu Asn Trp Leu Trp 770 775 780Arg Val Glu Thr
Val Asp Arg Phe Gln Ile Leu Thr Leu Trp Leu Pro785 790 795 800Asp
Ser Leu Thr Thr Trp Glu Ile His Gly Leu Ser Leu Ser Lys Thr 805 810
815Lys Gly Leu Cys Val Ala Thr Pro Val Gln Leu Arg Val Phe Arg Glu
820 825 830Phe His Leu His Leu Arg Leu Pro Met Ser Val Arg Arg Phe
Glu Gln 835 840 845Leu Glu Leu Arg Pro Val Leu Tyr Asn Tyr Leu Asp
Lys Asn Leu Thr 850 855 860Val Ser Val His Val Ser Pro Val Glu Gly
Leu Cys Leu Ala Gly Gly865 870 875 880Gly Gly Leu Ala Gln Gln Val
Leu Val Pro Ala Gly Ser Ala Arg Pro 885 890 895Val Ala Phe Ser Val
Val Pro Thr Ala Ala Ala Ala Val Ser Leu Lys 900 905 910Val Val Ala
Arg Gly Ser Phe Glu Phe Pro Val Gly Asp Ala Val Ser 915 920 925Lys
Val Leu Gln Ile Glu Lys Glu Gly Ala Ile His Arg Glu Glu Leu 930 935
940Val Tyr Glu Leu Asn Pro Leu Asp His Arg Gly Arg Thr Leu Glu
Ile945 950 955 960Pro Gly Asn Ser Asp Pro Asn Met Ile Pro Asp Gly
Asp Phe Asn Ser 965 970 975Tyr Val Arg Val Thr Ala Ser Asp Pro Leu
Asp Thr Leu Gly Ser Glu 980 985 990Gly Ala Leu Ser Pro Gly Gly Val
Ala Ser Leu Leu Arg Leu Pro Arg 995 1000 1005Gly Cys Gly Glu Gln
Thr Met Ile Tyr Leu Ala Pro Thr Leu Ala 1010 1015 1020Ala Ser Arg
Tyr Leu Asp Lys Thr Glu Gln Trp Ser Thr Leu Pro 1025 1030 1035Pro
Glu Thr Lys Asp His Ala Val Asp Leu Ile Gln Lys Gly Tyr 1040 1045
1050Met Arg Ile Gln Gln Phe Arg Lys Ala Asp Gly Ser Tyr Ala Ala
1055 1060 1065Trp Leu Ser Arg Asp Ser Ser Thr Trp Leu Thr Ala Phe
Val Leu 1070 1075 1080Lys Val Leu Ser Leu Ala Gln Glu Gln Val Gly
Gly Ser Pro Glu 1085 1090 1095Lys Leu Gln Glu Thr Ser Asn Trp Leu
Leu Ser Gln Gln Gln Ala 1100 1105 1110Asp Gly Ser Phe Gln Asp Pro
Cys Pro Val Leu Asp Arg Ser Met 1115 1120 1125Gln Gly Gly Leu Val
Gly Asn Asp Glu Thr Val Ala Leu Thr Ala 1130 1135 1140Phe Val Thr
Ile Ala Leu His His Gly Leu Ala Val Phe Gln Asp 1145 1150 1155Glu
Gly Ala Glu Pro Leu Lys Gln Arg Val Glu Ala Ser Ile Ser 1160 1165
1170Lys Ala Asn Ser Phe Leu Gly Glu Lys Ala Ser Ala Gly Leu Leu
1175 1180 1185Gly Ala His Ala Ala Ala Ile Thr Ala Tyr Ala Leu Ser
Leu Thr 1190 1195 1200Lys Ala Pro Val Asp Leu Leu Gly Val Ala His
Asn Asn Leu Met 1205 1210 1215Ala Met Ala Gln Glu Thr Gly Asp Asn
Leu Tyr Trp Gly Ser Val 1220 1225 1230Thr Gly Ser Gln Ser Asn Ala
Val Ser Pro Thr Pro Ala Pro Arg 1235 1240 1245Asn Pro Ser Asp Pro
Met Pro Gln Ala Pro Ala Leu Trp Ile Glu 1250 1255 1260Thr Thr Ala
Tyr Ala Leu Leu His Leu Leu Leu His Glu Gly Lys 1265 1270 1275Ala
Glu Met Ala Asp Gln Ala Ser Ala Trp Leu Thr Arg Gln Gly 1280 1285
1290Ser
Phe Gln Gly Gly Phe Arg Ser Thr Gln Asp Thr Val Ile Ala 1295 1300
1305Leu Asp Ala Leu Ser Ala Tyr Trp Ile Ala Ser His Thr Thr Glu
1310 1315 1320Glu Arg Gly Leu Asn Val Thr Leu Ser Ser Thr Gly Arg
Asn Gly 1325 1330 1335Phe Lys Ser His Ala Leu Gln Leu Asn Asn Arg
Gln Ile Arg Gly 1340 1345 1350Leu Glu Glu Glu Leu Gln Phe Ser Leu
Gly Ser Lys Ile Asn Val 1355 1360 1365Lys Val Gly Gly Asn Ser Lys
Gly Thr Leu Lys Val Leu Arg Thr 1370 1375 1380Tyr Asn Val Leu Asp
Met Lys Asn Thr Thr Cys Gln Asp Leu Gln 1385 1390 1395Ile Glu Val
Thr Val Lys Gly His Val Glu Tyr Thr Met Glu Ala 1400 1405 1410Asn
Glu Asp Tyr Glu Asp Tyr Glu Tyr Asp Glu Leu Pro Ala Lys 1415 1420
1425Asp Asp Pro Asp Ala Pro Leu Gln Pro Val Thr Pro Leu Gln Leu
1430 1435 1440Phe Glu Gly Arg Arg Asn Arg Arg Arg Arg Glu Ala Pro
Lys Val 1445 1450 1455Val Glu Glu Gln Glu Ser Arg Val His Tyr Thr
Val Cys Ile Trp 1460 1465 1470Arg Asn Gly Lys Val Gly Leu Ser Gly
Met Ala Ile Ala Asp Val 1475 1480 1485Thr Leu Leu Ser Gly Phe His
Ala Leu Arg Ala Asp Leu Glu Lys 1490 1495 1500Leu Thr Ser Leu Ser
Asp Arg Tyr Val Ser His Phe Glu Thr Glu 1505 1510 1515Gly Pro His
Val Leu Leu Tyr Phe Asp Ser Val Pro Thr Ser Arg 1520 1525 1530Glu
Cys Val Gly Phe Glu Ala Val Gln Glu Val Pro Val Gly Leu 1535 1540
1545Val Gln Pro Ala Ser Ala Thr Leu Tyr Asp Tyr Tyr Asn Pro Glu
1550 1555 1560Arg Arg Cys Ser Val Phe Tyr Gly Ala Pro Ser Lys Ser
Arg Leu 1565 1570 1575Leu Ala Thr Leu Cys Ser Ala Glu Val Cys Gln
Cys Ala Glu Gly 1580 1585 1590Lys Cys Pro Arg Gln Arg Arg Ala Leu
Glu Arg Gly Leu Gln Asp 1595 1600 1605Glu Asp Gly Tyr Arg Met Lys
Phe Ala Cys Tyr Tyr Pro Arg Val 1610 1615 1620Glu Tyr Gly Phe Gln
Val Lys Val Leu Arg Glu Asp Ser Arg Ala 1625 1630 1635Ala Phe Arg
Leu Phe Glu Thr Lys Ile Thr Gln Val Leu His Phe 1640 1645 1650Thr
Lys Asp Val Lys Ala Ala Ala Asn Gln Met Arg Asn Phe Leu 1655 1660
1665Val Arg Ala Ser Cys Arg Leu Arg Leu Glu Pro Gly Lys Glu Tyr
1670 1675 1680Leu Ile Met Gly Leu Asp Gly Ala Thr Tyr Asp Leu Glu
Gly His 1685 1690 1695Pro Gln Tyr Leu Leu Asp Ser Asn Ser Trp Ile
Glu Glu Met Pro 1700 1705 1710Ser Glu Arg Leu Cys Arg Ser Thr Arg
Gln Arg Ala Ala Cys Ala 1715 1720 1725Gln Leu Asn Asp Phe Leu Gln
Glu Tyr Gly Thr Gln Gly Cys Gln 1730 1735 1740Val111930PRTHomo
sapiens 111Met Lys Pro Pro Arg Pro Val Arg Thr Cys Ser Lys Val Leu
Val Leu1 5 10 15Leu Ser Leu Leu Ala Ile His Gln Thr Thr Thr Ala Glu
Lys Asn Gly 20 25 30Ile Asp Ile Tyr Ser Leu Thr Val Asp Ser Arg Val
Ser Ser Arg Phe 35 40 45Ala His Thr Val Val Thr Ser Arg Val Val Asn
Arg Ala Asn Thr Val 50 55 60Gln Glu Ala Thr Phe Gln Met Glu Leu Pro
Lys Lys Ala Phe Ile Thr65 70 75 80Asn Phe Ser Met Asn Ile Asp Gly
Met Thr Tyr Pro Gly Ile Ile Lys 85 90 95Glu Lys Ala Glu Ala Gln Ala
Gln Tyr Ser Ala Ala Val Ala Lys Gly 100 105 110Lys Ser Ala Gly Leu
Val Lys Ala Thr Gly Arg Asn Met Glu Gln Phe 115 120 125Gln Val Ser
Val Ser Val Ala Pro Asn Ala Lys Ile Thr Phe Glu Leu 130 135 140Val
Tyr Glu Glu Leu Leu Lys Arg Arg Leu Gly Val Tyr Glu Leu Leu145 150
155 160Leu Lys Val Arg Pro Gln Gln Leu Val Lys His Leu Gln Met Asp
Ile 165 170 175His Ile Phe Glu Pro Gln Gly Ile Ser Phe Leu Glu Thr
Glu Ser Thr 180 185 190Phe Met Thr Asn Gln Leu Val Asp Ala Leu Thr
Thr Trp Gln Asn Lys 195 200 205Thr Lys Ala His Ile Arg Phe Lys Pro
Thr Leu Ser Gln Gln Gln Lys 210 215 220Ser Pro Glu Gln Gln Glu Thr
Val Leu Asp Gly Asn Leu Ile Ile Arg225 230 235 240Tyr Asp Val Asp
Arg Ala Ile Ser Gly Gly Ser Ile Gln Ile Glu Asn 245 250 255Gly Tyr
Phe Val His Tyr Phe Ala Pro Glu Gly Leu Thr Thr Met Pro 260 265
270Lys Asn Val Val Phe Val Ile Asp Lys Ser Gly Ser Met Ser Gly Arg
275 280 285Lys Ile Gln Gln Thr Arg Glu Ala Leu Ile Lys Ile Leu Asp
Asp Leu 290 295 300Ser Pro Arg Asp Gln Phe Asn Leu Ile Val Phe Ser
Thr Glu Ala Thr305 310 315 320Gln Trp Arg Pro Ser Leu Val Pro Ala
Ser Ala Glu Asn Val Asn Lys 325 330 335Ala Arg Ser Phe Ala Ala Gly
Ile Gln Ala Leu Gly Gly Thr Asn Ile 340 345 350Asn Asp Ala Met Leu
Met Ala Val Gln Leu Leu Asp Ser Ser Asn Gln 355 360 365Glu Glu Arg
Leu Pro Glu Gly Ser Val Ser Leu Ile Ile Leu Leu Thr 370 375 380Asp
Gly Asp Pro Thr Val Gly Glu Thr Asn Pro Arg Ser Ile Gln Asn385 390
395 400Asn Val Arg Glu Ala Val Ser Gly Arg Tyr Ser Leu Phe Cys Leu
Gly 405 410 415Phe Gly Phe Asp Val Ser Tyr Ala Phe Leu Glu Lys Leu
Ala Leu Asp 420 425 430Asn Gly Gly Leu Ala Arg Arg Ile His Glu Asp
Ser Asp Ser Ala Leu 435 440 445Gln Leu Gln Asp Phe Tyr Gln Glu Val
Ala Asn Pro Leu Leu Thr Ala 450 455 460Val Thr Phe Glu Tyr Pro Ser
Asn Ala Val Glu Glu Val Thr Gln Asn465 470 475 480Asn Phe Arg Leu
Leu Phe Lys Gly Ser Glu Met Val Val Ala Gly Lys 485 490 495Leu Gln
Asp Arg Gly Pro Asp Val Leu Thr Ala Thr Val Ser Gly Lys 500 505
510Leu Pro Thr Gln Asn Ile Thr Phe Gln Thr Glu Ser Ser Val Ala Glu
515 520 525Gln Glu Ala Glu Phe Gln Ser Pro Lys Tyr Ile Phe His Asn
Phe Met 530 535 540Glu Arg Leu Trp Ala Tyr Leu Thr Ile Gln Gln Leu
Leu Glu Gln Thr545 550 555 560Val Ser Ala Ser Asp Ala Asp Gln Gln
Ala Leu Arg Asn Gln Ala Leu 565 570 575Asn Leu Ser Leu Ala Tyr Ser
Phe Val Thr Pro Leu Thr Ser Met Val 580 585 590Val Thr Lys Pro Asp
Asp Gln Glu Gln Ser Gln Val Ala Glu Lys Pro 595 600 605Met Glu Gly
Glu Ser Arg Asn Arg Asn Val His Ser Gly Ser Thr Phe 610 615 620Phe
Lys Tyr Tyr Leu Gln Gly Ala Lys Ile Pro Lys Pro Glu Ala Ser625 630
635 640Phe Ser Pro Arg Arg Gly Trp Asn Arg Gln Ala Gly Ala Ala Gly
Ser 645 650 655Arg Met Asn Phe Arg Pro Gly Val Leu Ser Ser Arg Gln
Leu Gly Leu 660 665 670Pro Gly Pro Pro Asp Val Pro Asp His Ala Ala
Tyr His Pro Phe Arg 675 680 685Arg Leu Ala Ile Leu Pro Ala Ser Ala
Pro Pro Ala Thr Ser Asn Pro 690 695 700Asp Pro Ala Val Ser Arg Val
Met Asn Met Lys Ile Glu Glu Thr Thr705 710 715 720Met Thr Thr Gln
Thr Pro Ala Pro Ile Gln Ala Pro Ser Ala Ile Leu 725 730 735Pro Leu
Pro Gly Gln Ser Val Glu Arg Leu Cys Val Asp Pro Arg His 740 745
750Arg Gln Gly Pro Val Asn Leu Leu Ser Asp Pro Glu Gln Gly Val Glu
755 760 765Val Thr Gly Gln Tyr Glu Arg Glu Lys Ala Gly Phe Ser Trp
Ile Glu 770 775 780Val Thr Phe Lys Asn Pro Leu Val Trp Val His Ala
Ser Pro Glu His785 790 795 800Val Val Val Thr Arg Asn Arg Arg Ser
Ser Ala Tyr Lys Trp Lys Glu 805 810 815Thr Leu Phe Ser Val Met Pro
Gly Leu Lys Met Thr Met Asp Lys Thr 820 825 830Gly Leu Leu Leu Leu
Ser Asp Pro Asp Lys Val Thr Ile Gly Leu Leu 835 840 845Phe Trp Asp
Gly Arg Gly Glu Gly Leu Arg Leu Leu Leu Arg Asp Thr 850 855 860Asp
Arg Phe Ser Ser His Val Gly Gly Thr Leu Gly Gln Phe Tyr Gln865 870
875 880Glu Val Leu Trp Gly Ser Pro Ala Ala Ser Asp Asp Gly Arg Arg
Thr 885 890 895Leu Arg Val Gln Gly Asn Asp His Ser Ala Thr Arg Glu
Arg Arg Leu 900 905 910Asp Tyr Gln Glu Gly Pro Pro Gly Val Glu Ile
Ser Cys Trp Ser Val 915 920 925Glu Leu 930112644PRTHomo sapiens
112Met Pro Lys Asn Val Val Phe Val Ile Asp Lys Ser Gly Ser Met Ser1
5 10 15Gly Arg Lys Ile Gln Gln Thr Arg Glu Ala Leu Ile Lys Ile Leu
Asp 20 25 30Asp Leu Ser Pro Arg Asp Gln Phe Asn Leu Ile Val Phe Ser
Thr Glu 35 40 45Ala Thr Gln Trp Arg Pro Ser Leu Val Pro Ala Ser Ala
Glu Asn Val 50 55 60Asn Lys Ala Arg Ser Phe Ala Ala Gly Ile Gln Ala
Leu Gly Gly Thr65 70 75 80Asn Ile Asn Asp Ala Met Leu Met Ala Val
Gln Leu Leu Asp Ser Ser 85 90 95Asn Gln Glu Glu Arg Leu Pro Glu Gly
Ser Val Ser Leu Ile Ile Leu 100 105 110Leu Thr Asp Gly Asp Pro Thr
Val Gly Glu Thr Asn Pro Arg Ser Ile 115 120 125Gln Asn Asn Val Arg
Glu Ala Val Ser Gly Arg Tyr Ser Leu Phe Cys 130 135 140Leu Gly Phe
Gly Phe Asp Val Ser Tyr Ala Phe Leu Glu Lys Leu Ala145 150 155
160Leu Asp Asn Gly Gly Leu Ala Arg Arg Ile His Glu Asp Ser Asp Ser
165 170 175Ala Leu Gln Leu Gln Asp Phe Tyr Gln Glu Val Ala Asn Pro
Leu Leu 180 185 190Thr Ala Val Thr Phe Glu Tyr Pro Ser Asn Ala Val
Glu Glu Val Thr 195 200 205Gln Asn Asn Phe Arg Leu Leu Phe Lys Gly
Ser Glu Met Val Val Ala 210 215 220Gly Lys Leu Gln Asp Arg Gly Pro
Asp Val Leu Thr Ala Thr Val Ser225 230 235 240Gly Lys Leu Pro Thr
Gln Asn Ile Thr Phe Gln Thr Glu Ser Ser Val 245 250 255Ala Glu Gln
Glu Ala Glu Phe Gln Ser Pro Lys Tyr Ile Phe His Asn 260 265 270Phe
Met Glu Arg Leu Trp Ala Tyr Leu Thr Ile Gln Gln Leu Leu Glu 275 280
285Gln Thr Val Ser Ala Ser Asp Ala Asp Gln Gln Ala Leu Arg Asn Gln
290 295 300Ala Leu Asn Leu Ser Leu Ala Tyr Ser Phe Val Thr Pro Leu
Thr Ser305 310 315 320Met Val Val Thr Lys Pro Asp Asp Gln Glu Gln
Ser Gln Val Ala Glu 325 330 335Lys Pro Met Glu Gly Glu Ser Arg Asn
Arg Asn Val His Ser Ala Gly 340 345 350Ala Ala Gly Ser Arg Met Asn
Phe Arg Pro Gly Val Leu Ser Ser Arg 355 360 365Gln Leu Gly Leu Pro
Gly Pro Pro Asp Val Pro Asp His Ala Ala Tyr 370 375 380His Pro Phe
Arg Arg Leu Ala Ile Leu Pro Ala Ser Ala Pro Pro Ala385 390 395
400Thr Ser Asn Pro Asp Pro Ala Val Ser Arg Val Met Asn Met Lys Ile
405 410 415Glu Glu Thr Thr Met Thr Thr Gln Thr Pro Ala Cys Pro Ser
Cys Ser 420 425 430Arg Ser Arg Ala Pro Ala Val Pro Ala Pro Ile Gln
Ala Pro Ser Ala 435 440 445Ile Leu Pro Leu Pro Gly Gln Ser Val Glu
Arg Leu Cys Val Asp Pro 450 455 460Arg His Arg Gln Gly Pro Val Asn
Leu Leu Ser Asp Pro Glu Gln Gly465 470 475 480Val Glu Val Thr Gly
Gln Tyr Glu Arg Glu Lys Ala Gly Phe Ser Trp 485 490 495Ile Glu Val
Thr Phe Lys Asn Pro Leu Val Trp Val His Ala Ser Pro 500 505 510Glu
His Val Val Val Thr Arg Asn Arg Arg Ser Ser Ala Tyr Lys Trp 515 520
525Lys Glu Thr Leu Phe Ser Val Met Pro Gly Leu Lys Met Thr Met Asp
530 535 540Lys Thr Gly Leu Leu Leu Leu Ser Asp Pro Asp Lys Val Thr
Ile Gly545 550 555 560Leu Leu Phe Trp Asp Gly Arg Gly Glu Gly Leu
Arg Leu Leu Leu Arg 565 570 575Asp Thr Asp Arg Phe Ser Ser His Val
Gly Gly Thr Leu Gly Gln Phe 580 585 590Tyr Gln Glu Val Leu Trp Gly
Ser Pro Ala Ala Ser Asp Asp Gly Arg 595 600 605Arg Thr Leu Arg Val
Gln Gly Asn Asp His Ser Ala Thr Arg Glu Arg 610 615 620Arg Leu Asp
Tyr Gln Glu Gly Pro Pro Gly Val Glu Ile Ser Cys Trp625 630 635
640Ser Val Glu Leu113267PRTHomo sapiens 113Met Lys Ala Ala Val Leu
Thr Leu Ala Val Leu Phe Leu Thr Gly Ser1 5 10 15Gln Ala Arg His Phe
Trp Gln Gln Asp Glu Pro Pro Gln Ser Pro Trp 20 25 30Asp Arg Val Lys
Asp Leu Ala Thr Val Tyr Val Asp Val Leu Lys Asp 35 40 45Ser Gly Arg
Asp Tyr Val Ser Gln Phe Glu Gly Ser Ala Leu Gly Lys 50 55 60Gln Leu
Asn Leu Lys Leu Leu Asp Asn Trp Asp Ser Val Thr Ser Thr65 70 75
80Phe Ser Lys Leu Arg Glu Gln Leu Gly Pro Val Thr Gln Glu Phe Trp
85 90 95Asp Asn Leu Glu Lys Glu Thr Glu Gly Leu Arg Gln Glu Met Ser
Lys 100 105 110Asp Leu Glu Glu Val Lys Ala Lys Val Gln Pro Tyr Leu
Asp Asp Phe 115 120 125Gln Lys Lys Trp Gln Glu Glu Met Glu Leu Tyr
Arg Gln Lys Val Glu 130 135 140Pro Leu Arg Ala Glu Leu Gly Glu Gly
Ala Arg Gln Lys Leu His Glu145 150 155 160Leu Gln Glu Lys Leu Ser
Pro Leu Gly Glu Glu Met Arg Asp Arg Ala 165 170 175Arg Ala His Val
Asp Ala Leu Arg Thr His Leu Ala Pro Tyr Ser Asp 180 185 190Glu Leu
Arg Gln Arg Leu Ala Ala Arg Leu Glu Ala Leu Lys Glu Asn 195 200
205Gly Gly Ala Arg Leu Ala Glu Tyr His Ala Lys Ala Thr Glu His Leu
210 215 220Ser Thr Leu Ser Glu Lys Ala Lys Pro Ala Leu Glu Asp Leu
Arg Gln225 230 235 240Gly Leu Leu Pro Val Leu Glu Ser Phe Lys Val
Ser Phe Leu Ser Ala 245 250 255Leu Glu Glu Tyr Thr Lys Lys Leu Asn
Thr Gln 260 265114396PRTHomo sapiens 114Met Phe Leu Lys Ala Val Val
Leu Thr Leu Ala Leu Val Ala Val Ala1 5 10 15Gly Ala Arg Ala Glu Val
Ser Ala Asp Gln Val Ala Thr Val Met Trp 20 25 30Asp Tyr Phe Ser Gln
Leu Ser Asn Asn Ala Lys Glu Ala Val Glu His 35 40 45Leu Gln Lys Ser
Glu Leu Thr Gln Gln Leu Asn Ala Leu Phe Gln Asp 50 55 60Lys Leu Gly
Glu Val Asn Thr Tyr Ala Gly Asp Leu Gln Lys Lys Leu65 70 75 80Val
Pro Phe Ala Thr Glu Leu His Glu Arg Leu Ala Lys Asp Ser Glu 85 90
95Lys Leu Lys Glu Glu Ile Gly Lys Glu Leu Glu Glu Leu Arg Ala Arg
100 105 110Leu Leu Pro His Ala Asn Glu Val Ser Gln Lys Ile Gly Asp
Asn Leu 115 120 125Arg Glu Leu Gln Gln Arg Leu Glu Pro Tyr Ala Asp
Gln Leu Arg Thr 130 135 140Gln Val Asn Thr Gln Ala Glu Gln Leu Arg
Arg Gln Leu Thr Pro Tyr145 150 155 160Ala Gln Arg Met Glu Arg Val
Leu Arg Glu
Asn Ala Asp Ser Leu Gln 165 170 175Ala Ser Leu Arg Pro His Ala Asp
Glu Leu Lys Ala Lys Ile Asp Gln 180 185 190Asn Val Glu Glu Leu Lys
Gly Arg Leu Thr Pro Tyr Ala Asp Glu Phe 195 200 205Lys Val Lys Ile
Asp Gln Thr Val Glu Glu Leu Arg Arg Ser Leu Ala 210 215 220Pro Tyr
Ala Gln Asp Thr Gln Glu Lys Leu Asn His Gln Leu Glu Gly225 230 235
240Leu Thr Phe Gln Met Lys Lys Asn Ala Glu Glu Leu Lys Ala Arg Ile
245 250 255Ser Ala Ser Ala Glu Glu Leu Arg Gln Arg Leu Ala Pro Leu
Ala Glu 260 265 270Asp Val Arg Gly Asn Leu Lys Gly Asn Thr Glu Gly
Leu Gln Lys Ser 275 280 285Leu Ala Glu Leu Gly Gly His Leu Asp Gln
Gln Val Glu Glu Phe Arg 290 295 300Arg Arg Val Glu Pro Tyr Gly Glu
Asn Phe Asn Lys Ala Leu Val Gln305 310 315 320Gln Met Glu Gln Leu
Arg Gln Lys Leu Gly Pro His Ala Gly Asp Val 325 330 335Glu Gly His
Leu Ser Phe Leu Glu Lys Asp Leu Arg Asp Lys Val Asn 340 345 350Ser
Phe Phe Ser Thr Phe Lys Glu Lys Glu Ser Gln Asp Lys Thr Leu 355 360
365Ser Leu Pro Glu Leu Glu Gln Gln Gln Glu Gln Gln Gln Glu Gln Gln
370 375 380Gln Glu Gln Val Gln Met Leu Ala Pro Glu Leu Ser385 390
395115317PRTHomo sapiens 115Met Lys Val Leu Trp Ala Ala Leu Leu Val
Thr Phe Leu Ala Gly Cys1 5 10 15Gln Ala Lys Val Glu Gln Ala Val Glu
Thr Glu Pro Glu Pro Glu Leu 20 25 30Arg Gln Gln Thr Glu Trp Gln Ser
Gly Gln Arg Trp Glu Leu Ala Leu 35 40 45Gly Arg Phe Trp Asp Tyr Leu
Arg Trp Val Gln Thr Leu Ser Glu Gln 50 55 60Val Gln Glu Glu Leu Leu
Ser Ser Gln Val Thr Gln Glu Leu Arg Ala65 70 75 80Leu Met Asp Glu
Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu 85 90 95Glu Glu Gln
Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser 100 105 110Lys
Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp 115 120
125Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
130 135 140Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His
Leu Arg145 150 155 160Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp
Asp Leu Gln Lys Arg 165 170 175Leu Ala Val Tyr Gln Ala Gly Ala Arg
Glu Gly Ala Glu Arg Gly Leu 180 185 190Ser Ala Ile Arg Glu Arg Leu
Gly Pro Leu Val Glu Gln Gly Arg Val 195 200 205Arg Ala Ala Thr Val
Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg 210 215 220Ala Gln Ala
Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly225 230 235
240Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
245 250 255Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu
Gln Ala 260 265 270Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu
Pro Leu Val Glu 275 280 285Asp Met Gln Arg Gln Trp Ala Gly Leu Val
Glu Lys Val Gln Ala Ala 290 295 300Val Gly Thr Ser Ala Ala Pro Val
Pro Ser Asp Asn His305 310 31511616PRTHomo sapiens 116Ala Asp Ser
Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg1 5 10
1511716PRTHomo sapiens 117Ala Asp Ser Gly Glu Gly Asp Phe Leu Ala
Glu Gly Gly Gly Val Arg1 5 10 1511816PRTHomo sapiens 118Ala Asp Ser
Gly Glu Gly Asp Phe Leu Ala Glu Gly Gly Gly Val Arg1 5 10
1511930PRTHomo sapiens 119Lys Ser Ser Ser Tyr Ser Lys Gln Phe Thr
Ser Ser Thr Ser Tyr Asn1 5 10 15Arg Gly Asp Ser Thr Phe Glu Ser Lys
Ser Tyr Lys Met Ala 20 25 3012029PRTHomo sapiens 120Lys Ser Ser Ser
Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn1 5 10 15Arg Gly Asp
Ser Thr Phe Glu Ser Lys Ser Tyr Lys Met 20 2512127PRTHomo sapiens
121Lys Ser Ser Ser Tyr Ser Lys Gln Phe Thr Ser Ser Thr Ser Tyr Asn1
5 10 15Arg Gly Asp Ser Thr Phe Glu Ser Lys Ser Tyr 20
2512226PRTHomo sapiens 122Lys Ser Ser Ser Tyr Ser Lys Gln Phe Thr
Ser Ser Thr Ser Tyr Asn1 5 10 15Arg Gly Asp Ser Thr Phe Glu Ser Lys
Ser 20 2512324PRTHomo sapiens 123Lys Ser Ser Ser Tyr Ser Lys Gln
Phe Thr Ser Ser Thr Ser Tyr Asn1 5 10 15Arg Gly Asp Ser Thr Phe Glu
Ser 2012429PRTHomo sapiens 124Arg Gly Ser Glu Ser Gly Ile Phe Thr
Asn Thr Lys Glu Ser Ser Ser1 5 10 15His His Pro Gly Ile Ala Glu Phe
Pro Ser Arg Gly Lys 20 2512531PRTHomo sapiens 125Ser Tyr Lys Met
Ala Asp Glu Ala Gly Ser Glu Ala Asp His Glu Gly1 5 10 15Thr His Ser
Thr Lys Arg Gly His Ala Lys Ser Arg Pro Val Arg 20 25
3012626PRTHomo sapiens 126Asp Glu Ala Gly Ser Glu Ala Asp His Glu
Gly Thr His Ser Thr Lys1 5 10 15Arg Gly His Ala Lys Ser Arg Pro Val
Arg 20 2512717PRTHomo sapiens 127Ser Ser Lys Ile Thr His Arg Ile
His Trp Glu Ser Ala Ser Leu Leu1 5 10 15Arg12811PRTHomo sapiens
128His Arg Ile His Trp Glu Ser Ala Ser Leu Leu1 5 1012918PRTHomo
sapiens 129Ser Ser Lys Ile Thr His Arg Ile His Val Ile Glu Ser Ala
Ser Leu1 5 10 15Leu Arg13011PRTHomo sapiens 130Asn Gly Phe Lys Ser
His Ala Leu Gln Leu Asn1 5 1013114PRTHomo sapiens 131Gly Pro Pro
Asp Val Pro Asp His Ala Ala Tyr His Pro Phe1 5 1013215PRTHomo
sapiens 132Pro Gly Pro Pro Asp Val Pro Asp His Ala Ala Tyr His Pro
Phe1 5 10 1513329PRTHomo sapiens 133Met Phe Arg Pro Gly Val Leu Ser
Ser Arg Gln Leu Gly Leu Pro Gly1 5 10 15Pro Pro Asp Val Pro Asp His
Ala Ala Tyr His Pro Phe 20 2513412PRTHomo sapiens 134Arg Pro His
Phe Phe Phe Pro Lys Ser Arg Ile Val1 5 1013530PRTHomo sapiens
135Ser Tyr Lys Met Ala Asp Glu Ala Gly Ser Glu Ala Asp His Glu Gly1
5 10 15Thr His Ser Thr Lys Arg Gly His Ala Lys Ser Arg Pro Val 20
25 3013630PRTHomo sapiens 136Gly Leu Glu Glu Glu Leu Gln Phe Ser
Leu Gly Ser Lys Ile Asn Val1 5 10 15Lys Val Gly Gly Asn Ser Lys Gly
Thr Leu Lys Val Leu Arg 20 25 3013727PRTHomo sapiens 137Pro Gly Val
Leu Ser Ser Arg Gln Leu Gly Leu Pro Gly Pro Pro Asp1 5 10 15Val Pro
Asp His Ala Ala Tyr His Pro Phe Arg 20 2513826PRTHomo sapiens
138Gly Val Leu Ser Ser Arg Gln Leu Gly Leu Pro Gly Pro Pro Asp Val1
5 10 15Pro Asp His Ala Ala Tyr His Pro Phe Arg 20 2513925PRTHomo
sapiens 139Val Leu Ser Ser Arg Gln Leu Gly Leu Pro Gly Pro Pro Asp
Val Pro1 5 10 15Asp His Ala Ala Tyr His Pro Phe Arg 20
2514024PRTHomo sapiens 140Leu Ser Ser Arg Gln Leu Gly Leu Pro Gly
Pro Pro Asp Val Pro Asp1 5 10 15His Ala Ala Tyr His Pro Phe Arg
2014123PRTHomo sapiens 141Ser Ser Arg Gln Leu Gly Leu Pro Gly Pro
Pro Asp Val Pro Asp His1 5 10 15Ala Ala Tyr His Pro Phe Arg
2014222PRTHomo sapiens 142Leu Met Ile Asp Gln Asn Thr Lys Ser Pro
Leu Phe Met Gly Lys Val1 5 10 15Val Asn Pro Thr Gln Lys
2014322PRTHomo sapiens 143Leu Met Ile Glu Gln Asn Thr Lys Ser Pro
Leu Phe Met Gly Lys Val1 5 10 15Val Asn Pro Thr Gln Lys
2014424PRTHomo sapiens 144Arg Tyr Thr Ile Ala Ala Leu Leu Ser Pro
Tyr Ser Tyr Ser Thr Thr1 5 10 15Ala Val Val Thr Asn Pro Lys Glu
2014523PRTHomo sapiens 145Tyr Thr Ile Ala Ala Leu Leu Ser Pro Tyr
Ser Tyr Ser Thr Thr Ala1 5 10 15Val Val Thr Asn Pro Lys Glu
2014610PRTHomo sapiens 146Arg Ile His Trp Glu Ser Ala Ala Leu Leu1
5 1014713PRTHomo sapiens 147Ile Thr His Arg Ile His Trp Glu Ser Ala
Ala Leu Leu1 5 1014816PRTHomo sapiens 148Ser Ser Lys Ile Thr His
Arg Ile His Trp Glu Ser Ala Ala Leu Leu1 5 10 15
* * * * *